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p53 is a critical tumour suppressor which acts to repair or remove abnormal cells and thus 
prevent cancer. Aberrant function of p53 is therefore a critical step in tumourigenesis and 
p53 is mutated in half of all cancers. Mutation of p53 leads to both a loss of normal wild-
type function as well as the gain of oncogenic function. p53 is considered to be a promising 
therapeutic target and therapeutic strategies for targeting of the p53 pathway include: 1. 
Activation of wild-type p53 (wtp53) protein function, 2. Refolding of mutant p53 (mtp53) 
into the wtp53 conformation, 3. Reduction of mtp53 protein levels. In this work a number of 
small molecule screening assays were used to identify potentially novel regulators of both 
wtp53 and mtp53. Screening of a protein kinase inhibitor library for small molecules which 
can stimulate wtp53 activity identified the GSK3 pathway and a CDK pathway as dominant 
suppressors of wtp53 function. Screening of the library for inhibitors which reduce mtp53 
protein levels led to the identification of two IKKβ inhibitors. The work then focused on 
investigating the effects of one of these compounds, IMD0354, on the mutant p53 pathway; 
with a specific focus on MDM2 as the most rapidly responding biomarker. IMD0354 is a well 
characterised inhibitor which has been shown to specifically inhibit IKKβ leading to the 
repression of the Nf-κB pathway. This study shows that IKKβ inhibition leads to the loss of a 
number of oncogenic proteins including mtp53, MDM2 and cyclin D. Mass-spectrometry 
based (ITRAQ) proteomic analysis was then employed to identify potential mediators and/or 
co-regulated factors in response to IKKβ-inhibition via IMD0354 treatment. This led to the 
identification of RPS3 as a potential negative regulator of MDM2 protein expression; the 
reduction in MDM2 protein in response to IMD0354 treatment is shown to be partially 
dependent on RPS3. Together this data has identified, using small molecule kinase inhibitor 
libraries: (i) dominant kinase signalling pathways that suppress wt-p53 and (ii) a dominant 
kinase signalling pathway that sustains expression of mutant p53 and MDM2 in cancer cell 
lines. This latter data supports further investigation to aid understanding of how the IKK 
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1.1 The molecular basis of Cancer 
Cancer is one of the western world’s biggest killers with approximately 1 in 3 
people in the UK getting cancer at some point in their lives (1). Cancer cells have 
undergone significant uncontrolled changes resulting in cells which have abnormal 
morphology, altered metabolism, the ability to evade cell death, insensitivity to anti-
growth signals and alterations in proliferation (2). The exact mechanism by which a 
cell becomes malignant is unknown but the prevailing model suggests that cells will 
accrue mutations over time which cause these changes (3). It is likely that one of the 
early events would be the loss of genomic stability which would thus allow 
mutations and other larger scale genomic derangements to occur at a faster rate (3). 
  Cancers are also frequently linked to carcinogens, chemicals known to be 
cancer causing which have usually been found to cause damage to the DNA. In fact 
it can be argued that all cancers will have been caused by long term exposure to 
carcinogens but that we simply do not know all of these damaging agents and thus 
are unable to make the link (4). Carcinogens or other stressors lead to mutations in 
a number of exposed cells, if one of these mutations proves a selective advantage 
e.g. results in faster proliferation, then that cell will multiply at the detriment of 
other normal cells. A single mutation will not cause a cell to become cancerous 
however the increased number of cells carrying a mutation increases the chance 
that one of these cells could accrue further mutations which again may provide a 
selective advantage. This is called clonal selection, a concept first proposed in 1976 
(5). 
Whilst there are many genes which may become mutated in cancer there are 
some specific genes which are frequently seen to be mutated in pre-cancerous cells 
which are thought to be important in the initiation of malignancy. These are 
frequently genes which are known to be tumour suppressors and include the gene 
p53 (6, 7). Tumour suppressor genes produce proteins which have roles in 
preventing a cell from becoming cancerous. They act directly or indirectly to ensure 
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DNA fidelity and typically they are involved in repression of the cell cycle, repair 
mechanisms and death mechanisms. Loss of these functions can allow the survival 
and replication of cells with abnormalities and thus allow tumourigenesis.   
 
1.2 The p53 pathway 
p53 is one of the best studied tumour suppressors in cancer.  p53 is important 
in mediating a variety of functions including cell cycle control, DNA repair, apoptosis 
and angiogenesis (8). It is activated by a number of stressors and ultimately acts to 
repair or kill damaged cells thus preventing abnormal cells from continuing to divide 
(8). The importance of this tumour suppressor can be highlighted by the fact that 
this gene is mutated in around 50% of cancers and its signaling pathway disrupted in 
many more (8).  
p53 mediates it’s outcomes by both transcriptional and transcription 
independent mechanisms (8, 9). p53 is however primarily thought of as a 
transcription factor; it binds to p53 response elements in the promoter region of 
specific genes leading to the up or down regulation of those genes (8). The severity 
of the initial stressor plays an important part in determining the subset of p53 
responsive genes which are regulated and thus determining the biological endpoint 
of activation (Arrest, repair or death) (10). Examples of these are shown in Fig 1.1. 
Exactly how p53 is able to choose between its different outcomes is not entirely 
clear but may be, at least partly, mediated by the different binding affinities 
between p53 and its response elements (11). 
p53’s transcription independent functions have only more recently been 
realized but have been shown to contribute to its role in apoptosis (9). 
Mitochondrial and cytoplasmic accumulation of p53 has been shown to lead to 
transcription independent apoptosis(9). p53 activation appears to be able to 
contribute to the intrinsic mitochondria-mediated pathway of apoptosis without 
altering gene transcription (9). The initiation of this pathway is usually reliant upon 
Bcl-2 family proteins. Multiple mechanisms of p53 activation of this pathway have 
18 
 
been put-forward and many suggest that p53 can directly or indirectly activate the 




Fig 1.1 Various stress signals can lead to the activation of p53. Active p53 causes the up or down 
regulation of a subset of p53 responsive genes. Depending on the genes regulated, activation of p53 
can lead to a number of different outcomes including DNA repair (12), growth arrest (12), apoptosis 
(13) or reduced angiogenesis (14) (examples of genes involved are shown). 
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1.3 Regulation of p53 
 In the body p53 is usually kept inactive in the vast majority of cells (Fig 1.2 
top panel), however when a cell experiences stress such as DNA damage, oncogene 
activation or hypoxia p53 must become active in order to mediate its effects (Fig 1.2 
bottom panel). p53 is not thought to be heavily regulated at the transcriptional 
levels but rather the level of p53 is regulated by its rate of degradation (8). The 
degradation of p53 occurs via the ubiquitin-proteasome pathway, p53 is 
ubiquitinated by an E3 ubiquitin ligase which targets it to the proteasome where it is 
degraded. One of the most important and best understood E3 ligases affecting p53 
degradation is MDM2 (15). Thus the availability and activity of MDM2 is an 
important factor in controlling the activity of p53 and is an important factor in 
keeping p53 inactive in normal healthy cells (8). The importance of MDM2 can be 
demonstrated by the fact that knocking out MDM2 is embryonically lethal in mice, 
however this can be rescued by also knocking out p53 which results in live births 
(16). The transcription of MDM2 is controlled by p53 which acts to up-regulate it. 
Thus p53 acts to negatively regulate itself via a regulatory feedback loop (15).  
 The ability of MDM2 to negatively regulate p53 is also controlled by post-
translational modifications of both p53 and MDM2 (8, 17, 18). Furthermore post-
translational modification and availability of co-factors are also important in 
regulating conformation, localisation and activity of p53 (8, 17, 18). Both p53 and 
MDM2 can interact with a large number of proteins and can be subject to post-
translational modification including ubiquitination, acetylation, phosphorylation, 
sumoylation, and glycosylation (17, 18).  One example of such post-translational 
regulation is the acetylation of the C-terminus of p53 by p300/CBP which occurs 
after DNA damage (19). The C-terminus of p53 is known to allosterically inhibit p53 
activity, however acetylation of residues in the C-terminus appears to relieve this 
inhibition and promote p53 activity (19). A further example is the modification of 
MDM2 which will indirectly affect p53 activity, for example sumolyation of MDM2 
by ubc9 is thought to increase its stability and increase its ability to inhibit p53 (20). 
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It should be noted that whist MDM2 is generally considered as a negative 
regulator  it has also been shown that MDM2 can bind p53 mRNA and increase its 
synthesis (21). The binding of p53 mRNA to MDM2 also reduces its E3 ligase 
function. The association between MDM2 and p53 mRNA was shown to be 
increased upon doxorubicin treatment indicating that the affinity between p53 
mRNA and MDM2 may play a role in p53 induction (21). 
Whilst the interactions of p53 with regulatory factors have been subject to 
intensive research and a huge number of regulatory proteins (22) have been 
identified further investigation is still warranted. It is apparent that p53 interacts 
with an enormous number of pathways and that many may yet to be discovered and 
many others are yet to be fully understood. For example a recent study looking for 
interactors of drosophila p53 yielded 91 previously unreported interactors (23). 
Whilst clearly more work needs to be done to assess these interactions it does 
demonstrate that our current knowledge of wild type p53 (wtp53) is far from 
complete.  Pathways that repress or activate p53 are potential targets in tumours 
containing wtp53  so that we can promote activation (see Activation of wtp53). 







Fig 1.2 Activity and stability of p53 in stressed and unstressed cells. In normal cells p53 is rapidly 
turned over. Various factors interact with MDM2 and p53 to repress its activity and promote its rapid 
degradation. MDM2 ubiquitinates p53 directing it to the proteasome. When the pathway is activated 
by stressors including DNA damage and oncogene activation different factors interact with p53 and 
MDM2. This represses the ability of MDM2 to target p53 to the proteasome and promotes p53 to 
enter to nucleus and act as a transcription factor. 
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1.4 Transcriptional regulation of MDM2 
As MDM2 is a major factor controlling p53 its stability and activity is important 
in determining p53 mediated outcomes (15). As mentioned, MDM2 has been shown 
to be regulated by a large number of proteins, however unlike p53 it is also 
regulated by transcription as well as post-translational modification (17, 24). At the 
transcriptional level the expression of MDM2 is controlled by two promoters known 
as P1 and P2 (24). The P1 promoter is not controlled by p53 and is thought to be 
responsible for low level basal MDM2 production (24). Control of this promoter is 
less well understood and research has mainly focussed on the second promoter site; 
P2. The level of transcription from the P2 promoter is thought to be around 6 times 
that at the P1 promoter (25). The P2 promoter contains two p53 binding elements 
and is highly inducible in response to p53 and thus is imperative to the negative 
feedback mechanism (24). However, it is apparent that the levels of MDM2 are 
controlled by other mechanisms than just p53. High levels of MDM2 can be 
observed in cancer cells without functional p53 (26) and research is revealing that 
there are a number of different response elements within the P2 promoter. For 
example it has been shown that the P2 promoter contains an NFAT1 consensus site 
and binding of NFAT1 at this site can enhance MDM2 production (27).  
 
1.5 Mutations in p53 
Mutation of the p53 gene is one of the most common mutations found in 
cancer and is often an early event in carcinogenesis (6, 7). p53 null mice develop 
tumours with an exceptionally high frequency (28) showing its importance as a 
tumour suppressor. Additionally germ line mutation of p53 has been shown to be 
responsible for Li Fraumeni syndrome. Li Fraumeni syndrome is an autosomal 
dominant disorder characterized by a high susceptibility to cancer. Patients with Li 
Fraumeni have a mutation in one copy of the p53 gene meaning that only one 
mutational event is required to entirely lose wild-type p53 activity. 
23 
 
Unlike most tumour suppressors, mutations of p53 tend to be point mutations 
(29). These mutations confer loss of normal function in a variety of ways. The most 
common mutations are in so called hot-spot regions of the p53 DNA binding domain 
(Fig 1.3). These either mutate residues which directly interact with the DNA thus 
preventing binding or cause the protein to lose thermo-stability, this means p53 
loses its normal conformation and therefore the availability of its interacting 
domains is compromised (29). These mutations thus reduce the affinity of p53 to its 
response element thus reducing or removing the ability of p53 to bring about the up 




Fig 1.3 Frequency and location of p53 mutations (Data extracted from p53.free.fr). The domains of 
p53 shown are the transactivation domain (TAD), the proline rich domain (PRD), the DNA-binding 
domain (DBD), the tetramerisation domain (TD) and the C-Terminal regulatory domain (C-REG). 
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1.5.1 Oncogenic potential of p53  
Mutation in p53 has been shown not only to cause loss of tumour 
suppressor phenotype but also lead to oncogenic gain of function (22). Most 
mutations in p53 are point mutations, whereas many other tumour suppressors are 
silenced by deletions (29). This has been suggested as evidence that gain of function 
rather than silencing is being selected for, however it has also been countered that 
the number of point mutations is not more than expected by chance and p53 may 
simply be more sensitive to silencing by this mechanism (29). Correlative evidence 
shows that the presence of p53 mutations does indicate a poorer outcome in cancer 
patients and that certain mutations may lead to poorer outcomes than others (30, 
31). Evidence from the laboratory supports the idea that gain of function may 
contribute to this; it has been shown that the introduction of p53 with specific 
mutations into p53 null cells can cause an increase in chemoresistance and so the 
presence of particular p53 mutations may lead to a poorer response to 
chemotherapy (32).   
The oncogenic capacity of mutant p53 (mtp53) can be attributed to both its 
dominant negative and gain-of-function capacities. It has been demonstrated that 
when mtp53 is expressed in a cell with wtp53, mtp53 represses the transcriptional 
activity of wild-type p53 (33). p53 naturally functions as a tetramer and it has been 
suggested that the binding of mtp53 to wtp53 within the tetramer will inhibit wtp53 
activity (33). mtp53 has also been noted to be able to inhibit its family members; 
p63 and p73 (34). p63 and p73 are also tumour suppressers capable of regulating 
the expression of many p53 regulated genes, although knockout experiments have 
shown that the functions are non-redundant (35). p53 with certain mutations have 
been shown to bind to p63 and/or p73 leading to negative regulation (34).  The 
interaction appears to be mediated through the DNA binding domains and it has 
been shown that the denatured DNA domain of p53 is capable of binding the DNA 
binding domain of both p73 and p63, preventing them from binding their target 
DNA (36).  
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Some of the observed “gain of function” effects could also be the result of 
mtp53 activating some of its normally regulated genes but not others. Pan and 
Haines (2000) showed that p53-R213Q was capable of promoting the transcription 
of MDM2 but not factors important in cell cycle arrest or apoptosis (37). 
In addition to repressing wtp53 and related family members, mtp53 has 
been described to have many other abnormal functions. Mtp53 like wild-type p53 
appears to be able to promote or repress a number of genes (38). However wtp53 
and mtp53 appear to regulate a distinct subset of genes. Whilst wtp53 dependent 
gene expression promotes apoptosis and cell cycle arrest certain gain-of-function 
interactions confer alterations including enhanced survival, proliferation and 
metastasis (38). It is becoming clear that mtp53 can interact with a number of 
factors that wtp53 does, however the outcomes are often different (38).  
The mechanism of how mtp53 controls transcription is unclear in many cases 
but some examples have shown that mtp53 can aberrantly interact with certain 
transcription factors and thus this could provide a mechanism of how mtp53 could 
achieve sequence specific binding (38). Examples of signalling pathways altered by 
mutant p53 including Nf-κB, EGR-1, TGF-β, and NF-Y will be discussed (summarised 
in Fig 1.4). These examples however are by no means exhaustive. 
Nf-κB is known to be an important factor in cancer and furthermore 
dysregulation in the cross-talk between the Nf-κB pathways and p53 pathways has 
been shown to contribute to oncogenesis (39). In normal tissues it has been shown 
that depending on the circumstances p53 and Nf-κB can work together to be pro-
apoptotic or work against each other with Nf-κB acting as a pro-survival factor (40). 
When p53 is mutated however it appears to act to promote Nf-κB via increased 
transcription of the p100/p52 Nf-κB subunit (41). This increase in Nf-kB enhances its 
activity which contributes to the cells survival and drug resistance (41). This is of 
particular interest as it has also been shown that mutation in p53 correlates with 
constitutive Nf-κB pathway activation (42). 
It has also been shown that mutant p53 can lead to the increased production 
of EGR-1 (43, 44). EGR-1 is a transcription factor important in controlling apoptosis 
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and growth, and its aberrant production has been shown to enhance survival in 
some cancers (45). Initial reports suggested that mtp53 directly binds to the EGR-1 
promoter (43) however more recent data suggests that mtp53 does not directly 
bind the promoter but enhances it activity by initiating a complex feedback loop 
involving EGFR and MEK signalling (44). The apparent reason for these discrepancies 
remains unclear although it is possible that different mechanisms are important in 
different cells or with different p53 mutants. Nonetheless EGR1, like many of the 
proteins affected by mutant p53, may represent a useful drugable target. Evidence 
shows that reduction of EGR1 by siRNA reduces tumour cell growth and increased 
apoptosis (43). 
The interaction between mtp53 and the TGF-β pathway is more complex and 
appears to be at least partially dependant on tumour stage and type. TGF-β is 
thought to act as a tumour suppressor although research has shown that this role 
may be more relevant in early tumourigenesis (46). Evidence has shown that mutant 
p53 can suppress TGF-β signalling consistent with the idea that mtp53 is 
tumourigenic and TGF-β signalling acts as a tumour suppressor (47). The pathway 
was shown to be repressed via reduced expression of TGFβ-RII as a result of p53 
binding to the promoter region (47). However another study has shown that mutant 
p53 may co-operate with the TGF-β pathway by binding to SMAD-2 and promoting 
its suppression of p63. This results in the attenuation of metastasis suppressor 
genes which are under the transcriptional control of p63 (46). This mechanism may 
be more important in late stage cancers and enhance a metastatic phenotype (46). 
Many of the above examples propose that mtp53 can regulate gene 
transcription however, in many cases, the mechanism by which this can occur is not 
entirely clear. The binding of mtp53 with transcription factors provides a mechanism 
of how mtp53 could selectively regulate certain genes. One example of mtp53 
interacting with a transcription factor is with NF-Y (48). When DNA damage occurs 
in cells with wt-p53 various genes including cyclin A and cyclin B1 are 
downregulated to prevent cell cycle progression. This transcriptional alteration is 
dependent upon a complex of both NF-Y and wt-p53 which leads to histone 
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deacetylases being recruited (48). Reduced acetylation of histones results in the 
DNA being more tightly wound and reduces transcription from that area. Mutant 
p53 has also been shown to bind to NF-Y however upon DNA damage this 
conversely leads to the up-regulation of these genes resulting from p300 histone 
acetyltransferase recruitment (49). Thus this binding results in aberrant activation of 
NF-Y genes and deregulation of the cell cycle. This is a particularly important 
example of mtp53 transcriptional activity as it provides at least a partial mechanism 
by which mtp53 is functioning.  
Further work will be needed to resolve the mechanism by which many 
proposed mtp53 responsive genes are controlled. No mtp53 consensus DNA binding 
site has been identified but clearly binding of mtp53 to other transcription factors 
provides it with site specific activity. It has also been suggested that structure 
specific binding may play a role in determining the mtp53 response (38) however 




Fig 1.4 Potential mechanisms of the pro-oncogenic function of p53. Figure adapted from Maslon 
and Hupp (2010) (A) mtp53 binds to wtp53 suppressing the wtp53 function. This acts to promote the 
malignant phenotype. (B)  mtp53 directly binds p63 or p73 thereby repressing their ability to induce 
the expression of p53 pathway genes. This acts to promote the malignant phenotype. (C) mtp53 
enhances the expression of Nf-κB. This results in evasion of apoptotic signals. (D) mtp53 co-operates 
with NF-Y to enhance the expression of genes important in cell cycle progression. This results in 
aberrant regulation of the cell cycle.  (E) mtp53 suppresses the expression of TGFβ-RII. This results in 
reduced cell migration but potentially allows cells to escape TGF-β tumour suppressor effects early in 
tumourigenesis. (F) TGF-β and Ras-CK1 signalling cooperate in enhancing the binding of mt-p53 and 
SMAD2 which represses p63 activity. This results in increased cell migration. (G+H) Two mechanisms 
of how mtp53 increases EGR-1 which results in evasion of apoptotic signals have been proposed: (G) 
mtp53 directly enhances the expression of EGR-1.  (H) mtp53 promotes MEK activity leading to the 
downstream transcription of EGR-1. EGR-1 then indirectly acts to increase MEK signalling which 




1.6 Regulation of mtp53 
As discussed mtp53 has altered interactions with various proteins in 
comparison to wtp53, such changes are important in its pro-oncogenic capacity. 
Similarly the mutant protein is also subject to different regulation and most notably 
mtp53 is much more stable in terms of its half-life than wtp53 in cancer cells (50, 
51). Evidence suggests that the proteins involved in the degradation of mtp53 may 
be different in comparison to wtp53 (50, 51). Some changes in regulation may result 
intrinsically from the alterations to the protein and other alterations may actively be 
selected for to increase the oncogenic capacity of the mutant protein. 
Understanding the pathway involved in mtp53 stability and degradation are of 
particular importance as evidence suggests reduction of p53 levels may be 
therapeutically useful (52, 53). 
 
1.6.1 mtp53 stability 
Despite the protein not triggering an arrest or apoptotic response, mtp53 
accumulates within the cell (50). Evidence suggests that this accumulation of p53 
may actually be selected for in a cancer cell (32, 54). Unlike with wtp53, MDM2 
appears to be incapable of directing p53 for degradation (51). However, despite this, 
mtp53 is often still ubiquitinated. In fact mtp53 has been seen to be 
hyperubiquitinated in comparison to wtp53 and this process may be at least 
partially dependent on other E3 ligases (50). As discussed mutation in p53 may 
confer a number of oncogenic gains of function and so an increased level of mtp53 
should be advantageous to the tumour cells. As such, bringing about the 
degradation of this mutant protein may provide a clinically desirable effect.  
 The simplest explanation of high levels of mutant p53 would be that due to 
its inability to bind to the DNA response element, MDM2 cannot be expressed and 
therefore p53 cannot be degraded. However high levels of mtp53 are sometimes 
concomitant with high levels of MDM2 (26). Furthermore Terzian et al. (2008) 
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showed that in mtp53 mice, normal tissues retained very low levels of p53 and it is 
only in tumours that high p53 levels are detectable (54). It was shown that in these 
normal tissues expressing mutant p53 that degradation of p53 is still at least 
partially MDM2 dependant. It should also be noted that low levels of mtp53 in 
normal tissues also precludes the idea that it is any other intrinsic attribute of the 
p53 mutant that causes its stability. This indicates that there must be further 
changes in cancer cells which lead to this accumulation of p53. Terzian et al. (2008) 
also showed that whilst most cancers in the mtp53 mice had increased levels of p53 
it was not universally true, showing that this accumulation is also not strictly 
necessary for the cancer phenotype (54).   
 One mechanism by which p53 could escape MDM2 mediated degradation is 
by altered cross-talk with the Retinoblastoma (Rb) pathway. The Retinoblastoma 
protein (Rb) is a tumour suppressor important in cell cycle control. In an 
unphosphorylated form it binds to, and represses, the transcription factor E2F1 
which normally acts to promote cell cycle progression (55).  Terzian et al. (2008) 
showed that if p53 alone was mutated then normal tissues retained normal p53 
levels. However if p16INK4a, a protein in the Rb pathway, was also lost then normal 
tissues had high levels of p53. There is significant cross-talk between the Rb and p53 
pathways and defects in the Rb/p16INK4a pathway can lead to hyperactivation of the 
transcription factor E2F1 which in-turn can result in an increase in p14ARF repressing 
MDM2 and promoting p53 stability (55). Retrospective analysis of tumours derived 
from mutant p53 mice revealed that a number of these tumours had reduced or 
showed no expression of p16INK4a or other alterations of other Rb pathway 
proteins. As members of the Rb pathway, including p16INK4a, are frequently found 
to be altered in cancer (55) this may be a mechanism which contributes to p53 
stability. However it should be noted that p16INK4a mutation did not lead to p53 
stabilisation in all normal tissues. In fact loss of MDM2 could not stabilise p53 in all 
tissues either. This suggests that the normal mechanisms controlling p53 are not the 
same for all cell types and so the mechanisms by which cancers achieve high p53 




1.6.2 mtp53 E3 ligases 
Whilst MDM2 is the best studied and best known p53 E3 ligase it has 
become clear that a number of other E3 ligases are able to ubiquitinate p53 both in 
normal and cancer tissues and include Cop1 (56), CHIP (57) and ARF-BP1 (58). It is 
unclear whether their importance are distinct in terms of cell type, location, 
developmental stage or other factors, however the embryonic lethality of MDM2 
(16) suggests at least some degree of distinct function.  
The relative importance of each of these in ubiquitinating p53 however may 
be altered for mutant p53. In general it appears that MDM2 may be less important 
in the turnover of mtp53 compared to wtp53 in many cancer cells and does not 
contribute greatly to its ubiquitination (50, 51). COP1 has been shown to able to 
ubiquitinate both wtp53 and mtp53 although any difference in the relative affinities 
is as yet unclear (50). COP1 has been shown to be up-regulated in a number of 
cancers however this up-regulation has been shown to be associated with low p53 
and so may be more important when wtp53 is present (59, 60). ARF-BP1 was 
identified as an ARF binding proteins which is known to repress MDM2 activity and 
promote p53 activity (58). ARF-BP1 was shown, at least in certain cases to 
ubiquitinate only wt p53 and does not appear to be important in mtp53 
ubiquitination (50). CHIP, however, is thought to be particularly important in the 
regulation of mtp53 although it is also capable of wtp53 degradation (50, 51). 
Lukashchuk et al. (2007) showed that if MDM2, ARF-BP1, COP1 and CHIP were 
silenced only COP1 and CHIP silencing obviously decreased mtp53 ubiquitination, 
with CHIP having the most substantial effect (50). 
Whilst mtp53 is ubiquitinated, at least by COP1 and CHIP, it is not efficiently 
degraded. One factor which may be important in protecting mtp53 from 
degradation is Hsp90. Hsp90 is a chaperone molecule that has been shown to 
interact with p53 (61). Hsp90 interacts with a large number of proteins and is 
thought to be important in protein folding (62). Under stress conditions hsp90 
interacts with a large number of proteins and is important in maintaining their 
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integrity and appears to holds true for a number of proteins in cancerous cells (62). 
Muller et al. (2008) found that mtp53 types with a more folded conformation 
appear to have longer half-lives and are dependent upon hsp90 for sustaining this 
conformation (51). The authors showed that inhibiting Hsp90 using the compound 
17-AAG led to an increase in the amount of p53 bound to hsp70 as well as increased 
p53 degradation of by the E3 ligase; CHIP. This again indicates that CHIP is one of the 
p53 E3 ligases best able to recognize p53 in its mutant form. Promotion of this 
activity may therefore be a useful therapy and 17-AAG has been pursued as a 
potential chemotherapeutic (62). Although it should be noted that the use of 17-
AAG is not restricted to cells with mutant p53 as it is important in the regulation of 
various oncogenic proteins. 
 
1.7 Mutations in MDM2 
Whilst mutation of p53 is a relatively common event mutation of MDM2 is 
rarely seen. Nonetheless a few cases of MDM2 mutation have been observed in 
cancer; Schlott et al. (1997) found mutations within the zinc finger region in a 
number of tumours (63). Lindstrӧm et al. (2007) later showed that these mutants 
have impaired ability to promote the degradation of p53 but retain the ability to 
repress p53 transcriptional activities (64). They also showed that such mutations in 
MDM2 prevented the binding of ribosomal genes including RPL11. RPL11 is thought 
to have a role in preventing MDM2 mediated repression of p53 during ribosomal 
stress thereby inducing cell cycle arrest. It was postulated therefore that these 
mutations could help tumours become insensitive to anti-growth signals generated 
by ribosomal stress (64). 
A single nucleotide polymorphism within the MDM2 promoter region has also 
been shown to be relevant in cancer susceptibility. SNP309 in the promoter of 
MDM2 has been shown to lead to enhanced binding of the SP-1 transcription factor 
leading to greater transcription and higher protein levels (65). SNP309 has been 
identified to be associated with earlier onset cancer (65) presumably as a result of 
p53 repression and other oncogenic abilities. 
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In view of the fact that MDM2 is largely considered to be oncogenic it is 
unsurprising that inactivating mutations are not generally observed. Whilst 
mutation of the MDM2 gene is thought to be a relatively rare event, MDM2 gene 
amplification in cancer is relatively frequently observed and is associated with 
protein overexpression (26, 66). This will be discussed below (See mechanisms of 
MDM2 overexpression). 
  
1.8 Dysregulation of wtp53 and MDM2 
As discussed, the loss of p53 activity is thought to be crucial to cancer 
progression and the frequency of p53 mutation is very high. Despite this a number 
of tumours retain wt p53, and p53 mutation is in fact a relatively uncommon event 
in some cancer types (67-69). However, in such cancers p53 activity is generally 
thought to be repressed by alternate mechanisms. As discussed, amplification of 
MDM2 is a relatively common occurrence in cancers and is thought to act to prevent 
p53 activation (70, 71). Other mechanisms of p53 activity repression have also been 
identified and include direct inhibition of p53 or promotion of MDM2 activities (72-
75). 
 
1.8.1 MDM2 overexpression 
MDM2 overexpression is a relatively frequent event in cancer and gene  
amplification is seen in many, but not all, cases (26). Alternative potential 
mechanisms of MDM2 overexpression include increased transcription, translation or 
stability changes. The overexpression of MDM2 results in inhibition of p53 which 
prevents its activation and promotes cell survival (76, 77). Interestingly, mutation of 
p53 is rarely seen alongside MDM2 gene amplification (26, 66) presumably as the 
major pressure for either genetic derangement is repression of wtp53. However in 
some cases MDM2 amplification and p53 mutation are seen together (26, 66), this 
suggests that both MDM2 and p53 mutation can independently offer some 
increased oncogenic abilities. 
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MDM2 can also be found to be overexpressed in the absence of gene 
amplification (26). The mechanisms by which such alterations actually occur in 
cancers are not clear however some potentially important factors are discussed. 
One potential mechanism is the alteration of MDM2 stability; a number of 
factors which are able to effect the degradation of MDM2 are altered in cancer. An 
example of this is β-TrCP1.  MDM2 is able to auto-ubiquitinate, however it has also 
been shown that it can be ubiquitinated by the E3 ligase β-TrCP1 (78). 
Ubiquitination by β-TrCP1 requires MDM2 to be phosphorylated at multiple sites; a 
process that requires CK1 (78). β-TrCP1 has been observed to be mutated in some 
cancers however overexpression is seen in others, leading to speculation as to 
whether β-TRCP is a tumour suppressor or an oncogene (79). Nonetheless it 
remains possible that altered activity within the β-TRCP pathway in certain cancers 
represents a mechanism of MDM2 dysregulation.  
An alternative pathway affecting MDM2 stability is interaction with SKI. SKI is 
an oncogene which has found to be overexpressed in a number of cancers (80), one 
proposed mechanism of action is its ability to increase MDM2 levels (81). SKI 
interacts with Ubc9, a SUMO conjugating E2, which leads to the increased 
sumolyation of MDM2 which enhances its stability (81). However, once again, the 
actual contribution of this pathway to p53 repression needs to be further explored 
in cancers. 
A number of studies have shown that some patient samples contain 
overexpression of MDM2 concomitant with increased MDM2 mRNA but without 
gene amplification (26). One potentially important mechanism for increased 
transcription relies on the NFAT1 transcription factor. NFAT1 has been shown to 
increase MDM2 transcription from the P2 promoter (27). NFAT1 has been shown to 
be overexpressed in certain cancers and this overexpression correlates with MDM2 
overexpression (27). 
Finally, it has also been shown that an increased rate of translation may also 
be important in MDM2 overexpression. Landers et al. (1997) showed that the 
MDM2 increase in a number of melanoma cell lines resulted from relatively small 
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increases in mRNA production from the P2 promoter (25). In normal cells expression 
from the P2 promoter is thought to be more important in induced expression as it is 
p53 responsive (24). The authors showed that the transcript produced had a shorter 
5’UTR and 3-6 fold increased translation in comparison to the transcript from the P1 
promoter (25). This means that which transcript is produced will also affect the rate 
of translation. 
 
1.8.2 Other mechanisms preventing p53 activity 
Whilst MDM2 overexpression is a relatively common occurrence in wtp53 
cancers, not all wtp53 cancers show overexpression of MDM2 and a number of 
other mechanisms by which p53 can be repressed have been identified. In some 
cancers the MDM2 family protein MDMX is also found to be overexpressed (73). 
MDMX appears to be a negative regulator of p53 however it has not been shown to 
have appreciable p53 E3 ligase activity. Nonetheless its activity as a negative 
regulator of p53 is exemplified by the fact that MDMX knockout is embryonically 
lethal but is rescued by p53 knockout (82). MDMX appears to act on p53 directly by 
binding and blocking the transactivation domain (83) but also indirectly by 
stabilising MDM2 (84).  Furthermore, research has shown that overexpression of 
MDMX can inhibit the activation of p53 by the MDM2 inhibitor Nutlin and therefore 
suggests that MDMX may be an important potential target in certain cancers (85).  
The p53 family protein, p73, is generally thought of as a tumour suppressor 
gene however it has been shown that it can be overexpressed in cancer (72). 
Research has shown that specifically a splice variant of p73 lacking the 
transactivation domain ΔNp73 may be overexpressed (72). ΔNp73 binds to and 
inhibits both p53 and full length p73 resulting in enhanced drug resistance and 
reduced apoptosis (72) suggesting that ΔNp73 may be a particularly important 
factor in cells expressing wtp53. 
Loss of expression from the CDKN2A locus on chromosome 9p21 is another 
relatively common occurrence in cancer (74, 75) which has been suggested to 
impact p53 activity. This gene expresses alternative transcripts which encode the 
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proteins p14ARF (ARF) and p16INK4a (INK4a)(86). INK4a is an inhibitor of cyclin 
dependent kinases, cdk4 and cdk6. Cdk4 and cdk6 promote cell cycle progression 
and thus INK4a inhibitory action can lead to cell cycle arrest (86). Likewise ARF also 
acts to inhibit the cell cycle but in a p53 dependent manner. ARF binds to and 
inhibits MDM2 thus promoting p53 activation (87, 88). Silencing of ARF in mice has 
been shown to lead to them becoming highly prone to tumour development (89), 
however such mice do not succumb to the same spectrum of tumours as p53 
knockout mice (89) suggesting that p53 independent functions exist. Some studies 
have shown that MDM2 overexpression and ARF loss tend to be seen in wt-p53 cells 
(74) and that MDM2 overexpression and ARF loss tend to be exclusive (75) 
suggesting that the inhibition of p53 is the reason such changes occur. However, 
other studies have shown that such events are not exclusive (90) and thus suggest 
that other p53-independent mechanisms of ARF loss may be important for 
tumourigenesis in some cancers. Nonetheless this does not discount the idea that 
ARF loss is a major mechanism of p53 inactivation in cancer. 
A final example of a potentially important mechanism in repressing p53 is 
the overexpression of TWIST. TWIST is an oncogene that has been shown to be 
overexpressed in some cancers and binds to, and inhibits the activity of p53 (91). 
TWIST has been shown to bind to p53 and block its phosphorylation at ser392 which 
enhances the availability of p53 to MDM2 (91). 
These examples of mechanisms of p53 activity repression are not exhaustive 
and it is likely that many mechanisms are yet to be discovered. Identification of such 
mechanisms is critical and many may represent drugable targets to aid cancer 
treatment (See 10.10.1 Activation of wtp53).  
 
1.9 p53 independent roles of MDM2 
As discussed MDM2 is frequently overexpressed or misregulated in cancer. 
This is often considered to occur because of its role in the regulation and 
degradation of p53. However, whilst p53 mutation and MDM2 overexpression are 
more frequently not seen together this is not always the case. This hints at the 
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possibility that other p53-independent roles may contribute to cancer. In is 
becoming apparent that MDM2 is important in multiple p53 independent pathways. 
It has been shown that whilst p53-/- mice and p53-/- mice overexpressing MDM2 give 
rise to tumours with a similar frequency the spectrum of tumours is changed 
suggesting a p53 independent role of MDM2 in tumourigenesis (92). Furthermore 
MDM2 splice variants which cannot bind p53 have also been seen to be oncogenic 
(93).  
MDM2 can affect the cell cycle via its interaction with a number of proteins 
including Rb family proteins. When Rb is in an unphosphorylated form it binds to, 
and represses, the transcription factor E2F1 which normally acts to promote cell 
cycle progression (55). There is significant cross-talk between the p53 pathway and 
the Rb pathway however it appears that MDM2 can have a regulatory role in the 
pathway independently of p53 (55). It has been shown that MDM2 is capable of 
ubiquitinating Rb and so promotes its degradation. Overexpression of MDM2 
therefore represses the tumour suppressor activities of Rb (94). The relief of Rb 
negative regulation of E2F1 also leads to an up-regulation of genes including 
DNMT3A (95). DNMT3A leads to the silencing of genes including tumour suppressor 
genes by DNA methylation. MDM2 also appears to be able to directly enhance E2F1 
activities independently of Rb ; MDM2 binds to E2F1 which reduces the ability of 
SKP2, the E2F1 E3 ligase, from binding and ubiquitinating E2F1 (96). 
MDM2 is also able to act as an E3 ligase for the protein Numb; a protein 
important in cellular differentiation.  It is thought to act as a tumour suppressor by 
multiple mechanisms including reducing the interaction of MDM2 and p53 (97) and 
also through its inhibitory action on notch (98). The balance between notch and 
Numb is important in controlling cell proliferation and the loss of Numb is thought 
to be particularly important in breast cancer (98). Overexpression of MDM2 is 
thought to reduce the levels of Numb and it has been shown that high levels of 
MDM2 negatively associate with Numb (97). 
Additionally, MDM2 has also been demonstrated to be capable of increasing 
the transcription of the Nf-κB subunits. Nf-κB has numerous functions in the cell 
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including roles in apoptosis, inflammation, immunity and cancer (99, 100). Nf-κB is 
considered to be oncogenic as it frequently acts as an anti-apoptotic factor (99). Gu 
et al. (2002) showed that increased MDM2 levels lead to an increase in the Nf-κB 
family protein p65, which increased doxorubicin resistance (101). In the presence of 
p53 MDM2 appeared to relieve negative regulation of p53 on p65. However, in the 
absence of p53 MDM2 still increased p65 levels and was seen to directly bind to the 
promoter. Similarly Vaughan et al. (2011) found that MDM2 can lead to the up-
regulation of the p100/p52 Nf-κB subunit in a p53 independent fashion which lead 
to an increase in the transcription of Nf-κB target genes and also enhanced cell 
survival (102).  
MDM2 has also been shown to interact with a number of ribosomal subunits. 
A number of studies have shown that this interaction can inhibit the E3 ligase 
activity and promote p53 (103). It has been suggested that this provides a functional 
link between ribosomal stress and apoptosis. As mentioned previously MDM2 has 
also been shown to be capable of binding RNA strands and can positively regulate 
p53 transcription (21). The fact that MDM2 can bind both RNA and ribosome 
proteins has led to further speculation as to whether MDM2 may have a greater role 
in transcriptional regulation of other proteins. It has since been found that MDM2 
also regulates the transcription of XIAP (104). XIAP is an anti-apoptotic protein 
which is important in survival in stress conditions. Gu et al. (2009) showed that 
MDM2 is capable of binding the internal ribosome entry site of XIAP and enhance its 
translation (104). This effect was shown to be important in mediating resistance to 
stress such as ionising radiation. 
 
1.10 Targeting p53 
As discussed the p53 pathway is an attractive therapeutic target, however 
there are multiple ways in which it could be targeted, in part depending on the p53 
status of the cell. If wtp53 is present in the cell then therapy can aim to enhance its 
activation. If mtp53 is present therapy can aim either to reactivate p53, in order to 
bring about wild-type function, or alternatively abolish any oncogenic gain of 
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activity the protein may have. Targeting the oncogenic p53 function could be 
achieved by two different methods, either such functions could be identified and 
specifically targeted or degradation of mtp53 could be enhanced in order to reduce 
all potentially oncogenic activities. The various ways of targeting wtp53 and mtp53 
are summarised in Fig 1.4 and a number of examples are discussed below.  
The different approaches to p53 targeting highlights the requirement to know 
the mutational status of p53 in the cancer. For example administering a therapy 
which activates p53 would be useful for patients with wtp53 cancers but could be 
useless or potentially detrimental to those harbouring p53 mutations.  





Fig 1.5. Targeting wtp53 and mtp53 (Fig modified from Hupp et al. (2012) (105)). Wtp53 can be 
targeted by manipulation of factors controlling activation, transcription, unfolding, export and 
degradation. Mutant p53 can be targeted by promotion of wild-type function (Reactivation), removal 
of protein (Degradation, Transcription) or inhibition of specific gains of function. Examples of 
potential targets or drugs to manipulate these factors are shown.  
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1.10.1 Activation of wtp53 
Many cancers retain wtp53 and there are a number of cancer types where 
p53 is rarely mutated (67-69). It has been suggested that direct p53 activation 
should be more harmful to cancer cells than normal cells and some studies have 
shown that activation is more likely to causes apoptosis in cancer and cell cycle 
arrest in normal cells (106, 107), however this will likely be dependent on the 
particular mechanism utilised. As p53 interacts with such a large number of other 
proteins it could potentially be activated by a number of mechanisms. Therapy 
could potentially seek to alter p53 stability, subcellular localisation (export), 
transcriptional abilities, folding or the activity of p53 activating kinases (Fig 4). 
Examples of compounds or targets affecting these different mechanisms will now be 
discussed and the structures of these compounds are detailed in Fig 1.6.  
The stability of p53 could be increased by targeting factors involved in the 
degradation of p53. Inhibiting the activity of MDM2 is thought to be a particularly 
attractive option as MDM2 is overexpressed in many cancers (26). A number of 
MDM2 inhibitors have been developed but the furthest advanced is Nutlin. Nutlin-3 
is the most commonly used variation of this drug and its structure is shown in Fig 
1.6. The Nutlin compounds mimics 3 residues within the transactivation domain of 
p53 and thus competitively inhibits the binding of p53 with MDM2 (108). At least 
within cancer cells inhibition of MDM2 appears to be sufficient to activate p53 and 
Nutlin was shown to lead to p53 dependant apoptosis and cell cycle arrest in cancer 
cells. Furthermore in studies on mice with human tumour xenographs treatment 
with non-toxic doses of Nutlin lead to tumour shrinkage (108). Nutlin is now in early 
stage clinical trials (109). 
An alternative way to increase the stability of p53 is inhibition of the 
proteasome. Clearly this is a less specific therapy which would affect proteins 
outside the p53 pathway however a number of proteasome inhibitors are being 
considered for, or used as, cancer therapeutics. This includes Bortezomib which is 
currently used in the treatment of multiple myeloma and mantle cell lymphoma 
(110). These drugs are thought to work because a number of tumour suppressor 
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proteins are removed from cancer cells due to rapid turnover by the proteasome 
system, thus inhibition of this system will allow these proteins to accumulate and 
inhibit or kill the cancer cell (110). Clearly this approach is relatively non-specific but 
data supports the fact that Bortezomib causes apoptosis in cancer cells (110, 111). 
Studies have shown that Bortezomib does lead to the accumulation and activation 
of p53 (111) however studies have found that cell death in some cancers appears to 
be independent of p53 (112, 113). This may be because other accumulating pro-
apoptotic factors in certain cells are able to more rapidly induce apoptosis. 
Altering subcellular localisation has also been seen to influence p53 activity. 
In order to be transcriptionally active p53 needs to be located to the nucleus and 
nuclear export can prevent its activation. The compound Leptomycin B (LMB) which 
inhibits the nuclear export protein CRM1 has been shown to increase the activity of 
p53 (114). Again, it should be noted that CRM1 inhibition will also affect a number 
of other proteins which could contribute to its activity. Inhibition of CRM1 prevents 
the degradation of p53 and sequesters p53 in the nucleus which is required for its 
activity (115). LMB showed significant toxicity in vivo, however newer nuclear 
export inhibitors are being developed which have lower toxicities. For example 
Mutka et al. (2009) showed that a LMB derivative lead to apoptosis in cancer cells 
but cell cycle arrest in normal cells and additionally was shown to have an anti-
tumourigenic effect in vivo in a mouse model (116). 
A further example of a potential therapeutic which activates p53 is Tenovin; 
Tenovin was discovered via a screen of small molecules using cells with a p53 
responsive β-gal reporter construct (117). Fig 1.6 shows the structure of Tenovin-6 a 
more water-soluble and therefore more easily administered version of the original 
Tenovin molecule (117). Characterisation showed that Tenovin leads to p53 
activation and cell death in culture and reduced tumour growth in vivo (117). This 
effect was suggested to be promoted by p53 activation but it was shown that p53 
activity was not essential as Tenovin could kill cells with mtp53 or no p53 (117). The 
target of Tenovin was shown to be SirT1 and SirT2 deacetylases which act to 
deacetylate p53 as well as other targets (117). SirT1 is known to deacetylate p53 at 
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ser382 decreasing its activity and Tenovin was also shown to increase p53 
acetylation at ser382 and increase its activity (108). 
The conformation of p53 is also important for its activity. A recent study by 
Fraser et al. (2010) demonstrated that the phosphorylation of p53 at either of two 
residues (ser215 and ser269) can promote p53 to attain an unfolded mutant-like 
conformation which is transcriptionally inactive; this may be an important 
mechanism of p53 control (118). This is particularly interesting in the pursuit of p53 
activating therapies as inhibition of Aurora kinase which phosphorylates p53 at 
ser215 has been proposed as a potential chemotherapeutic. Inhibition of Aurora 
kinase with MLN8054 has been shown to increase p53 and p21 and leads to 
senescence both in vitro and in vivo (119). A number of Aurora kinase inhibitors are 
being pursued in clinical trials. The requirement for p53 in mediating the effects of 
Aurora kinase inhibition is unclear, it is possible that the status of p53 plays a part in 
determining the specific route of action but may not be specifically required for an 
anti-tumorigenic effect (120).  
Factors important in attenuating p53 activity in cancer are slowly being 
uncovered and a number of these may well represent targets that will in the future 
lead to therapies. One such proposed target is TWIST, as discussed earlier the 
binding of TWIST to p53 prevents the phosphorylation of p53 at ser392 repressing 
its activity (91). TWIST represents a potential therapeutic target and is of particular 






Fig 1.6 Chemical activators of wtp53. 
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1.10.2 Reactivation of mtp53 
There are a number of potential methods by which mtp53 could be targeted 
(Summarized in Fig 1.4). Much effort has been put into the discovery of techniques 
to reactive mutant p53. Proof of concept experiments have shown that many p53 
mutants are reactivatable for example it has been shown that both DNA binding and 
conformational mutants are rescuable by second site mutations; proving that 
manipulation outside of the mutation site can restore function (121, 122). In a 
further proof of concept experiment Selivanova et al. (1999) showed that short 
peptides derived from the C-terminus were capable of restoring some binding 
ability to the response element of certain p53 mutants and more critically promote 
p53 dependent apoptosis (123). The C-terminus of p53 is thought to have an 
allosteric negative regulatory function. The short peptides used by Selivanova et al. 
(1999) were shown to bind to the C-terminus and the core domain. It was suggested 
that it functions by displacing the C-terminus regulatory region and so helping to 
keep p53 in an active conformation. Additionally it may help to stabilize the core 
domain or promote novel contacts as the peptide did appear to be able to bring 
functionality to mutants with mutations in DNA contact regions. 
Whilst these proof-of-concept experiments enhance our confidence that 
activity can be restored to certain mutants, and furthers our understanding of the 
control of p53, small molecules will likely have the greatest chance of yielding a 
clinically effective therapy. Numerous screens for molecules capable of reactivating 
p53 have been undertaken and have led to the discovery of a number of molecules 
including CP-31398, PRIMA-1, MIRA and WR-1065 (124-127). Whilst these all have 
been shown to enhance p53 binding to its response element, increase the levels of 
p53 controlled proteins or mediate apoptosis the mechanisms by which this 
happens has often proved difficult to elucidate.  
CP-31398 was identified in a screen to find chemicals which could restore 
normal p53 DNA binding domain conformation (126). This was determined by 
binding the PAb1620 antibody which is specific to p53 with normal conformation. 
CP-31398 was shown to lead to p53 activation in both wtp53 and mtp53 cells and 
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inhibits the growth of cell lines and xenograph tumours (126, 128). However the 
mechanism is yet to be elucidated and CP-31398 does not appear to directly bind 
p53 (129). In wtp53 cells it has been shown that CP-31398 reduces p53 
ubiquitination without blocking MDM2 and p53 binding (128). Interestingly 
activation of mtp53 does not lead to the transcription of all the expected activated 
wtp53 regulated genes and only activates a specific subset (130). There is however 
considerable debate as to whether all the effects of CP-31398 are p53 dependent or 
not (131, 132) . It appears that CP31398 has a complex mechanism of action 
affecting a number of pathways including p53. 
Whilst PRIMA-1 was discovered in 2002 (124) its mechanisms of action are 
also still unclear. PRIMA-1 was again identified by screening and a number of reports 
have shown that PRIMA-1 can restore sequence specific binding and transactivation 
to a number of p53 mutants (124, 133). It has been shown that PRIMA-1 needs to 
be broken down in the body in order to be biologically active and one of the 
degradation products then alkylates thiol groups on p53 (133). Critically this may be 
a common mechanism shared with other mtp53 activators. Research has shown 
that oxidation reactions may be important in the regulation of p53 and that the 
formation of disulphide bonds inhibit its ability to bind DNA (134). Modifications 
such as the acetylation of thiol groups could prevent the formation of disulphide 
bonds and so it is feasible that compounds which could promote p53 reduction may 
be able to alter p53/mtp53 conformation and activity. The mechanism of action of 
PRIMA however still remains controversial and other reports have suggested that 
the effect of PRIMA-1 may be independent of transcription or even independent of 
mtp53 (135, 136). Such data suggests that PRIMA-1 may function via a number of 
complex mechanisms nonetheless PRIMA-1 appears to be a potentially useful 
chemotherapeutic agent and is currently in early stage clinical trials (137).  
Another drug suggested to potentially reactivate p53 by interaction with 
thiol groups on p53 is MIRA (127). MIRA was shown to increase the proportion of 
mtp53 with wild-type-like conformation, increase DNA binding as well as the 
expression of p53 responsive genes (127). Furthermore it was shown to have anti-
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tumourigenic effects both in vitro and in vivo however did show toxicity in mice at 
higher doses (127). It was found that a number of MIRA-1 analogs showed the 
ability to reactive p53 and critical to this activity was the presence of a reactive 
group that was surmised to be able to react with thiol and amino groups (127). 
WR-1065 is an aminothiol with cytoprotective effects in normal cells 
compared to cancer cells (138). It has also been shown that WR-1065 can also cause 
the activation of wtp53 as well as mtp53 (125, 139). North et al. (2002) showed that 
WR-1065 was able to restore partial function to a temperature sensitive p53 mutant 
at a non-permissive temperature (125). This was concomitant with an increase in 
p53 in the normal conformation suggesting that WR-1065 is capable of modifying 
p53 conformation to increase its activity. Similar to PRIMA-1 and MIRA-1 this 
compound also contains reactive groups which may directly interact with p53 and it 
has been shown that MIRA-1 can cause the reduction of p53 which enhances its 
DNA binding ability (139).  
In an alternative approach to identify compounds that are able to increase 
the thermostability of p53, Boeckler et al. (2008) used an in silico screening 
approach to identify a compound which increases the activity of p53-Y220C. This 
mutation causes a crevice in the structure which reduces its thermostability (140). 
The authors used a modeling approach to select drugs which would bind in this 
crevice. PhiKan083 was shown to bind in this crevice and enhance the stability of 
the protein. However further work will be required to assess the biological effect of 
the drug in vitro and in vivo. 
Further investigations into the mechanisms of molecules that reactive p53 
will help to understand p53 regulation as well as allow rational design to optimize 
these compounds and discover new ones. 
 
1.10.3 Degradation of mtp53 
Reactivation of mt53 represents the ideal therapeutic scenario as it would 
both remove the pro-oncogenic signal (mtp53) that the cancer is dependent upon 
and also reintroduce the tumour suppressor signal provided by a functionally 
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normal p53. However this represents a huge challenge and it is possible that some 
mtp53 is too abnormal to be refolded. An alternative and somewhat more simplistic 
method is to just reduce the levels of p53. To date only a small number of drugs 
have been identified which are able to accomplish this, which is likely due to the fact 
that research has mainly focussed on identification of compounds which can 
reactivate mtp53. Nonetheless proof-of-concept experiments have shown that 
siRNA knockdown of mtp53 in cells leads to cell death indicating that many tumours 
may be reliant on oncogenic mtp53 (52, 141). Furthermore introduction of mtp53 
into null cells increases resistance to classic chemotherapeutics (32) suggesting that 
combined therapy may be useful. 
As discussed above (see Regulation of mtp53) the Hsp90 inhibitor 17-AAG 
can induce the degradation of a number of oncogenic proteins including mtp53 (51). 
Inhibiting Hsp90 prevents this chaperone protein from binding mtp53 and allows it 
to become available to the degradation machinery (51). This approach is useful as it 
exploits a mechanism that is altered in the processing of mtp53. Because mtp53 
binds much more stably to Hsp90 than wtp53 it has little effect on wild-type p53 
levels (51). Hsp90 inhibitors are considered to be a potentially very useful 
therapeutic and a number of them are currently in clinical trials (62). Although it 
should be noted, that these inhibitors lead to changes in a number of oncogenic 
proteins not just p53.  
As discussed previously (see Activation of wtp53) PRIMA-1 is a drug that was 
identified as capable of reactivating p53 and leading to apoptosis. Its mechanism of 
action however is complex and contradictory evidence exists as to how it affects 
mtp53. It has been suggested that its ability to cause apoptosis may be better linked 
to its ability to reduce mtp53 rather than activate it. Russo et al. (2010) showed that 
PRIMA-1 leads to the degradation of mtp53 by the proteasome (142). This result 
may not however be contradictory to previous results showing that PRIMA-1 
reactivates mtp53; if mtp53 achieves a more normal conformation it may help it to 
become available to the degradation machinery and so levels of the highly 
accumulated protein would fall.  
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Interestingly arsenic which is used to treat acute promyelocytic leukemia has 
also been shown to be able to promote degradation of a number of proteins 
including mtp53 (143). Conversely arsenic does not cause the degradation of wtp53 
but induces its expression (143). However arsenic clearly does not represent an 
advance in therapy and has severe toxic side effects. Nonetheless it may be useful to 
deduce the mechanism of action so that a more specific and less toxic therapy can 
be identified.  
Finally, whilst p53 is normally degraded by the proteasome it may also be 
useful to consider other routes of degradation. Abnormally aggregated protein are 
often degraded by autophagy. Autophagy is often altered in cancer and it has been 
shown that mtp53 can inhibit autophagy (144). Rodriguez et al. (2012) however 
showed that if cells are deprived of glucose then this can reduce mtp53 acetylation 
and promote its degradation by autophagy (145). This led to a robust autophagy 
activation leading to cell death. They further showed that when nude mice were fed 
a low carbohydrate diet this reduced tumour formation by injection of cancer cells 
compared to controls. The authors suggest that if further work supports the 
generality of their results a low glucose diet may be useful for people with Li-
Fraumeni syndrome. Whilst diet is clearly unlikely to cure cancer understanding such 
pathways clearly enhances our chances of identifying useful targets to lower p53 
levels. 
 
1.10.4 Suppression of mtp53 activity 
Mtp53 leads to a number of oncogenic changes and thus research into 
mtp53 can lead to the identification of new targets. Targeting of such proteins may 
not always be reliant on p53 as such factors may be controlled by a number of 
mechanisms. However one drug which has specifically been identified to interfere 
with mtp53 activity is RETRA. RETRA was discovered in a high-through put screen of 
cells with a p53 activated β-gal reporter gene (146).  RETRA was shown to activate 
apoptosis in cells with mtp53 but not wtp53 (146). This activation was also shown to 
be p73 dependent and functions by preventing mutant p53 repression of p73, thus 
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allowing p73 to activate p53/p73 target genes. The exact mechanisms by which this 
alleviation of repression occurs needs to be further investigated however RETRA 






As discussed above p53 is thought to be a useful potential target in the 
treatment of cancer and p53 could be targeted via a number of mechanisms 
depending on the p53 status within the cell. Investigation of the p53 pathway has 
revealed that a large numbers of proteins are important in the regulation of p53 
stability, localisation and activity. As discussed a number of p53 activators have been 
identified and are in various stages of development. However the identification of 
other such targets will provide us with more potential tools to attack different 
cancers and help further our understanding of p53 in cancer. Additionally by 
comparison very little is known about the regulation of mtp53. Clearly investigation 
into the control of mtp53 is vital as mtp53 is present in around half of all cancers 
and can be critical to tumour survival.  
This project initially aimed to investigate two of the potential ways of 
targeting p53, namely activation of p53 in cells with wild type p53 and degradation 
of p53 in cells with mutant p53. This was accomplished using various screening 
methods to identify compounds capable of these effects (Chapter 3). As will be 
described screening led to the identification of a number of inhibitors able to affect 
either the activity or stability of mtp53 or wtp53 respectively. Of particular interest 
were two IKKβ inhibitors which lead to the reduction of mtp53. Thus the focus of 
this work was then to further characterise inhibition of this pathway in terms of its 
effect on p53. The aim was to use classic molecular and biochemical techniques 
(Chapter 4) as well as proteomic techniques (Chapter 5) to elucidate important 
effector and co-regulated proteins within this pathway. The ultimate goal was to 













2. Materials and Methods 
2.1 Reagents 
All Reagents were purchased from Sigma Aldrich unless otherwise stated. All tissue 
culture reagents including DMEM, RPMI and Trypsin were purchased from 
Invitrogen. FBS was purchased from Biosera.  
 
2.2 Equipment 
DNA concentration was measured using a NanoDrop spectrophotometer. Bradford 
and BSA assay was measured on a PerkinElmer VICTOR 1420 Multilabel counter. 
Alamar Blue intensity was measured on a PerkinElmer Envision Multilabel reader. 
qPCR was conducted using a PTC-200 Peltier Thermal cycler. PCR was conducted 
using a PTC-225 Peltier Thermal cycler. X-ray films were developed using a Mediphot 
937 developer. SDS-PAGE was carried out using Biorad II Minigel System. In cell 
western results were analysed using an Odyssey SA plate reader. Mass spectrometry 
analysis was completed using an ABSciex Qstar Elite or ABSciex 5600.  
 
2.3 Cell procedures: 
2.3.1 Tissue culture 
All cells were grown in humidified incubators at 37oC. The CO2 saturation for each 
cell line is indicated in Table 2.1. All cells lines were grown in either RPMI or DMEM 
as indicted in Table 2.1. Cells were passaged between 1-3 times per week as 
required. Passaging was conducted as follows. Media was discarded and then cells 
were washed with sterile PBS (10ml/10cm plate) and Trypsin was added (2ml/10cm 
Plate). Plates were then incubated for ~5-10mins at 37oC until cells became 
detached from the plate. Media was then added to plate (8ml/10cm plate) and cells 
were then re-plated at the desired dilution. 
 
Table 2.1 Cell lines and culture conditions used in this study 
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Name Cancer Type p53 Status Media % CO2 Maximum Dilution at 
passage 
T47D Breast L194F RPMI 5% 1:5 
A375 Melanoma Wild type DMEM 10% 1:10 
ARN8 A375 with stabily 
integrated p53-βgal 
reporter gene 
Wild type DMEM 10% 1:10 
BT-549 Breast R249S DMEM 5% 1:5 
H1299 non-small cell lung 
carcinoma 
Null RPMI 5% 1:10 
MDA-
MB-231 
Breast R280K RPMI 5% 1:10 
 
2.3.2 Freezing of cells 
For long-term storage all cells were kept in liquid nitrogen storage tanks. Cells were 
grown to confluency in a 10cm plate. Cells were then trypsinised by the same 
procedure as during cell passaging. Once the cells had detached, and media was 
added, cells were pelleted by centrifugation at 1000rpm for 5mins. The media and 
trypsin was then discarded. Cells were then resuspended in 5mls of cell freezing 
solution composed of 10% DMSO in FBS. The resuspended cells were then split into 
~5 Nunc cryovials. Vials were then frozen at a rate of 1oC per minute in an 
isopropranol bath before being transferred to liquid nitrogen storage. When cells 
were recovered they were rapidly thawed in a 37oC water bath before being plated 
into 10cm plates with 9ml of media. After 24Hrs the media and freezing solution 
was discarded and fresh media added. Cells were then grown to confluency before 
their first passage.  
 
 
2.3.3 Drug treatment 




Cells were seeded in 10cm, 6cm, 6well, 24well, or 96well plates 24Hrs prior to 
treatment. The compounds were diluted to the appropriate concentration (Detailed 
in Table 2.2) in cell culture media. As a control DMSO only was also diluted to the 
equivalent concentration to media. These were then transferred to the cells and 
cells incubated for the stated time. 
 
Table 2.2 Compounds used in this study 
Drug Concentration Supplier 
Tocris kinase inhibitor toolbox 
(for details see  
supplementary data) 
50µM-0.4 µM Tocris 
LOPAC compounds 
(for details see chapter 1) 
50µM-0.4 µM Sigma 
MG132 10 µM Sigma 
Cycloheximide 30 µg/ml Sigma 
17-AAG 5uM-20nM LC Laboratories 
Nutlin 20uM-160nM Enzo Life Sciences 
LMB 30uM-230nM Sigma 
Roscovitine 50µM-0.4 µM Sigma 
BMS-345541 50µM-0.4 µM Sigma 
DMSO control 




2.3.4 Plasmid Transfection 
Transfection mixture (10cm Plate) 
5-10µg Plasmid DNA 
10-15µl Attractene 
Made up to final volume of 300µl with serum free media 
Cells were seeded 24Hrs prior to transfection and grown to 40% confluency. Media 
was discarded and fresh added just prior to transfection. Transfection mixture was 




2.3.6 FRT Stable cell selection 
Cells were transfected with the required plasmid and pOGG44 plasmid at a ratio of 
1:9 (0.5µg + 4.5µg or 1µg + 9µg respectively). A control plate of cells was transfected 
with pOGG44 only. 24Hrs after transfection media was supplemented with 
hygromycin to a final concentration of 50mg/ml. Media and hygromycin was 
refreshed every 2-3 days for ~2weeks until control cells had died and colonies were 
evident on the other plates. Colonies was then trypsinised from the plates, seeded 
in 10cm plates and grown to confluency. 
 
2.3.7 siRNA treatment 
Transfection solution 1 
190µl Serum free media 
4µl siRNA (from 20µM stock) 
Transfection solution 2 
190µl Serum free media 
4µl Dhamafect 4 
Cells were seeded in 6 well plates 24hrs prior to treatment. Media was discarded 
and fresh added just prior to transfection. Transfection solutions were made up as 
indicated and incubated for 5 mins at room temperature before the two solutions 
were combined. This solution was then incubated for a further 20 mins at room 
temperature before being added drop-wise to cells.  If required a second 




 Table 2.3 siRNA used in this study 
Target Final concentration Number of siRNA 
transfections 
IKKβ 40nM 2 
MDM2 40nM 1 
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MS hits library 40nM 1 
 
2.3.7 Harvesting cells 
When harvesting all plates were kept on ice. Media was discarded before cells were 
washed with cold phosphate buffered saline (PBS). Cells were scraped into 1ml cold 
PBS using a cell scraper and transferred to an eppendorf. Cells were then 
centrifuged at 5000rpm for 5Mins at 4oC. PBS was then discarded and pellets snap 
frozen in liquid nitrogen. 
 
2.3.8 Cell lysis 
NP40 Lysis Buffer 
1% NP40 
150mM NaCl 
50mM Tris-HCl pH8 
1mM DTT 
+ Protease inhibitor cocktail (Roche) 
Cells were lysed in NP40 lysis buffer unless otherwise stated. Cell pellets were 
suspended in 3 times pellet volume and incubated on ice for 20mins. The solution 
was then centrifuged at full speed for 10mins at 4oC in order to remove any 
insoluble material. Supernatant was then collected and either snap-frozen in liquid 
nitrogen and stored at -80oC or immediately used for further analysis. 
 
2.4 Assays: 
2.4.1 Determination of protein concentration 
For general use including protein concentration determination prior to SDS-PAGE 
protein concentration was determined by Bradford assay. For protect concentration 




2.4.2 Bradford assay 
Bradford reagent 
0.01% (w/v) coomassie blue G250 
4.25% Ethanol (v/v) 
8.5% Phosphoric acid (v/v) 
 
BSA standards (0.25-4mg/ml) were diluted 1µl in 200µl of Bradford reagent in a 96 
well plate (in triplicate). The same volume of each sample of unknown 
concentration was also added to 200µl Bradford reagent (in triplicate). The 
absorbance was then read at 595nm using a VICTOR 1420 multilabel plate reader. A 
standard curve was then created using absorbances for the BSA standards. Sample 
concentrations were then calculated from standard fit. 
 
2.4.3 BCA assay 
BCA assay was conducted using the Pierce BCA assay kit. Working reagent was 
prepared by combining reagents A and B at a ratio of 50:1. 10µl BSA 
standards/samples were then combined with 200µl working reagent in 96 well 
plates. Plates were then incubated at 37oC for 30mins. The absorbance was 
measured at 562nm. As with the Bradford assay, read-outs were converted to 
concentration with the use of a standard curve created from BSA standards. 
  





ARN8 (containing a stability integrated p53 β-gal reporter gene) cells were grown in 
24 well plates and treated as indicated. The media was then discarded and cells 
were washed with 1ml PBS. The cells were then incubated with 300µl fixing solution 
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for 10mins at room temperature. Cells were then washed twice in 1ml PBS. 300µl of 
staining solution was then added to each well and incubated at 37oC for 2Hrs. Cells 
were then visually inspected for the blue colouration. 
 
2.5 Microbiological techniques: 
2.5.3 Bacterial culture on agar plates 
LB agar (Luria-Bertani) 
1 % (w/v) Tryptone 
1 % (w/v) NaCl 
0.5 % (w/v) Yeast extract 
1.5 % (w/v) Agar 
Antibiotics: Ampicillin (50µg/ml), Kanamycin (100µg/ml) 
LB agar was melted in a microwave and allowed to cool to approximately body 
temperature to the touch. If antibiotics were required they were added at the 
appropriate concentration. The agar was then poured into 10cm petri dishes and 
left to set. Plates were stored at 4oC. Bacterial cultures were inoculated onto the 
plates either by picking colonies from previous plates or glycerol stocks and streaked 
using a sterile loop or by plating directly from transformed cultures. 
 
2.5.4 Bacterial culture in broth 
LB Broth (Luria-Bertani) 
1 % (w/v) Tryptone 
1 % (w/v) NaCl 
0.5 % (w/v) Yeast extract 
Antibiotics: Ampicillin (50µg/ml), Kanamycin (100µg/ml) 
5ml LB Broth (supplemented with selective antibiotics if required) was inoculated 
with a bacterial colony. This was incubated at 37oC for ~6Hrs at 225rpm. This starter 
culture was then added to 250mls LB (again supplemented with selective antibiotics 




2.5.1 Preparation of competent cells 
Buffer 1 




15% (v/v) Glycerol 
 Adjusted to pH 5.8 with acetic acid 





15% (v/v) Glycerol 
 Adjusted to pH 6.5 with KOH 
 Sterilised by filtration 
 
A 5ml LB Broth was inoculated with a DH5α bacterial colony from a stock plate. This 
was incubated at 37oC overnight at 225rpm. This starter culture was then added to 
250mls LB and incubated in the same conditions until the OD600nm was between 0.3-
0.5. The cells were pelleted by centrifugation (10min, 8000rpm, 4oC) and then 
resuspended in 80ml cold buffer 1. The sample was then incubated for 10mins on 
ice. Cells were again pelleted (5mins, 2500rpm, 4oC) and resuspended in 8mls cold 
buffer 2. Cells were incubated on ice for 15mins and aliquoted into 50µls. Samples 




2.5.2 Transformation of bacteria 
100μl of DH5α cells were defrosted on ice and 0.1-0.5μg of plasmid DNA was then 
added to the cells. The cells were incubated on ice for 1hr. The cells were then heat-
shocked by incubation in a water bath for 2 min at 42°C. The cells were then 
incubated on ice for a further 2 mins prior to the addition of 1ml LB media. The 
culture was incubated at 37 °C at 225 rpm for 30 mins. The culture was 
subsequently plated onto LB agar plates overnight at 37 °C. 
 
2.5.5 Glycerol stocks 
Glycerol stocks were used for the long-term storage of bacteria. 200µl of overnight 
bacterial culture in LB broth was added to 800µl of Glycerol. This was then snap-
frozen and stored at -80oC. 
 
2.5.6 Maxi/Mini preps  
Maxi/mini preps were used for purification of plasmid DNA from bacteria. DH5α 
cells were transformed with the appropriate plasmid. The bacterial cells were grown 
up in LB broth as described above. The bacterial cells were then pelleted by 
centrifugation at 6000rpm for 20mins at 4oC. DNA was isolated using Qiagen Mini or 
Maxi prep kits according to manufacturer’s instructions. DNA was eluted in 
nuclease-free H2O and stored at -20
oC. DNA concentrations were determined using 
a Nanodrop spectrophotometer. 
 
 
2. 6 Molecular Biology techniques: 
2.6.1 SDS-PAGE and Western blotting 
10% Resolution gel: 
30 % Acrylamide mix (30 % (w/v) acrylamide and 0.8 % (w/v) bis-acrylamide) 
1.5 M Tris (pH 8.8) 
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10 % SDS 




30 % Acrylamide mix (30 % (w/v) acrylamide and 0.8 % (w/v) bis-acrylamide.) 
1.5 M Tris (pH 6.8)  
10 % SDS  
10 % Ammonium persulphate 
TEMED 
 
SDS sample buffer 
125 mM Tris pH 6.8 
5 % (w/v) SDS 
25 % (v/v) Glycerol 
0.02 % (w/v) Bromophenol blue 
DTT (1 M) added fresh to buffer prior to use 
 
Running Buffer: 
192 mM Glycine 
25 mM Tris 





192 mM Glycine 
25 mM Tris 




Gels were made using Biorad system. Approximately 4ml of resolution buffer was 
made fresh and poured between the glass plates. Water was then added to the top 
to ensure a clean, straight edge to the resolution gel. The gel was then left to 
polymerise. Once set the water was poured off, stacking buffer was added and a 
comb was added to create the well. The stacking buffer was then left to polymerise. 
20µg of sample was combined with sample buffer. This was then boiled at 95oC for 
5mins. A protein ladder and the samples were then loaded onto the gels in biorad 
tanks. Running buffer was then added to the tanks and the gels run at 180-200V for 
~1hr until the bromophenol blue front reached the end of the gel. The glass plates 
were then opened up and the stacking gel sliced off. The gels were then gently 
transferred to blotting paper. Nitrocelulose membrane was added to the top of the 
gel and a second piece of blotting paper was added to the top. This was then 
sandwiched between 2 pads under transfer buffer to remove bubbles. This was then 
encased in a biorad cassette. The gels are then transferred in the biorad tanks at 
300mA for 90mins or 30mA overnight. 
 
2.6.2 Immunoblotting 
ECL Solution 1 
100 mM Tris pH 8.5 
2.5 mM Luminol  
0.4 mM p-Coumaric acid 
 
ECL Solution 2 
100 mM Tris pH 8.5 
0.02 % (v/v) H2O2 
Solutions stored at 4 ºC and protected from light 
 
5% Milk 




Following SDS-PAGE and transfer, membranes were blocked in 5% milk for 1hr at 
room temperature with shaking. The membrane was then incubated with primary 
antibody diluted to the appropriate concentration (as shown in Table 2.4) either at 
room temperature for 1hr or at 4oC overnight. The blot was then washed 3 times for 
5 mins each with PBS-t (0.1% (v/v) Tween 20 in PBS) to remove unbound antibody. 
The blot was then incubated with the appropriate secondary antibody (see Table 
2.4) at room temperature for 1hr. Again the blot was then washed 3 times for 5 mins 
each with PBS-t to remove excess antibody. The membrane was then incubated with 
ECL1 and ECL2 solutions mixed at a 1:1 ratio for 1min at room temperature. X-ray 



















































Abcam Sheep anti 
rabbit 
- 1:1000 - 
IKBα 
Abcam Swine anti 
rabbit 






- 1:1000 - 
p21 
Calbiochem Rabbit anti 
mouse 
- 1:1000 - 
β-Actin 
Abcam Rabbit anti 
mouse 
- 1:5000 - 
RPS3 
ProteinTech group Rabbit anti 
mouse 
- 1:1000 - 
Cyclin D1 
Calbiochem Rabbit anti 
mouse 
- 1:1000 - 
Cyclin D3 
Santa Cruz Rabbit anti 
mouse 





2.6.3 In cell western 
PBS-Triton 
1% (v/v) Triton in PBS 
Fixative solution 
3.8% (v/v) Formaldehyde in PBS-t 
3% BSA 
3% (w/v) Bovine serum albumin in PBS-t 
 
Cells were seeded in 96 well plates 24Hrs prior to treatment. Cells were then treated 
with the appropriate compound for the indicated time. After appropriate incubation 
the media is discarded and fixative solution added (100µl/well). The plates were 
then incubated at room temperature for 20mins. The cells are then permeabilised 
by 5 x 5min washes with PBS-Triton. The wells are then blocked to prevent non-
specific antibody binding with 3% BSA for 1Hr30mins at room temperature with 
shaking. All wells with the exception of 1 control well per plate were then incubated 
in primary antibody diluted (As indicated in Table 2.4) in 3% BSA for 2Hrs at room 
temperature with shaking or overnight with shaking. The wells are then washed 5 
times in PBS-t for 5mins each. Secondary antibody (diluted to 1:1000) and DRAQ5 
(diluted to 1:10000) in 3% BSA was then added to each well. The control well was 
incubated with secondary antibody only. Plates were incubated with shaking for 1hr 
at room temperature and protected from light. Wells were then washed 5 times 
with PBS-t for 5mins each. Plates were then scanned using an Odyssey SA plate 
reader. 
 
For all analyses average intensities were used. All antibody fluorescence levels were 
normalised against the secondary only control by deducting secondary only value 
from the primary values. These values were then normalised to total cells number 







DNA sequencing was carried out using the Big Dye Terminator V3.1 cycle sequence 
kit as follows. 
 
Master Mix      Parameters 
1µl Template 96oC 1 min 
10µM Primer (as indicated in Table 2.5)  96oC 10 secs 
2µl Big Dye      50oC 5 secs 
2µl Big dye sequencing buffer  60oC 4 mins 
 Up to 10µl with H2O    Cycle to step 2 x30 
 
The reaction mix was made up as indicated. The reaction was then conducted on a 
thermocycler at the indicated parameters.  
EDTA/Ethanol precipitation 
The PCR product was then transferred to a new tube and 2.5µl of 125mM EDTA 
added. 30µl of 100% Ethanol was then added to each sample to precipitate the 
DNA. Samples were mixed by vortexing and then incubated at room temperature for 
15mins. The precipitated DNA was then pelleted by centrifugation (13000rpm, 
20mins) and the ethanol was removed. Samples were then centrifuged for a further 
5mins and any remaining ethanol removed. 30µl of 70% Ethanol was then added to 
each sample and samples were centrifuged at 13000rpm for 5mins at 4oC and the 
Ethanol discarded. Samples were centrifuged again at 13000rpm for 5mins at 4oC 
and any residual ethanol removed. Samples were then allowed to dry in a fume 




Table 2.5 Sequencing primers used in this study 
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Name Site Sequence 
IKKβ-pEF5/FRT/V5-DEST 1 Within pEF5/FRT/V5-DEST 1 
vector prior to gene integration 
site 
GTAAAACGACGGCCAG 
IKKβ-pEF5/FRT/V5-DEST 2 Within IKKβ CAAGCTCTTTACCCTACCC 
IKKβ-pEF5/FRT/V5-DEST 3 Within IKKβ GCCACACATTGGACATGGA 
IKKβ-pEF5/FRT/V5-DEST 4 Within IKKβ CTGCTGCTGGCCTGGAG 
 
2.6.5 qPCR 
2.6.5.1 RNA extraction  
Cells were seeded in 6 well plates and treated as indicated. After treatment cells 
were harvested as normal and RNA was extracted using a Qiagen RNeasy kit in 
accordance with manufacturer’s instructions. Samples were homogenised using 
QIAshredder columns. RNA was eluted using RNase free water and immediately 
used to synthesise cDNA as detailed below 
2.6.5.2 Synthesis of cDNA from RNA 
RT  reaction mixture 
2µl 10x RT Buffer 
2µl 5µM dNTP 
2µl 10x RT Buffer 
0.2µl 0.5mg/ml oligo dT primes 
0.2µl 40 U/µl RNase inhibitor 
2µl 100mM DTT 
5.6µl nuclease free water 
 
0.5µg RNA was diluted in 7µl of water and incubated at 65oC for 5 minutes. RNA was 
cooled and combines with 13µl RT reaction mixture. The mixture was then 
incubated for 1hr at 37oC. cDNA was then used for qPCR. 
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2.6.5.3 qPCR reaction 
Reaction mix     Cycle parameters 
12.5µl Solaris master mix   95oC 15 mins 
Solaris primer/probe set   95 oC 15 secs 
250-1000ng cDNA    60 oC 60 secs 
Made up to 25µl with H2O   Cycle to step 2 40 times 
 
The reaction mixture was set up as indicated in white qPCR tubes with clear optical 
lids. The reaction was run on a PTC-200 Peltier Thermal cycler using the indicated 
cycle parameters. When the Ct values were obtained relative change was calculated 
using the equation 2-ΔΔCt. ΔCt indicates the difference between average ct for the 
gene of interest and average ct for control gene (e.g. β-actin). ΔΔCt indicates the 
difference between ΔCt for the treatment condition and control condition (e.g. 
DMSO). 
2.6.6 Gateway cloning  
In order to clone the gene of interest (GOI) the following Gateway system 
(Invirtogen) protocol was used. Firstly the GOI (IKKβ) was flanked by attB sites was 
generated (2.4.8.1). Next this was inserted into the entry vector using the BP 
reaction (2.4.8.2). Finally the gene was transferred to the destination clone (2.4.8.2). 
2.6.8.1 Producing IKKβ-AttB product 
Master mix     Cycling Conditions 
5µl 10 x PFU master mix   Activation: 95oC 15mins 
1µg Template (IKKβ- pCMV2)  Denaturation: 95oC 30Secs 
0.1µM Forward and Reverse primers Annealing: 56 oC 30secs 
Up to 50µl with ddH2O   Elongation: 72
oC 1min 
      Cycle to step 2 30 times 
      72oC 5mins 




PCR was used to amplify the IKKβ gene from an IKKβ- pCMV2 vector (obtained from 
addgene). The primers designed (Detailed in Table 2.6) also contained leader 
sequences with Att sites in order to obtain a product of IKKβ flanked by Att sites. 
PCR master mix was made as indicated and the reaction was then run at the 
indicated cycling conditions in thin walled PCR tubes.  
 
 Table 2.6 PCR primers used in this study 
Name Site Sequence 
IKKβ Forward (With 
leader Att sites) 
IKKβ start  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCG 
AAGGAGATAGAACCATGAGCTGGTCACCTTCC 
IKKβ Reverse (With 
leader Att sites) 
IKKβ End GGGGACCACTTTGTACAAGAAAGCTGGGTCCT 
ATCATGAGGCCTGCTCCAG 
 
2.6.10 BP reaction 
Reaction mixture 
15-150ng att-PCR product 
150µg pDONR221 
2µl BP Clonase 
Up to 8µl TE Buffer pH8 
The IKKβ PCR product (flanked with Att sites) was incorporated into the pDONR221 
vector using a BP reaction. The reaction mixture was made up as indicated and 
incubated at room temperature overnight. The reaction was then stopped using 1µl 
proteinase K (37oC, 10mins). 50µl of DH5α were then transformed using 1µl of the 
reaction sample. The transformed bacteria were then plated onto LB agar plates 
supplemented with KAN and incubated at 37oC overnight. Individual colonies were 
then picked and grown up in 5ml LB broth. The plasmid DNA was then isolated using 





2.6.11 LR Reaction 
Reaction mixture 
150ng entry clone 
150ng Destination vector 
2µl LR Clonase 
 Up to 8µl with TE buffer 
An LR reaction was used to transfer the IKKβ gene from the entry clone (pDONR221) 
to destination vector (pEF5/FRT/V5-DEST 1). The reaction mixture was set up as 
shown and incubated overnight at 25oC. To stop the reaction 1µl of proteinase K was 
added and the sample heated to 37oC for 10mins. 50µl of DH5α were then 
transformed using 1µl of the reaction sample. The transformed bacteria were then 
plated onto LB agar plates supplemented with AMP and incubated at 37oC 
overnight. Individual colonies were then picked and grown up in 5ml LB broth. The 
plasmid DNA was then isolated using the miniprep kit. Plasmids were then 
sequenced to confirm the LR reaction was successful. 
 
2.6.7 Site-directed mutagenesis 
Master mix     Cycle parameters 
5µl 10 x PFU master mix   95oC 15 mins 
50ng Template   95oC 30 Secs 
0.125µM Forward and Reverse primers 55oC 30 Secs 
Up to 50µl with ddH2O   72
oC 1 mins 
      Cycle to step 2 x30 
 
Specific mutations in the IKKβ gene (within the pEF5/FRT/V5-DEST 1 vector) were 
created using site-directed mutagenesis. The reaction mixture was made up as 
shown and the reaction conducted on a thermocycler using the indicated cycle 
parameters. 10µl of the PCR product was transferred to a new tube (no dpn 
control). 1µl of dpn was then added to the remaining 40µls and incubated for 3Hrs 
at 37oC. 50µl DH5α were then transformed with 1µl of the reaction mixture/no dpn 
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control. DH5α cells were then plated onto LB agar and grown overnight at 37oC.  
Colonies were picked and grown up in 5ml LB broth overnight. Plasmid DNA was 
then extracted by mini-prep and sequenced. 
 
Table 2.7 Mutagenesis primers used in this study 
Name Sequence 
IKKβ K44M Forward CAGATTGCCATCATGCAGTGCCG 










2.7 Mass spectrometry 
All Mass-spectrometry work was completed in Prof. Mark Molloy’s Lab/APAF 
(Australian Proteomics Analysis Facility) in Sydney, Australia. All sample preparations 
and MS analysis were completed with the help of Thiri Zaw (APAF). All SCX work was 
completed by Natasha Lucas (APAF). Data analysis work was completed with the 
help of Thiri Zaw, Natasha Lucas, Robert Parker and Mark Molloy (APAF and Molloy 
group). 
 
2.7.1 iTRAQ proteomics experiment: 
2.7.1.1. iTRAQ sample preparation: Cell treatment, lysis and trypsinisation 
Lysis buffer 
0.15%SDS 






 +Protease inhibitors 
 
T47D cells were seeded in 20cm tissue culture plates to reach 80-90% confluency 
24hrs later. They were then treated with 5µM IMD0354. Plates were harvested 0, 
30, 60 and 120mins after treatment. Prior to harvesting, cells were washed 3 times 
in cold PBS to ensure all media and FBS was removed. Cells were centrifuged for 
3mins at 3000rpm and the supernatant discarded. Cells were then resuspended 
with 1ml SDS lysis buffer. They were briefly sonicated and then incubated on ice for 
20mins. Cells were then centrifuged (13500rpm 10mins) to remove insoluble 
fragments; the supernatant was kept for analysis. Protein concentration was 
determined by BCA assay. 100µg of each sample was then diluted 1:3 with ddH2O. 
 
2.7.1.2. iTRAQ sample preparation:  Sample reduction, alkylation and 
trypsinisation 
TCEP was added to each of the 100µg lysate samples to give a final concentration of 
5mM and incubated at 60oC for 1hour with shaking. MMTS was then added to give a 
final concentration of 10mM. Samples were incubated at room temperature for 
10mins. 4µg of Trypsin was then added to each sample and samples were incubated 
at 37oC overnight. Samples were lyophilized using a vacuum centrifuge for ~1-3Hrs 
and pellets were resuspended in 30ul TEAB. 
 
2.7.1.3. iTRAQ sample preparation: Labelling reaction 
iTRAQ labels (114, 115, 116, and 117) were resuspended in 70ul Ethanol and added 
to the prepared samples. Samples were incubated at room-temperature with 
shaking for 2hrs. The samples were then checked to ensure that they had been 
successfully labelled. To do this 2µl of each sample was then combined and de-
salted by Zip-tipping (Millipore). Zip-tips were activated by washing 5 times with 5µl 
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of acetonitrile, 0.1% TFA and then washed 5 times with 5µl 0.1% TFA. 5µl of the 
sample was pipetted and repipetted a total of 10 times. Zip tips were again washed 
5 times with 0.1% TFA. De-salted sample was then eluted with 2µl 4mg/ml MALDI 
matrix resuspended in 70% acetonitrile, 0.06% TFA and spotted onto a 384 Opti-TOF 
matrix. Additionally MALDI peptide standards were also pipetted onto the plate. 
Samples were then analysed on an ABSciex 4800 Plus Proteomics analyser 
automated MALDI-TOF/TOF to check the samples had been labelled. Once this was 
established all samples were then combined and lyophilised by vacuum 
centrifugation for 3-4Hrs. Samples were then subject to Strong cation exchange. 
 
2.7.1.4. iTRAQ sample preparation: Strong cation exchange 
Strong cation exchange was completed by the Australian Proteomics Analysis Facility 
(APAF). Once the fractions had been separated they were resuspended in 100µl 
0.1%TFA, 2% acetonitrile. Fractions with lower peptide content were pooled to 
create a total of 20 separate samples for MS analysis. 
 
2.7.1.5. iTRAQ MS/MS analysis 
Samples were analysed by LC-MS/MS using an ABSciex QStar Elite mass-
spectrometer and a ABSciex 5600 mass-spectrometer. Proteins were identified using 
ProteinPilot (Applied Biosystems). 
 
2.7.2 SILAC phosphoproteomics experiment 
2.7.2.1. SILAC sample preparation: Labelling  
T47D cells were grown in SILAC control DMEM (R0K0 – “Light”) or SILAC DMEM 
media containing 13C and 15N labelled arginine, and 13C and 15N labelled lysine 




2.7.2.2. SILAC sample preparation: Cell treatment and lysis  
Urea lysis buffer 




 +Protease and phosphatase inhibitors 
 
Cells were then grown in 20cm tissue culture dishes until ~80% confluent. “Heavy” 
labelled cells were treated with 5µM IMD0354 for 2Hrs, “Light” labelled cells were 
treated with DMSO for 2Hrs. Cells were then washed 5 times in cold PBS to ensure 
all media and FBS was removed and then scraped into 1ml cold PBS. Cells were 
pelleted by centrifugation (3000rpm 3mins) and the supernatant discarded. Cells 
were resuspended in urea buffer, they were briefly sonicated and incubated on ice 
for 20mins. Samples were centrifuged at top speed for 10mins. The supernatant 
was retained and the insoluble fraction discarded. 
 
2.7.2.3. SILAC sample preparation: Sample reduction and alkylation 
10µl 200mM DTT was added to each lysate sample and samples were then 
incubated for 40mins at 56oC. Samples were allowed to cool to room temp and 10µl 
400mM IAA was added. Samples were incubated for 20mins at room temperature 
in the dark. The prepared samples were then transferred to 15ml tubes for acetone 
precipitation. 
 
2.7.2.4. SILAC sample preparation: Acetone precipitation 
5-10 volumes of cold acetone was added to each sample. Samples were incubated 
at -20oC overnight. Samples were centrifuged at 5000-10000g for 20mins. Acetone 
was removed by decanting. Any residual acetone was removed by drying in a fume 
hood for ~5mins. 
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200µl of 100mM ammonium bicarbonate/8M urea was added to samples and 
incubated for 30mins at room temperature to dissolve the pellet. 800µl 100mM 
ammonium bicarbonate was then added to reduce the urea concentration to 1.6M. 
Samples were then transferred to 1.5ml eppendorfs. 
 
2.7.2.5. SILAC sample preparation: Trypsin digestion 
Protein concentration was determined by BCA assay. 1mg of each sample was 
digested. 20µg of trypsin (Promega) was added to each sample and incubated at 
37oC overnight. 
 
2.7.2.6. SILAC sample preparation: C18 Clean up  
Trypsinised samples were then purified on C18 columns (Nest Group Macro spin 
columns). To activate columns 500µl Methanol was added to each C18 spin column. 
Columns were centrifuged at 100rcf for 2mins and flow-through discarded. Columns 
were washed with 500µl H2O. Columns were centrifuged at 100rcf for 2mins and 
flow-through discarded. Samples were added to the columns (30-300µg/column). 
Columns were centrifuged at 100rcf for 2mins and flow though was reapplied to 
columns. Columns were centrifuged again at 100rcf for 2mins and flow-through 
discarded. Columns were again washed using 250µl H2O which was added to each 
column. Columns were centrifuged at 100rcf for 2mins and flow-through discarded. 
This wash step was repeated twice more. Proteins were then eluted from the 
column with 90%ACN, 0.1%Formic acid and centrifuged at 100rcf for 2mins. 
Samples were then lyophilised using a vacuum centrifuge until volume was ~20µl. 






2.7.2.7. SILAC sample preparation: phosphopeptide enrichment. 
Buffers: 
 Buffer A: 80% ACN, 0.4% TFA 
 Buffer B: 1ml Buffer A+400µl Lactic acid 
 Elution 1: 20µl ammonium hydroxide + 380µl H2O 
 Elution 2: 20µl Pyrrolidine +380µl H2O 
 2.5% TFA 
 
The columns were prepared by washing with 20µl Buffer A which was added to each 
TiO2 tip and centrifuged at 3000 x g for 2mins. Flow-through was then discarded. 
The tips were then washed with 20µl Buffer B and centrifuged at 3000 x g for 2mins. 
Flow-through was then discarded. Peptide samples were resuspended in 150µl 
buffer B and applied to the spin tip. Tips were centrifuged at 1000 x g for 10mins. 
Samples were reapplied to the spin tip and centrifuged at 1000 x g for 10mins and 
flow-through was discarded. The columns were washed by adding 20µl buffer B and 
centrifuged at 3000 x g for 2mins and flow-through was discarded. The columns 
were washed by adding 20µl buffer A and centrifuged at 3000 x g for 2mins and 
flow-through was discarded. This wash with buffer A was repeated twice more. The 
tips were placed in new tubes and 50µl of elution buffer 1 was added and tips were 
centrifuged at 1000 x g for 5mins. Using the same collection tubes 50µl of elution 
buffer 2 was added to each spin tip and tips were centrifuged at 1000 x g for 5mins. 
The eluate was then retained and acidified by adding 100µl 2.5%TFA until sample 
was pH2-2.5. 
 
2.7.2.8. SILAC sample preparation: Graphite clean-up  
After Phosphopeptide enrichment samples were purified using Pierce Graphite spin 
columns in accordance with recommendations of the enrichment kit. Columns were 
placed into 1.5mL collection tubes and centrifuged at 2000 × g for 1 min to remove 
storage buffer. 100µL of 1M NH4OH was added to each tube and then centrifuged at 
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2000 × g 1 min; flow-through was discarded. This wash step was then repeated. The 
graphite columns were then activated by adding 100μL of acetonitrile. Columns 
were then centrifuged at 2000 × g for 1 min and flow-through discarded. Next 100μL 
of 1% TFA was added to each and centrifuged at 2000 × g for 1 min. Again flow-
through was discarded. This was then repeated once. Columns were then placed 
into a new collection tube and the sample was applied on top of the resin bed and 
allowed to bind for 10 minutes with periodic mixing. The columns were then 
centrifuged at 1000 x g for 3 mins and the flow-through discarded. The columns 
were then placed into a new collection tube and the columns were washed by 
adding 200µL of 1.0% TFA and centrifuged at 2000 × g for 1 min; the flow-through 
was discarded. This wash step was then repeated. Columns were then placed into 
new collection tube and 100µL of 0.1% formic acid in 50% acetonitrile was added to 
elute the sample. Columns were centrifuged at 2000 × g for 1 min. This step was 
repeated three more times using the same collection tube for a total elution volume 
of 400µL. Samples were then dried in a vacuum centrifuge for ~3-4Hrs. Sample were 
resuspended in 0.1% TFA. 
 
2.7.2.9. SILAC analysis by MS/MS 
Samples were analysed by LC-MS/MS using an ABSciex QStar Elite mass-
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3. Identification of potential novel regulators of wild-type and mutant p53 
3.1 Introduction 
p53 is a transcription factor with a critical role in preventing tumourigenesis 
(8). When a cell becomes stressed due to factors including DNA damage and 
oncogene activation, p53 is activated leading to cell cycle arrest and repair, or 
apoptosis if the stress is severe enough (8). This acts to remove damaged or 
oncogenic cells from replication. In its normal state it functions as a tumour 
suppressor but can also be considered a proto-oncogene as mutation frequently 
leads to oncogenic gain of function as well as loss of normal function (22). Due to 
these facts p53 is considered an attractive therapeutic target. As discussed in 
Chapter 1 a number of strategies have been developed to target p53 in cancer. 
Which strategy would be implemented will be at least partly dependent upon the 
mutational status of the tumour. Ways to target p53 include activation of wild-type 
p53 (wtp53), reactivation of mutant p53 (mtp53) and suppression of mtp53. 
 In cancers that retain wtp53 it will, in many cases, be beneficial to activate 
the pathway to bring about senescence or death. Many classic chemotherapeutics 
bring about p53 activation as a result of DNA damage however this can lead to 
significant toxicity to normal cells. It has been suggested however that if p53 is 
activated without initiating DNA damage then toxicity will be much higher in cancer 
cells than in normal cells. Empirical evidence suggests this may be true, for example 
a number of MDM2 inhibitors which activate p53 have been shown that they have 
greater toxicity to cancer cells; xenograph experiments have shown MDM2 
inhibitors can lead to tumour shrinkage without substantial toxic side effects (106, 
147). 
In cancers with mtp53 the best option therapeutically may be to reactivate 
p53. If a therapy can be found that induces mtp53 to achieve its normal 
confirmation this could both remove the oncogenic gain of functions associated 
with the mutant conformation and also restore some wild-type functionality. Proof-
of-concept experiments have shown that many p53 mutations lead to temperature 
sensitive changes; when the temperature is lowered p53 can gain normal 
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confirmation and become active (148). Such changes have also been achieved using 
second-site suppressor mutations or by the introduction of peptides which help to 
lock p53 in a normal conformation (121-123). There has been substantial research 
to identify chemical therapeutics which could be used to gain such reactivation and 
a number of promising compounds have been identified (124-127).  
Whilst reactivating p53 is an attractive therapeutic option it may not be 
feasible in all cases. Some mutation of p53 may lead to extensive derangement and 
produce a protein that could not be refolded. Empirical evidence supports the idea 
that the amount of p53 in the normal or unfolded conformation varies between 
different mutations (51). An alternative to the reactivation approach would be to 
simply reduce the amount or activity of mtp53 in the cell. Experiments have shown 
that in tumour cells with mtp53 they are often dependent on it. It has been shown 
that siRNA mediated knockdown of mtp53 leads to reduced cell growth and 
apoptosis (149) (52). This provides proof of concept that compounds that reduce 
mtp53 levels may be therapeutically useful.  
 This study will focus on identifying factors which cause the activation of 
wtp53 and factors which promote the reduction of mtp53 protein levels. This will be 
addressed by 3 separate screens; 
- Screen 1: Screening of small molecules that can activate p53 using cells 
with a p53-β-gal reporter construct. 
- Screen 2: Screening of polymer and hydropolymer matrices that can 
activate p53 using cells with a p53-β-gal reporter construct. 
- Screen 3: Screening of small molecules that can reduce mtp53, assessed 
by in cell western. 
The screens will be presented as three separate studies but overall results will also 
be concluded at the end of this chapter.  
 
3.2 Screen 1: Screening for small molecules that activate wtp53 
p53 is thought to be mutated in around half of all cancers (8). This clearly 
demonstrates the importance of p53 in preventing cancer however it means that at 
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least 50% of tumours retain wtp53, be it in a homozygous or heterozygous state. In 
certain cancer types p53 is not typically seen to be mutated e.g. melanoma (67, 150, 
151). In cancers where wtp53 is present its function is usually supressed by an 
alternative mechanism in order to circumvent death signals and promote cell 
survival. For example ARF is frequently lost in melanoma, ARF normally binds to 
MDM2 preventing its ubiquitination of p53 thus its loss promotes MDM2 and 
inhibits p53 (152). A number of different pathways have been identified in cancer 
cells which are able to interfere with the normal activation of wtp53. As activation 
of wtp53 is considered to be therapeutically beneficial any pathways that prevent or 
promote the activation of p53 could represent potential targets.  
The aim of the first screen in this chapter is to identify small molecule 
inhibitors able to promote the activation of wtp53. This screen utilised cells 
containing a p53 responsive reporter construct in order to screen for drugs capable 
of activating wtp53 (Work flow is shown in Fig 3.1). Similar cells have previously 
been used to successfully screen chemical libraries for drugs which can modify the 
p53 pathway. Kravchenko et al. (2007) used A431 cells (mtp53) with a β-gal reporter 
gene under the control of multiple p53 binding elements to screen for chemicals 
able to reactivate the mtp53 pathway (146). They successfully identified RETRA, a 
drug which leads to an increase in p53 pathway genes via its effects on the p53 
family protein; p73. Lain et al. (2008) used T22 cells with a β-gal reporter gene 
under the control of a ribosomal gene cluster promoter (p53 responsive) to identify 
compounds able to activate wtp53 (117). This led to the identification of Tenovin, a 





Fig 3.1 Work-flow for Screen 1. ARN8 cells were seeded in 24 well plates and treated with: 1. Known 
activators of p53, 2. A subset of the LOPAC library and 3. All compounds in the Tocris kinase inhibitor 
library.  Cells were treated with each compound and were tested at 8 different concentrations 
ranging from 0.4 µM- 50µM and incubated for 16Hrs. Cells were then β-gal stained in order to 




3.2.1.1 Validating the assay 
This screen utilised a human melanoma cell line (A375) containing a stable 
p53 dependent β-gal reporter construct known as ARN8 cells. This cell line was 
selected as they contain wtp53 which has been shown to be activatable by a 
number of mechanisms including MDM2 inhibition (153). As p53 is rarely mutated 
in melanoma (67, 150, 151) this cell line would be representative of a type where 
p53 activation could be advantageous. 
The work-flow for this screen is shown in Fig 3.1. The cells were treated with 
8 different concentrations of each drug ranging from 391nM to 50µM for 16Hrs. 
They were then β-gal stained in order to detect any p53 activity. These cells contain 
a lacZ gene attached to a p53 responsive ribosomal gene cluster (RGC) promoter. To 
test for p53 activation the compound x-gal can be added to these cells, if p53 is 
activate β-galactosidase will be expressed from the lacZ gene which will cleave X-gal 
leading to the production of a blue precipitate. This will result in the cells appearing 
to turn blue which is observable under a standard microscope. Fig 3.2 shows an 
example of positive β-gal staining of a p53 activating compound hit. Cell death as a 
result of inhibitor treatment was not specifically tested for, however when inhibitors 
led to loss of, or damage to, the cell monolayer this was noted. This was due to the 
fact that if most cells have detached from the surface then clearly β-gal staining is 
not possible and thus a negative result cannot be recorded. Also the contraction and 
detachment of cells could be indicative of cell death and so it is conceivable that 
apoptosis and p53 activation preceded this state. 
In order to assess the validity of this assay, cells were treated with 3 known 
activators of p53 as positive controls as well as DMSO as a negative control. The 
three activators used were LMB, Nutlin and Roscovitine. These three drugs activate 
p53 via different mechanisms. LMB is a nuclear export inhibitor which prevents p53 
from exiting the nucleus. As p53 is a transcription factor it needs to be localised to 
the nucleus to function, LMB therefore allows p53 to stay active by prohibiting its 
nuclear exit (114). Nutlin is an inhibitor of the p53 negative regulator; MDM2.  
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Nutlin prevents the binding of MDM2 to p53, thus preventing MDM2 mediated 
ubiquitination and subsequent degradation of p53 (108). Roscovitine is a Cdk 
inhibitor which causes the activation of p53 via multiple systems including 
repression of MDM2 and disruption of the nucleolus (154, 155). 
As detailed in Table 1 all three compounds produced strong p53 activation at 
a range of concentrations. It was observed that none of these drugs appeared to 
cause substantial cell loss from the plate compared to DMSO. These results suggest 
that β-gal staining of ARN8 cells is capable of correctly identifying compounds which 
activate p53 via a number of different upstream mechanisms. It was therefore 
considered that this assay could be used to screen compounds to identify novel 
activators of p53 
 
3.2.1.2 LOPAC library compounds 
An initial pilot screen completed in the lab (data not published) identified a 
number of compounds from the LOPAC library that appeared to activate p53. The 
compounds identified in that screen, which are detailed in Table 3.3, were assessed 
in this screen. As shown in Table 3.1, only 3 of the 16 compounds tested activated 
p53 in this screen. These were Apigenin, Aminopterin and Z-L-phe 
chloromethylketone. As an example of the typical staining observed, Figure 3.2 
shows the presence of blue cells (activated p53) that can be seen with Apigenin. 
Both Apigenin and Aminopterin did not appear to lead to cell death after 16hrs as 
the number or morphology of cells did not obviously appear to be affected. Z-L-Phe 
chloromethylketone however did appear to cause loss of cells from the plate surface 
(Table 3.1).  
 
3.2.1.3 Kinase inhibitor library 
Kinases are critical in the regulation of many cellular mechanisms. p53 is 
heavily regulated by various kinases and has been shown to have >20 
phosphoacceptor sites (156). Furthermore, kinases are considered good drug 
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targets and are considered an important group in the “drugable genome” (157). 
Therefore, this screen was also used to test a kinase inhibitor library (Tocris Kinase 
inhibitor toolbox) for inhibitors that can activate wtp53. This library contains 80 
compounds targeting 35 kinases which are detailed in the supplementary data 
(Table S1). The results of this screen are shown in Tables 3.1 and 3.2. Screening of 
the kinase library identified 9 inhibitors which were able to activate p53. These 
represent 7 specific targets as two inhibitors target Cdk and 1 inhibitor (Ro-31-8220) 
is a broad spectrum inhibitor. Two of the inhibitors; Aminopurvalonol A and Ro-31-
8220, a Cdk and broad spectrum inhibitor respectively, showed disruption of the cell 
monolayer at the higher concentrations with activation of p53 at lower 
concentrations. This disruption is likely due to cell death although this was not 
specifically assessed. It could be speculated that such cell death may be due to p53 
mediated apoptosis, however this remains to be confirmed. A number of the 
inhibitors, which did not stain positive for p53 activation, also appeared to lead to 
substantial monolayer disruption; again however, it remains undetermined whether 





Fig 3.2 Apigenin activates p53 in ARN8 cells. ARN8 cells were treated with the indicated 
concentration of Apigenin and then β-gal stained in order to assess p53 activity. The strength of 





Table 3.1. Compounds identified as activators of p53 in Screen 1. ARN8 cells containing a p53 β-gal 
reporter construct were treated with various drugs (detailed in 3.2.1.1, Table 3.3 and Table S3) at 
0.4µM-50µM for 16Hrs, p53 activation was then assessed by β-gal staining. Relative strength of 
activation was determined qualitatively based on the number of blue cells (++ = high, + = low). ☠ 
indicates substantial disruption/loss of the cell monolayer (assessed by eye). If no p53 activation or 
loss of cells were observed at a given concentration the grid cell is left blank. Drugs are only 
contained in this table if any p53 activation was observed. DMSO was tested as a control but did not 
lead to p53 activation and so is not included within this table. 
Drug Target 50µM 25µM 12.5µM 6.3µM 3.1µM 1.6µM 0.8µM 0.4µM 
Roscovitine Cdk ++ ++ ++      
Nutlin MDM2 ++ ++ ++ ++ ++ ++   
LMB CRM1 ++ ++ ++ ++ ++ ++ ++  
Apigenin Broad 
spectrum 
++ +       





☠ ☠ ☠ ++ ++ ++ ++ ++ 
Fasudil 
Hydrochloride 
ROCK ++        
GF109203X PCK + +       
Genistein EGFR + +       
Olomucine Cdk +        
PP1 Src  +       
Purvalanol A Cdk ☠ ☠ +      





☠ ☠ ☠   ++ ++ + 
Dorsomorphin 
dihydrochloride 





Table 3.2. Compounds leading to disruption of ARN8 cell monolayer in Screen 1. ARN8 cells 
containing a p53 β-gal reporter construct were treated with various drugs (detailed in 3.2.1.1, Table 
3.3 and Table S3) at 0.4µM-50µM for 16Hrs. p53 activation was then assessed by β-gal staining 
(Results detailed in Table 3.1). Additionally cells were visually checked for substantial disruption/loss 
of the cell monolayer. Detailed within this table are drugs which caused only cell monolayer 
disruption, this is indicated by ☠. If no loss of cells were observed at a given concentration the grid 
cell is left blank. DMSO was tested as a control but did not lead to monolayer disruption and so is not 
included within this table. 
 Drug Target 50µM 25µM 12.5µM 6.3µM 3.1µM 1.6µM 0.8µM 0.4µM 
ZM449829 JAK3 ☠             
ZM39923 
Hydrochloride 
JAK3 ☠ ☠            
Amino- 
purvalanol A 
Cdk ☠             
BIBX 1382 
dihydrochloride 
EGFR ☠             
CGP 53353 PKC ☠             
IKK16 IKKβ ☠ ☠            
10-DEBC 
hydrochloride 
PKB ☠ ☠            
CGK 733 ATR/ATM ☠ ☠            
PHA 665752 cMET ☠ ☠ ☠           
PD 407824 Chk1 ☠             
PQ 401 IGF-1R ☠ ☠            
EO 1428 p38 
MAPK 
☠             
H89 
dihydrochloride 
PKA ☠             
BIO GSK3 ☠ ☠            




Table 3.3. LOPAC library compounds tested for ability to active p53. Descriptions supplied with 
information from manufacture (Sigma). 
Drug Target Action Class Description 
Aminopterin Dihydrofolate 
reductase 
Inhibitor Antibiotic Dihydrofolate reductase inhibitor 
Apigenin   Inhibitor Cell Cycle   
Chlorzoxazone iNOS Inhibitor Nitric Oxide Inducible nitric oxide synthetase 
inhibitor; skeletal muscle relaxant 
Psora 4 Kv1.3 Inhibitor K+ Channel Potent Kv1.3 potassium channel 
inhibitor. 
ATPA Kainate Agonist Glutamate Selective kainate glutamate 
receptor agonist 
SKF-89145 hydrobromide D1 Agonist Dopamine D1 dopamine receptor agonist 
Tracazolate   Modulator GABA Non-benzodiazepine anxiolytic 
which has a high differential 




Adenylate cyclase Inhibitor Cyclic  
Nucleotides 
Cell-permeable, non-competitive 
adenylyl cyclase inhibitor; targets 
the P-site domain 
L-(-)-norepinephrine (+)-
bitartrate salt monohydrate 
  Agonist Adrenoceptor Adrenergic neurotransmitter 
AraC   Inhibitor DNA  
Metabolism 
Selective inhibitor of DNA 
synthesis 






Inhibitor Biochemistry Bovine chymotrypsin A-gamma 
inhibitor 
Org 24598 lithium salt GlyT1 Inhibitor Neuro-
transmission 
Selective, potent inhibitor of glial 




Collagen Inhibitor Biochemistry Inhibits collagen synthesis 
acetamide Carbonic 
anhydrase 
Inhibitor Biochemistry Carbonic anhydrase inhibitor; 
diuretic 
sandoz 58-035 ACAT Inhibitor Lipid Acyl-CoA:cholesterol 




3.2.1.4 Preliminary validation of four activators of p53 
In the above experiments 15 compounds were shown to activate p53 in the 
β-gal assay. A number of these represent drugs which have previously been shown 
to be able to activate p53 which supports the validity of the assay. Apigenin, 
Aminopterin, Olomucine, Roscovitine, Nutlin and LMB have all been extensively 
shown (or the class of drug shown) to lead to p53 activation (108, 114, 154, 155, 
158-161). The remaining compounds represent either novel activators of p53 or 
compounds that have previously been shown to activate p53 but where the 
evidence is more limited. In either case, this screen can potentially help increase our 
understanding of the importance of the drug targets contribution to the p53 
pathway. Not all 15 compounds could be further investigated within the confines of 
this study but 4 compounds were selected for preliminary validation. The drugs 
selected were Dorsomorphin dihydrochloride, SB-415286, GF109203X and Genistein 
which are described as AMPK, GSK3, PKC and EGFR inhibitors respectively.  
When p53 is activated it escapes degradation and is often seen to be 
stabilised within the cell (162). As a result increased p53 protein within the cell 
could be indicative of p53 activation. If the p53 is activated this should be coupled 
with a rise in the levels of p53 responsive genes including MDM2 and p21 (163). In 
order to validate the results, cells treated with Dorsomorphin dihydrochloride, SB-
415286, GF109203X and Genistein were analysed by western blot for the effect of 
the drug on p53, MDM2 and p21 protein levels. As can be seen in Fig 3.3 all 4 
compounds show some stabilisation of p53, MDM2 and p21. Dorsomorphin 
dihydrochloride lead to an increase in all three p53 pathway genes in a 
concentration dependant manner. SB-415286, GF109203X and Genistein also 
showed a general increase with increasing drug concentration however small 
fluctuations were seen in MDM2, p21 and p53 meaning that a strict concentration 
dependent effect is not observed. Activation of p53 is known to increase the levels 
of MDM2 however MDM2 in turn acts to negatively regulate p53 forming a negative 
feedback-loop. This feedback loop leads to cycling fluctuations in the levels of both 
p53 and MDM2 (164). Similarly p21 levels are also known to fluctuate due to 
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regulatory feedback (165). The apparent lack of adherence to a strict concentration 
dependent effect likely reflects where in this fluctuating cycle proteins were at the 
time of harvesting. 
Overall the increased levels of p53, MDM2 and p21 suggest that p53 is being 
activated by the compounds, supporting the results of the β-gal screen and 
suggesting that SB-415286, Dorsomorphin dihydrochloride, GF109203X and 







Fig 3.3. Activation of p53 by Dorsomorphin, SB-415286, GF109203X  and Genistein. A375 cells were 
treated with (A) Dorsomorphin, (B) SB-415286, (C) GF109203X  and (D) Genistein for 16Hrs. Cell 
lysates (20µg/well) were then assessed by western blotting to determine relative levels ofp53, 
MDM2 and p21 using anti-p53 (DO1), anti-MDM2 (2A10) and anti-p21 antibodies. Equal loading was 





This screen successfully identified a number of inhibitors which are able to 
activate p53. The rationale for the subset of LOPAC library inhibitors tested was 
based on a previous screen conducted in the lab (data not published). This pilot 
screen used the same cell type with a p53 dependent β-gal reporter construct 
(ARN8 cells) to screen the LOPAC library. This current screen was used to attempt to 
replicate the results of the hit compounds. The replication of results of the previous 
screen in the lab did not show strong consistency, with only 19% (3/16) of results 
being replicated. This level of reproducibility is surprisingly low but highlights the 
need for results to be further validated. p53 is a stress related protein which can be 
strongly affected by numerous factors (8). If cells are being grown in sub-optimal 
conditions then p53 may be much more likely to activate by additional stressors or 
drugs.  
Two of these hits confirmed from the previous screen, Apigenin and 
Aminopterin, have previously been shown to activate p53 further validating the 
effectiveness of this screen. A derivative of aminopterin, methotrexate, is a 
commonly used chemotherapeutic used in the treatment of a range of cancers. 
These drugs inhibit dihydrofolate reductase an enzyme involved in the production of 
purines, thymidylic acid, and certain amino acids and thus important in DNA 
synthesis and repair. Inhibition of this enzyme causes phosphorylation of p53 at ser-
15 and acetylation at Lys373/382 (159). Acetylation and phosphorylation of p53 can 
both increase the activity of p53 by preventing the interaction with MDM2 or 
enhancing its ability to bind DNA (18). 
Apigenin is a plant derivative which is thought to have potentially useful 
chemotherapeutic and chemopreventative properties. Apigenin leads to the 
activation and increased stability of p53 via phosphorylation and a decrease in 
MDM2 and can lead to p53 dependent apoptosis (160). Whilst these drugs do not 
represent novel activators of p53 they provide confidence that the assay is able to 
detect such activators.  
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The final set of drugs tested in this assay was the Tocris kinase inhibitor 
toolbox. Kinases are enzymes which transfer phosphate groups from donor 
molecules such as ATP to their substrates. There are thought to be >500 kinases 
present in the human cell and each has a specific and limited number of substrates 
(166). Phosphorylation often directly affects the activity and localisation of its 
substrates and kinases orchestrate the activity of virtually all cellular processes 
(167). Critically, deregulation of kinase activity is often a major mechanism by which 
cancer cells survive and grow (168). Inhibition of a specific kinase could therefore 
prevent or enhance a process which is critical or detrimental to only cancer cells. 
There are a growing number of kinase inhibitors which have been approved for 
clinical use(168). The use and further development of kinase inhibitors is particularly 
attractive in view of the fact that conventional cancer treatment often utilises 
chemicals which lead to DNA damage in all cells and relies on the fact that cancer 
cells die faster than normal cells (169, 170). The problem comes when selecting 
which kinases of the >500 present in cells would be an appropriate target. Screening 
therefore provides a useful mechanism by which kinases important to the pathway 
of interest, in this case p53, can be identified.  
Screening of the Tocris kinase inhibitor toolbox revealed 9 compounds that 
lead to positive β-gal staining. Once again some of the inhibitors identified have 
previously been shown to activate p53. One of the hits, olomucine, has been 
established to activate the p53 pathway in certain cells (171). Olomucine is a Cdk 
inhibitor from which roscovitine is derived. A third Cdk inhibitor aminopuvalanol A 
was also identified by the screen. Cdks are a family of kinases which are important 
in cell cycle progression as well as the control of transcription.  Roscovitine and 
olomucine have been shown to most strongly inhibit cdks 1, 2 and 5  which are 
involved in cell cycle progression although they have also been shown to repress 
transcription which may be mediated by inhibition of cdk 7 / 9 (172). Whereas 
aminopurvalanol A is reported to most strongly inhibit cdks 1 and 2 (172). 
Aminopurvalanol A however has not been as widely characterised as 
Roscovitine/olomucine. Cdk inhibition can lead to activation of p53 by a number of 
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mechanisms including inhibition of MDM2 and disruption of the nucleolus (154, 
155). p53, however, appears not to be required for cell death mediated by 
roscovitine/olomucine as such inhibitors appear to have multiple mechanisms of 
action (173). Nonetheless Cdk inhibitors are thought to be an attractive therapeutic 
target and a number are currently in clinical trials (174). p53 is not thought to be 
strictly necessarily for the anticancer effects of cdk inhibitors however the 
anticancer effects of some are enhanced in the presence of wtp53 (173). 
 A number of the compounds identified represent potentially novel modifiers 
of the p53 pathway however further work would be required in order to confirm 
these results. Nonetheless, these results represent promising leads for future 
analysis. Within this study four drugs were selected for preliminary validation; 
GF109203X, Dorsomorphin dihydrochloride, Genistein and SB-415286. All four of 
these drugs showed the ability to activate p53 by the β-gal reporter assay and by 
western blotting which enhances confidence in the initial results of the screen. 
However the observed activation by both the β-gal reporter assay and by western 
blotting with all four drugs was at relatively high concentrations. This  increases the 
need for further research to show whether or not p53 activation results from on-
target effects. However there is evidence in the literature to support the idea that 
inhibition of some of these targets could activate p53 and will be discussed now. 
 GF109203X is a PKC inhibitor. PKC is a family of kinases which are important 
in the transduction of many signalling pathways. There are 10 isoforms of PKC with 
numerous targets and roles in various pathways including receptor desensitisation, 
transcription, immune response and cell cycle regulation. The outcome of PKC 
inhibition is variable and different isoforms have been shown to have differential 
effects on p53 with some being inhibitory and others enhancing its activity (175). 
The effect of inhibition will also be effected by the level of expression of each 
isoform within the cell as some PKC isoforms have been shown to be overexpressed 
in cancer (176). GF109203X is an PKC inhibitor with highest activity towards PKCα 
(177). PKCα has been shown to be overexpressed in some cancers and consistent 
with the findings here, at least in certain circumstances, PKCα inhibition has been 
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shown to lead to reduced proliferation and p53 activation (176). The molecular 
mechanism of PKCα pro-proliferative role is not clear but may involve the 
phosphorylation and activation of antiapoptotic proteins Bcl-2(178), and Akt (179). 
 Dorsomorphin is an AMPK inhibitor; AMPK is primarily thought to be 
involved in energy homeostasis. Conversely to the findings presented here AMPK 
activators are being explored as a cancer therapy and it has been shown that AMPK 
activation in some cases can induce p53 dependent apoptosis (180). However some 
studies have, in agreement with the findings here, found inhibition to increase 
apoptosis. For example it has been shown that AMPK protects cisplatin treated cells 
from apoptosis and AMPK inhibition can synergise with cisplatin to induce p53 
dependant apoptosis (181).  
Genistein was also shown to activate p53 by western blot and β-gal staining. 
Genistein is an isoflavone which is naturally occurring in a number of plant food 
sources. It is primarily known as an inhibitor of EGFR however it also affects a 
number of other pathways including activation of PPARs, inhibition of 
topoisomerase and activation of beta oestrogen receptors (182, 183) as such its 
ability to activate p53 cannot specifically be assigned to inhibition of EGFR. As 
Genistein affects a number of systems the direct and indirect effects from 
subsequent cross talk are complex. Consistent with the findings here Genistein has 
been shown in the literature to activate p53. This may occur as a result of changes 
to a number of pathways including repression of MDM2 and positive regulation of 
the ATM and PTEN pathways which can act to promote p53 (184-186). 
 Finally a GSK-3 inhibitor; SB-415286 was shown to activate p53. GSK-3 is a 
serine/threonine kinase which has a diverse range of roles including in glycogen 
metabolism, cell cycle regulation and apoptosis. Depending on experimental 
conditions GSK-3 appears to have contradictory roles in apoptosis and can act as 
both a pro or anti-apoptotic factor. GSK-3 is a target of interest in many 
neurodegenerative diseases and its inhibition has been shown to reduce neuronal 
cell death (187). In neuroblastoma cells it was shown that the apoptotic effect of 
staurosporine treatment was at least partially dependant on GSK-3 
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(188). Conversely in many other cancers GSK-3 has been shown to have an anti-
apoptotic effect and may be a potential therapeutic target. Ghosh et al. (2005) 
showed that GSK-3 inhibition maybe a potential target in colorectal cancer. They 
showed that chemical inhibition, siRNA and dominant negative GSK3 lead to p53 
dependent apoptosis (189). This anti-apoptotic effect of GSK-3 may be mediated by 
a number of mechanisms. GSK-3 phosphorylates MDM2 thereby promoting the 
degradation of p53 (190) and as such GSK-3 inhibition could allow p53 to escape 
degradation. Furthermore GSK-3 has also been shown to positively regulate NF-kB 
which, in some cases, protects cells from apoptosis (191).  
The relatively large number of compounds identified from this small scale 
screen could reflect the large number of pathways involved in p53 control (22). 
However it has been suggested that the conditions in cell culture make p53 
activation more likely and could lead to responses that would not be seen in a whole 
organism (192). Whilst this does emphasise the need for further testing, ideally in a 
whole organism, this limitation is difficult to get around in a first line screen. Normal 
tissue is also likely to react differently to cancer tissues and the testing of a large 
numbers of compounds in tumours growing in animal models is impractical. 
 In conclusion, this screen has found a number of inhibitors that appear to be 
able to activate p53. Some of these represent potentially novel activators of p53 
although further work will be needed to confirm this activity. However, four of the 
compounds were confirmed to be activators of p53 by western blotting in this study. 
Future work on these compounds would need to explore the mechanism of this 
activity and establish whether perturbation of the kinase target i.e. by RNAi could 
also lead to p53 activation. 
 
3.3 Screen 2:  Tissue engineering approach to p53 activation 
Cell signalling occurs both within a cell and between cells over both small 
and large distances. It is also apparent that cells can be altered as a result of other 
materials in, or introduced into, their environment (193, 194). From an 
immunological perspective it is vital that any material or prosthesis introduced in 
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the body is relatively inert. However some changes in cells induced by various 
materials can be exploited by medical and biological science in order to manipulate 
certain activities. If cells are grown in contact with biosynthetic materials then the 
cells can be altered by such contact (193-195) and this is exploited in the field of 
bioengineering.  
The ability of biosynthetic materials to support and manipulate cell growth is 
controlled by both the chemistry and topology of such materials (195). Research has 
shown that by altering these factors a diverse range of cellular responses can be 
manipulated, these include cell adhesion, growth, survival and differentiation (193, 
194, 196). Testing of polymers to identify those which achieve the desired outcome 
can be a slow and iterative process and the desires to move towards high-through 
put screening has led to the development of polymer arrays (197). Such arrays 
typically consist of spots of different polymers arrayed on glass slides allowing 
hundreds of polymers to be screened in one experiment. 
One example of intensive biopolymer research where arrays have been 
utilised is within bone regeneration. Research is aiming to identify polymers which 
can be injected into a site where bone has been lost to provide a scaffold for bone 
growth. The ideal biomaterial will promote bone cell differentiation and growth and 
provide a surface to direct the formation of the new tissue. Khan et al. (2010) 
screened a range of polymer blends for those that would support growth and a 
number of blends were successfully identified. Further analysis of one of these 
blends showed that it supported growth of bone progenitor cells and initiated early 
differentiation. In vivo models showed that the scaffold enhanced bone 
regeneration (193). 
A further example of the use of polymer microarrays is the study by Hansen 
et al. (2011). They screened polymers on a microarray to identify polymers capable 
of causing the activation and aggregation of platelets (194). They were successful in 
identifying a number of polymers and suggested that they could be used to coat 
bandages to quickly staunch blood flow in trauma victims. 
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 The effect of biomaterials on p53 signalling however, has been investigated 
largely in terms of understanding any oncogenic effects of materials to be used in 
the body. Clearly a material that was particularly suppressive to p53 may represent a 
carcinogenic risk whereas a material which strongly promoted p53 may inhibit 
wound healing. Van kooten et al. (2000) showed that in umbilical cord derived cells, 
grown in the presence of various metals, p53 levels increased after around 48hrs 
and was negatively associated with the proliferation marker Ki67 (198). This 
illustrates the point that proteins important in the cell cycle can be affected by 
growth surface. Bombonato-Prado et al. (2007) did a more extensive analysis of 
various different materials including glass, stainless steel, polymethylmethacrylate 
(PMMA) and titanium (199). Using microarray analysis they showed that both 
PMMA and stainless steel led to a reduction in p53 mRNA. Whilst any material that 
strongly suppresses or promotes p53 may be harmful to the body it could 
potentially provide a useful tool to study p53 pathway control. 
The aim of this study is to screen arrays to identify polymers which can affect 
the activation of p53. Such polymers would provide an extremely useful research 
tool. In order to study the p53 pathway in an active state research frequently relies 
on the addition of drugs. If p53 activating polymers were identified, cells could be 
grown on plates coated with such polymers to activate the pathway. As well as 
providing an alternative to small molecules this could provide a number of other 
advantages. Plates could be half coated in the material or coated in a gradient 
concentration and cells grown over the surface. The effect of activation could then 
be studied by techniques such as in cell western or microscopy within one well. This 
would remove any uncontrolled variable effects of using multiple wells such as 
differences in cell density and microenvironment. 
 
3.3.1 Results 
3.3.1.1 Polymer and hydropolymers arrays  
The use of polymer arrays was developed in part by Mark Bradley’s group 
(200). Two types of arrays previously used by the group were selected for testing to 
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identify polymers able to activate p53. The 2 categories of arrays used are from here 
on referred to as polymers and hydropolymers arrays. The hydropolymers and 
polymer arrays were produced by Rong Zhang and Mei Wu (Mark Bradley Lab, 
Edinburgh University) respectively. Details of the production of the polymer arrays 
can be found in Tourniaire et al. (2006) (200) and details of the specific polymers 
used can be found in Wu et al. (2012) (201). Arrays were composed, as described, of 
652 polymers in triplicate, including 468 polyacrylates and 164 polyurethanes. 
Polymer arrays were made by the contact printing of pre-synthesised linear 
polymers. Polymer arrays were spotted on slides coated with agarose which aids 
contact printing but does not support cell adhesion. 
Details of the production and polymer types in the hydropolymer arrays can 
be found in Zhang et al. (2009) (196). Hydropolymer arrays were composed of 609 
polymers in quadruplicate composed of different combinations of the 19 monomers 
described in Zhang et al. (2009) (196). The arrays used within this experiment 
differed slightly from those described in that fewer combination ratios of the 
described monomers were used. As detailed hydropolymer arrays were produced by 
printing of monomers which were polymerised in situ. To construct the 
hydropolymer arrays slides were first printed with a 20% sucrose aqueous solution 
to form a sugar array which was then treated with tridecafluoro-1,1,2,2-
tetrahydrooctyl-dimethylchlorosilane (fluorosilane). This surface allows cellular 
binding and so cells could adhere to the entire slide. Monomers were then printed 
onto the plates and polymerised in situ.  
The work-flow for this screen is shown in Fig. 3.4 A. To analyse the effect of 
each polymer and hydropolymer on p53, ARN8 cells (containing a p53 responsive β-
gal reporter gene) were grown on the arrays and reporter expression was analysed. 
In order to observe β-gal staining each polymer spot was photographed and then 
images were manually checked. The polymers were screened over a time course of 
6, 12, 24, 48 and 72Hrs. The hydropolymers were screened at only one time point 
due to the limited number of hydropolymer slides available.  
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The hydropolymers were also tested for their ability to repress p53 activated 
by roscovitine treatment. The work-flow for this screen is shown in Fig 3.4 B. 
Hydropolymer spots were again individually photographed and were this time 
analysed to identify spots which had reduced β-gal staining. Roscovitine was 
selected to activate p53 as it is known as a strong activator of p53. It was validated 






Fig 3.4 Work-flow for Screen 2. (A) ARN8 cells were grown on polymer/hydropolymer slides. The 
cells were then β-gal stained to identify any polymers/hydropolymers which activate p53. (B) ARN8 
cells were grown on hydropolymer slides. Cells were treated with Roscovitine for 16Hrs. The cells 




3.3.1.2 p53 activation by polymers  
When ARN8 cells were grown over the surface of the polymer slides, as 
predicted cells were not seen to bind to blank areas of the slide and whilst it was 
not specifically assessed it was noted that the different polymers appear to affect 
the adhesion and growth of cells over the surface causing different growth patterns 
to be observed (Fig 3.5A). The thickness of the polymers over the spot surface may 
not have been continuous, which could influence cell growth over the surface. 
However, such changes cannot be due to the printing method alone as if this were 
the case the same pattern of cells should be observed over every spot. However, 
unfortunately no p53 activation was seen at any time point as assessed by β-gal 
staining (Fig 3.5B). Potentially p53 could have been activated for a short time period 
in some of the spots but the cells died and quickly detached before the next time 
point. However, as the purpose of this study is to identify a growth surface that will 
activate p53 in order to use it as a research tool, a short activation window followed 
by rapid death would not allow much time for any type of analysis or 
experimentation. This outcome would be desirable when seeking to identify 
chemotherapeutics but may not provide an ideal research tool. For this reason extra 
time points over the period were not further investigated. 
 
3.3.1.3 p53 activation by hydropolymers 
 ARN8 cells were grown over the hydropolymer arrays for 24Hrs and then 
assessed for β-gal staining. Similarly to the polymer arrays it was noticed that some 
hydropolymers support better growth than others. However, as with the polymer 
spots, the hydropolymers also showed no ability to activate p53 (Fig 3.5C).  
 
3.3.1.4 p53 repression by hydropolymers 
 Hydropolymer slides were then analysed for their ability to repress p53 
activation by roscovitine. As can be seen in Fig 3.6 Roscovitine provided an even 
spread of cells with activated p53. Whilst it does not cause p53 in all cells to become 
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active, the cells are dense enough for several blue cells to be observed over the 
surface of each hydropolymer spot. Using this approach meant that hydropolymers 
that completely or highly repressed p53 activation could be identified, although it 
would be difficult to observe hydropolymers with weak ability to repress p53. 








Fig 3.5 No polymers/hydropolymers spots were identified which activated p53. (A) Examples of the 
different growth patterns observed when ARN8 cells were grown over polymer microarrays. As can 
be seen some polymers supported cell growth better than others, some restricted this growth to only 
the outside or central regions (B) Examples of β-gal stained ARN8 cells grown on polymer arrays 
(negative results are shown as no hydropolymers activated p53). Polymers are demarked by circular 
dashed lines and expanded sections shows the cell attached over this area. (C) Examples of β-gal 
stained ARN8 cells grown on hydropolymer arrays (negative results are shown as no hydropolymers 
activated p53). Hydropolymers are demarked by circular dashed lines and expanded sections shows 









Fig 3.6. No hydropolymers were identified which prevented p53 activation by Roscovitine. ARN8 
cells were grown on hydropolymers spots for 24Hrs and treated with Roscovitine for 16Hrs. After 
treatment they were fixed and β-gal stained to assess p53 activity. Typical examples of hydropolymer 
spots after staining are shown. Dashed lines demark the hydropolymer spots. The level of activation 
on the hydro polymer spot was compared to the level of activation in the surrounding area where no 




This screen aimed to identify polymers and hydropolymers able to regulate 
the p53 pathway. Polymers were analysed for their ability to cause p53 activation, 
and this was assessed at a number of time points. Hydropolymers were analysed for 
their ability to either activate or repress p53 activation 24 hrs after seeding.  
Both arrays have previously, or since been, successfully used in other studies. 
The hydropolymer array was used to identify hydropolymers which allow cell 
binding and proliferation and subsequently thermal release (196). The polymer 
array was used to identify polymers which inhibited or aided Cryptosporidium 
parvum oocyte binding and assess the effect of hydrophobicity, roughness and 
polymer composition on the outcome (201). Unfortunately however, no polymers in 
either of these arrays that activated p53 were identified. Growth over the different 
polymers was observed to vary, however β-gal staining did not indicate that any 
polymers or hydropolymers lead to the activation of p53.  
Polymers have been shown to be capable of greatly altering protein 
expression and activity bringing about differentiation (193, 198). This suggests that 
polymers could be found that could alter activity of a specific protein. p53 can be 
activated by affecting any of a large number of mechanisms and furthermore other 
studies have demonstrated that biomaterials are capable of affecting p53 (198).  
One explanation may be that polymers that activate p53 may be less likely to 
support initial growth and so any potential activation is never realised. Due to the 
fact that p53 is activated by cellular stress it is conceivable that such “stressful” 
conditions would be less likely to support initial growth. Activation of p53 will 
typically cause cell cycle arrest or apoptosis (8). If signals from the growth surface 
cause apoptosis clearly few cells would be observed on that surface and so these 
materials would be difficult to identify. However, biomaterials that increase p53 
have been previously identified; Van Kooten et al. (2000) showed that various 
metals could increase p53 protein level in umbilical cord derived cells (198). 
Although, it should be noted that this study did not specifically investigate activity of 
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p53. Nonetheless, it does suggest that materials do exist that could allow cell 
attachment and affect p53.  
Hydropolymers were also screened to identify any polymers that were able 
to repress the activation of p53 by roscovitine. Again, no such hydropolymers were 
successfully identified. One issue with this study is that roscovitine does not lead to 
an observable response in all cells, only a proportion. This is an issue as if only a 
proportion of the cells are activated in the control it makes it much harder to 
discern subtle differences with the hydropolymers. This means it can be said for 
certain that no hydropolymers led to the complete repression of activation but 
reduced activation may not have been identified. In future work it may be beneficial 
to repeat this with a stronger activator of p53. Alternatively a more quantitative 
technique could be used to assess any changes. As discussed in the following screen, 
in cell western is a useful technique to look at protein expression within fixed cells. 
Future work could use this technique to identify polymers which lead to a decrease 
or increase in p53 and down-stream proteins such as MDM2 and p21. This would 
allow a more quantitative approach to assessing p53 activity. 
 
In conclusion, this study suggests that finding a biomaterial which activates 
p53 is difficult and such materials are not easily identified. This study utilised 
polymer arrays containing polyacrylates and polyurethanes as well as 
hydropolymers composed of combinations of 19 monomers. Clearly this only 
represents a fraction of total possible polymers. In future work it may be useful to 
use larger arrays as a starting point. This study also failed to identify hydropolymers 
that repressed the activation of p53 by roscovitine. This study was technically 
challenging as roscovitine only produced observable activation in a proportion of 
cells. Further work would be needed to identify either a stronger activator of p53 or 
an alternative read-out of p53 activity; this would allow hydropolymers that caused 




3.4 Screen 3: Small molecule screening for drugs able to reduce levels of mtp53 
A number of diseases are associated with the aberrant accumulation of 
specific proteins within the cell. This is also true of many cancers, as mutation in p53 
frequently leads to its accumulation within the cell (202, 203). Mutation within the 
p53 gene frequently confers oncogenicity (32). The oncogenic capability of mtp53 is 
mediated by aberrant interaction with a number of proteins including the p53 family 
proteins; p63 and p73. Mtp53 has been shown to stably interact with p63 and p73 
preventing them from activating p53 pathway genes (36). Other pathways where 
mtp53 has been shown to have altered roles include EGR-1, Nf-κB, NF-Y and TGFβ 
(43, 47, 49). Such aberrant interactions have generally been found to enhance anti-
apoptotic signals, cell growth and invasion (22). Studies have shown that the 
removal of mtp53 from the cell can inhibit growth or even induce cell death (52). 
The evasion of degradation is not an intrinsic characteristic of p53 mutation (54) and 
is therefore selected for in cancer cells. However, this suggests that pathways that 
contribute to increasing the levels of mtp53 could be targeted in order to reduce 
mtp53 load.   
One of the few drugs known to be able to reduce mtp53 load is 17-AAG; a 
Hsp90 inhibitor(51). Hsp90 is a chaperone protein which transiently binds numerous 
proteins and assists in protein folding. Many types of mtp53 appear to require 
Hsp90 in order to achieve their conformation and, unlike wtp53, bind Hsp90 very 
stably (51). It appears that this binding protects from degradation and if Hsp90 is 
inhibited it allows the protein to be released and the protein will then become 
available to be ubiquitinated by the E3 ligase CHIP (51). Additionally Hsp90 
inhibition also leads to the degradation of a number of other oncogenic proteins 
which also appear to be dependent on the chaperone. A number of hsp90 inhibitors 
are currently in clinical trials this includes the hsp90 inhibitor AUY922 which is in 
phase II clinical trials for breast and gastric cancer (204).  
The aim of this study is to identify kinase inhibitors which are capable of 
reducing the amount of mtp53 within a cancer cell line. This will provide further 
information as to how high levels of mtp53 are sustained within the cell and also 
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potentially provide possible novel therapeutic targets. The levels of mtp53 in T47D 
cells (L194F) will be assessed in this screen by in cell western. The in cell western 
technique is based on similar methodology as western blotting except protein 
detection by antibody is achieved in a permabilised fixed cell rather than the 
proteins being extracted first (for full method see chapter 2). This has been shown 




3.4.1.1 Assay validation 
In this screen T47D cells; a human breast cancer cell line (mtp53 -L194F) 
were screened by in cell western for kinase inhibitors capable of reducing the DO1 
(p53 specific antibody) signal. The workflow for this screen is summarised in Fig 3.7.  
DO1 is an ideal antibody to be used in this type of experiment as it does not detect 
any non-specific bands (Fig 3.8A). This is important in the in cell western technique 
as non-specific bands cannot be excluded based on size. T47D cells were chosen as 
the L194F p53 mutation has been shown to be relatively difficult to destroy by 17-
AAG in comparison to other cancer cell lines carrying mtp53 (51). It is therefore 
useful to identify mechanisms by which such p53 can be reduced in cells. 
Additionally, this mutation has been suggested to confer gain of function both in 
terms of its ability to repress p63 and p73 and also in terms of other pro-
tumorigenic effects (52, 149, 206, 207). It has been shown in this cell line that 
repression of the mtp53 by RNAi leads to apoptosis (52). Therefore, identification of 
a drug that could reduce mtp53 levels would be advantageous. 
Whilst T47D is not as responsive to 17-AAG as other cell lines, it is still 
thought to be capable of leading to some reduction in the levels of mtp53 in this cell 
line (51). As 17-AAG is one of the best described drugs capable of reducing mtp53 it 
was used as a positive control. As can be seen in Fig 3.8 B-C 17-AAG did lead to a 
reduction in mtp53 levels in T47D cells in this assay. 







Fig 3.7 Workflow for Screen 3. T47D cells were treated with each compound at 8 different 
concentrations (0.4µM - 50µM). After 16Hrs cells were fixed and permeabilised. Cells were then 
incubated with the primary antibody DO1. After washing, the cells were then incubated with the 
secondary antibody. After a second round of washing the relative amounts of p53 could then be 
assessed by quantifying the fluorescent signal using the Licor Odyssey scanner. For full details see 






Fig 3.8 In cell western technique can be used to screen for drugs which reduce mtp53 levels. (A) 
The DO1 antibody used in this assay does not appear to identify non-specific bands. T47D cell lysate 
was immunoblotted for p53 using DO1. Only 1 band of ~53KDa was observed. (B) T47D cells were 
treated with 17-AAG (20µM-0.2µM) or DMSO for 16Hrs. p53 levels (Green) using the antibody DO1 
were assessed by western blotting. Cells were additionally stained with DRAQ5 (red) to assess the 
relative cell densities. (C) T47D cells were treated with the indicated concentration of 17-AAG (or 
DMSO only) for 16Hrs. p53 levels were assessed by in cell western and normalised to the relative cell 
densities (determined by DRAQ5 staining).  
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3.4.1.2 Kinase library screen 
The Tocris kinase library was screened, with each drug tested at 8 different 
concentrations (391nM-50µM). Hits were determined as those where p53 signal 
appeared to be reduced by comparison to DMSO treated cells and also appeared to 
have a concentration dependent effect.  
Nine kinase inhibitors in the Tocris kinase inhibitor library were identified as 
potentially reducing total mtp53 protein in this screen and are detailed in Table 3.4. 
These hits represent six specific targets. Two drugs were both seen to target Cdk, 
two were seen to target IKKβ and one kinase inhibitor is considered to be a broad 
spectrum inhibitor. Interestingly 3 of the inhibitors were noted during Screen 1; 
Aminopurvanol A and IKK16 were noted to cause a loss of cells at higher 
concentrations and Ro 31-8220 mesylate was noted to cause p53 activation at lower 








Ro-mesylate Broad spectrum 





(-)-Terreric acid BTK 






3.4.1.3 Preliminary validation 
The 9 compounds identified in this screen are potentially capable of reducing 
mtp53 levels however selection of hits was qualitative. Whilst this screen cannot 
definitively identify compounds that do or do not lead to alterations in the levels of 
p53 it provides a means of lead generation. Two of the identified drugs IMD0354 
and IKK16 were selected for further analysis. Results of the initial screen were 
repeated in triplicate in both T47D cells and BT-549 cells. BT-549 cells also have 
mutant p53 (R249S) so this meant it was possible to determine if the effect of IKK16 
and IMD0354 were specific to only T47D cells or the L194F mutant p53. As can be 
seen in Fig 3.9 IMD0354 leads to a reduction in mtp53 levels in both T47D and BT-
549 cells. IKK16 appeared to lead to the reduction in mtp53 in both cell lines but 
also caused substantial loss of cells from the wells, presumably as a result of cell 
death, and thus any reduction in mtp53 was difficult to determine. Calculation of 
p53 intensity relative to cell density (DRAQ5) with higher concentrations of IKK16 
lead to negative values. This appeared to result from errors in the determination of 
total cells (DNA stain) with very low numbers of cells although such errors were not 






Fig 3.9. IKK16 and IMD0354 reduce p53 levels in T47D and BT-549 cells (A) T47D and (B) BT549 cells 
were treated with the indicated concentration of IMD0354 and IKK16 or the equivalent quantity of 
DMSO for 16Hrs. Relative p53 levels and relative cell densities were analysed by in cell western using 







In this screen, T47D cells with the p53 mutation L194F were selected for 
screening. Mutation in p53 at codon 194 is present in roughly 0.5% of cancers with 
p53 mutation (The p53 Database: http://p53.free.fr/index.html). However, many 
other mutations found in cancer are also gain of function including some of the 
most common mutations e.g. 175 present in 5% of cancers with p53 mutation (41, 
43). The exact number of p53 mutations with gain of function is unknown as the 
mechanisms for these gains of function are numerous and only just beginning to be 
understood. Additionally a large number of different mutations have been 
identified; over 90% of residues have been seen to be mutated in one or more case 
of cancer (see Fig 1.3). 
This screen led to the identification of a number of inhibitors which 
appeared to reduce levels of mtp53. Further work is required to validate these 
results but the screen successfully provided a means of lead identification. One 
interesting target lead is Cdk, this screen identified two Cdk inhibitors which 
appeared to reduce the levels of mtp53; Aminopurvanol A and Ryuvidine. Curiously, 
three Cdk inhibitors were identified as being able to activate wt p53 in Screen 1 
(Table 3.1). Cdks are a small family of kinases which by definition need to be in 
complex with a cyclin family protein to be active. Cdks have been shown to have 
roles in the cell cycle as well as regulation of transcription (208). Cdks display 
specificity towards which cyclins they bind. As the amount of each cyclin protein 
fluxes during the cell cycle this can control the activity of each Cdk and thus control 
progression of the cell cycle (208). Cdk members are important in control of the cell 
cycle and some Cdk inhibitors lead to p53 activation and cell cycle arrest (171). 
However some Cdks have been shown to have roles in transcriptional regulation 
(209) and therefore inhibition of some cdks can reduce transcription (210) which 
could provide a mechanism by which p53 is being reduced. The ability of Cdk 
inhibitors to reduce transcription may be part of the therapeutic value of some such 
inhibitors (210). Cancers are particularly sensitive to such inhibitors, possibly as they 
are thought to be particularly reliant on rapidly turned over oncogenic proteins. 
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Chemical inhibitors of Cdks typically show activity towards a number of cdks but 
each may affect a different subset of the Cdk family. For this reason it would not be 
expected that all, or even most, cdk inhibitors should produce the same effect. 
Interestingly of the four cdk inhibitors tested in both assays, two were active in each 
but none were active in both.  
As mentioned, further work will be needed to confirm the ability of these 
identified inhibitors to reduce mtp53 and further to explore whether the observed 
effects are due to on-target inhibition. Two of the identified inhibitors targeting IKKβ 
were however selected for preliminary validation. Repetition of in cell westerns in 
triplicate confirmed that IMD0354 and IKK16 reduced the DO1 signal in both T47D 
and BT-549 cells. IKKβ is known to be involved in many processes including 
regulation of cell cycle, apoptosis, inflammation and immunity (211, 212). It has 
numerous substrates, the best known of which is the transcription factor Nf-κB. 
There are numerous examples of cross talk between the IKK/Nf-κB and p53 
pathways (39). For example mtp53 has been shown to enhance Nf-κB 
transcription(41). However it has not been reported, to our knowledge, that IKK 
sustains mtp53 levels and thus may be an interesting line of inquiry. The interactions 
between the two pathways will be more fully discussed in the next chapter.   
In chapter 4 the effect of IKKβ inhibition on p53 and its pathway will be 
validated and further defined. Whilst the other inhibitors will not be pursued within 
the confines of this study this screen has provided a number of compounds 




The above screens identified a number of small molecules that are able to 
activate wtp53 and reduce the levels of mtp53. No matrices were identified that 
could activate or repress wtp53. This highlights the usefulness of small molecules in 
manipulating the p53 pathway. The Tocris kinase inhibitor library was analysed in 
both Screen 1 and Screen 3. These two screens which aimed to identify compounds 
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activating wtp53 and reducing mtp53 identified mainly different inhibitors. 
However, one inhibitor Ro 31-8220 was seen to both activate wtp53 and reduce 
mtp53, although at different concentration ranges. Ro 31-8220 has previously been 
seen to activate wtp53 (213) but to our knowledge not to reduce mtp53. Ro 31-
8220 was first described as a PKC inhibitor (214) and interestingly other PKC 
inhibitors were identified in both screens. GF109203X and Rottlerin were identified 
in Screen 1 and Screen 3 respectively. As previously discussed PKC has many 
isoforms which have differential effects on p53 (175). Different drugs (or 
concentrations) may hit different subsets of the PKC proteins and so could lead to 
opposing effects. An additional problem is that a number of PKC inhibitors have 
been shown to have off-target effects. For example both Ro 31-8220 and Rottlerin 
have been shown to inhibit other kinases (215). In terms of the effect of Ro 3108220 
it is possible that p53 activation at lower concentrations is due to the effect on 
certain kinases and that at higher concentrations of the drug, which reduce mtp53, 
additional targets are inhibited. 
Another target that was identified in both studies was Cdk, although no 
specific Cdk inhibitor was identified in both. Again cdks are a family of kinases and 
so drugs targeting cdk will inhibit a different subset of the family and therefore can 
lead to different effects. This highlights the importance of characterising individual 
inhibitors. 
In conclusion, these screens have demonstrated that small scale screening is 
an effective method of identifying potentially novel and dominant pathways in the 
regulation of wtp53 and mtp53. The screens presented here identified lists of 
potential p53 regulators; they do not however have the power to confirm whether 
the these compounds or target molecules are true regulators of p53. Some 
validation with the data sets can be found, for example, when known regulators are 
identified this enhances the confidence within the screen. Such screens can provide 
a useful starting point in the further exploration of regulatory proteins important 
within the pathway. This project further focuses on two kinase inhibitors (both 
targeting IKKβ) identified with screen 3 as regulators of mtp53, however future work 
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could validate and further explore other inhibitor and targets identified in the 












4. Inhibition of IKKβ leads to a loss of p53 pathway proteins 
4.1 Introduction 
p53 is frequently mutated in cancers and this is often associated with 
accumulation of p53 within the cell (54, 202, 203). Despite the high association 
between p53 mutation and accumulation it has recently been demonstrated that 
this accumulation is not a condition innately confirmed by the mutation (54). As p53 
mutation also frequently leads to oncogenic gain of function (22), this accumulation 
is thought to be selected for in cancer cells.  Therefore other systems have to be 
altered within the cell to bring about such accumulation. The implication of this is 
that these other systems could be targeted in order to reduce the levels of mutant 
p53 (mtp53). 
The final screen in Chapter 3 showed that inhibition of a number of kinases 
were potentially able to affect the levels of mtp53. This screen was designed to 
identify kinases potentially involved in mtp53 stability, however further validation is 
required to show whether these proteins are in fact important in p53 stability. In 
chapter 3 it was shown that IKKβ inhibitors; IKK16 and IMD0354, led to a reduction 
in mtp53 signal in in cell westerns. IKK is a multi-subunit complex composed of IKKα, 
IKKβ and nemo. α and β are kinase subunits whereas nemo is a regulatory subunit 
with no known kinase activity. IKK is important in many different roles including cell 
cycle and apoptosis; functions where p53 also have a critical role (216). Its 
contribution to apoptosis is complex and can have both pro and anti-apoptotic roles 
(40). IKK phosphorylates a number of different substrates to mediate these effects 
but the best known and understood is Nf-κB. Activation of Nf-κB by IKK occurs via 
two distinct pathways (Fig 4.1)(212). In the classic pathway homo or heterodimers of 
IKKα or IKKβ bound to nemo phosphorylate IkB, which triggers ubiquitination and 
ultimately degradation of this protein. IkB is a negative regulator of Nf-κB and so 
active IKK relieves the inhibition of Nf-κB, this allows Nf-κB to enter the nucleus and 
function as a transcription factor (212). In the non-classical pathway homodimers of 
IKKα directly phosphorylate inhibitory subunits of Nf-κB again allowing active Nf-κB 
to enter the nucleus (212). 
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The identification of IKK16 and IMD0354 as being potentially capable of 
modifying mtp53 suggests IKKβ may play a role in mtp53 regulation. Previous 
research has largely focussed on the effect IKKβ wtp53. Evidence from the literature 
however shows that there is significant cross-talk between wild type p53(wtp53) 
and IKK (39). Cross-talk between these two pathways is complex and certain studies 
have shown that IKK acts to oppose the apoptotic effect of p53 whilst others have 
shown that IKK or the downstream factor, Nf-κB, is required for p53 mediated 
apoptosis.  
IKK/Nf-κB have, however, largely been thought of as anti-apoptotic factors. 
This is supported by the fact that the pathway is hyper-activated in a large number 
of cancers and appears to contribute to survival (99). The IKK and p53 pathways 
have been shown to be oppositely regulated by a number of pathways. For example, 
the Akt pathway has been shown to repress p53 by positive regulation of MDM2 
(217) and also phosphorylates IKK which leads to the activation of Nf-κB (218). On 
the other hand ARF represses MDM2 activity leading to increased p53 activity (88) 
whilst repressing Nf-κB by inhibition of the Nf-κB subunit Rel A (219). 
It has also been shown that the two pathways can directly oppose each 
other. For example, Nf-κB has been shown to lead to positive regulation of MDM2 
(220-222) which would inhibit p53 activity. A number of mechanisms by which this 
can happen have been demonstrated although the factors controlling which 
mechanism is observed are unknown. In MEFs Nf-κB has been shown to lead to the 
up-regulation of MDM2 mRNA transcription via a mechanism which is dependent 
on both p53 and Nf-κB but which does not result from direct binding of Nf-κB to the 
promoter (220). Busuttil et al. (2010) however showed that in T-cells Nf-κB could 
lead to the direct increase in MDM2 mRNA via binding of Nf-κB to the P1 promoter 
(221). Although within the context of T-cells this lead to p73 mediated apoptosis 
rather than p53 mediated effects. Lau et al. (2012) also recently showed that IKK can 
also lead to the post-translational modification of MDM2 as well as transcriptional 
changes (222). They demonstrated that Nf-κB pathway activation by knockdown of 
the Nf-κB pathway inhibitor cIAP2 leads to increased MDM2 activity; this resulted 
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from a transient increase in mRNA levels and a sustained IKK dependent increase in 
phosphorylation and sumolyation of MDM2. This resulted in decreased p53 levels.   
IKK can also inhibit the p53 pathway via Nf-κB independent mechanisms. 
IKKβ can directly phosphorylate p53 at ser362 and ser366 which leads to its 
degradation via the E3 ligase β-TrCP1 (223). Furthermore IKKβ can also indirectly 
inhibit p53 transcriptional activities. IKKβ has been shown to phosphorylate ΔNp73α 
at ser422 (224). ΔNp73α is an isoform of the p53 family protein p73 and it has been 
shown to repress the activity of both p53 and p73 (72). When ΔNp73α is 
phosphorylated by IKKβ its ability to bind response elements of p53 controlled 
genes is enhanced and thus prevents the binding and transcriptional activities of 
p53 (224). 
However, as mentioned previously, IKK is not just an anti-apoptotic factor 
and in certain situations can be pro-apoptotic. In some cases IKK has also been seen 
to promote p53 activity/stability. Fujioka et al. (2004) showed that the superoxide 
inducing agent doxycycline leads to the activation of both Nf-κB and p53 and that 
the activation of p53 was dependent on Nf-κB (225). The authors showed that Nf-κB 
induced p53 activity by both transcriptional and post-translational mechanisms. 
They showed that p53 mRNA levels were increased, MDM2 levels were reduced and 
phosphorylation of p53 at ser20 was increased; demonstrating that Nf-kB can 
regulate p53 activity at multiple levels. IKK has also been shown to positively 
regulate the p53 pathway via Nf-κB independent means. During H2O2 stress IKKβ has 
been shown to phosphorylate and activate S6K1 which leads to the phosphorylation 
of MDM2 at Ser166 (226). Phosphorylation at this residue leads to inhibition of 
MDM2 nuclear entry meaning that it is unable to promote nuclear p53 degradation 
(226). This pathway was shown to be important in mediating cell death resulting 
from H2O2 stress (226).  
The mechanisms controlling when or how IKK activation is pro or anti-
apoptotic are not well understood, although progress is being made in this area. It is 
known that the outcome of IKK/Nf-κB activation appears to be at least in part 
dependent on the initial stimuli: Lin et al. (1999) showed that whilst both T-cell 
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activators and glucocorticoids can both induce apoptosis within T-cells, ablation of 
Nf-κB activity has opposite effects (40).  Blockade of Nf-κB activity enhanced 
glucocorticoid mediated apoptosis but conversely T-cell activation induced cell 
death by PMA/ionomycin appears to require Nf-κB and its inhibition reduced 
apoptosis. Ryan et al. (2002) showed that induction of p53 activity lead to an 
increase in Nf-κB which was required for cell death (227). Conversely they found 
that Nf-κB acted to protect cells in TNFα induced cell death. The authors suggested 
that activation of Nf-κB in these systems relied on different mechanisms. They 
showed that NIK, an upstream mediator of IKK, was required for TNFα induced, but 
not p53 induced, Nf-κB. Activation of Nf-κB by p53 was instead reliant on MEK and 
pp90
rsk. Consistent with this result O’Prey et al. (2010) also showed that TNFα leads 
to Nf-κB acting as an anti-apoptotic factor but p53 activation required Nf-κB for an 
apoptotic response (228). They further elucidate this mechanism by showing that 
Nf-κB was not required for the regulation of all down-stream p53 targets but was 
required for the pro-apoptotic factors, p53AIP1 and Noxa.  
 The impact of this cross-talk between IKK and p53 in cells with mtp53 is 
unclear. As discussed, IKK can act to promote or inhibit p53 activity and/or stability 
and the outcome is, at least partly, determined by stimulus.  Clearly some of the 
regulatory mechanisms discussed would likely not have the same impact on mtp53 
as wtp53. For example, MDM2 is poorly able to modulate mtp53 levels (50) and 
thus regulation via this route may be reduced. Furthermore the IKK/Nf-kB pathway 
is often deranged in cancer further complicating our understanding of the 
interaction between these two pathways in cancer. In fact it has been shown that 
hyper-activation of the IKK pathway may be associated with mutation of p53 (42). 
Mtp53 is usually highly stable in terms of its half-life in cancer (202, 203) suggesting 
that it may not be significantly downregulated by the hyperactive IKK pathway. 
Empirical evidence shows that certain mutants of p53 are able to up-regulate the 
Nf-κB pathway. For example, mtp53 (R175H, R273H, and D281G) appears to act to 
promote Nf-κB via increased transcription and thus enhance its anti-apoptotic 
abilities (41). This provides a potential mechanism for the association of mutation of 
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p53 and IKK pathway activation. However, if inhibition of IKK is confirmed to reduce 
mtp53 levels this suggests that IKK could also act to increase mtp53 stability. The 
following chapter examines the potential for small molecule inhibitors of IKKβ 
(IMD0354/IKK16) to alter mtp53 and wtp53 in cancer cells. Second, it seeks to 
identify whether other proteins within the p53 pathway (specifically MDM2 and 
p21) are altered by IMD0354 treatment. Finally, it attempts to address the 




Fig 4.1. Nf-κB can be activated by two IKK dependent pathways. (A) In the Classical pathway upon 
activation of the IKK complex IkB is phosphorylated. This causes IkB to dissociate from Nf-κB subunits 
RelA and p50 and be targeted for degradation. This exposes the nuclear localisation sequence on Nf-
κB subunits allowing them to enter the nucleus. (B) In the Non-Classical pathway activated IKKα 
dimers phosphorylate p100. This both allows RelB to be released and also promotes the processing 





4.2.1 mtp53 is reduced by the IKKβ inhibitor IMD0354 
The final screen (Screen 3) in Chapter 3 revealed a number of small molecule 
inhibitors which appeared to reduce the levels of mtp53 (L194F) in T47D breast 
cancer cells as shown by the in cell western technique. This included the IKKβ 
inhibitor, IMD0354, and the mechanism by which this drug affects the p53 pathway 
will be explored in this chapter. A second IKKβ inhibitor, IKK16 was also identified to 
reduce mtp53 in the same screen; however, this inhibitor caused significant cell 
death, so therefore further work focuses mainly on IMD0354. IMD0354 has been 
proposed as a potentially useful chemotherapeutic and has been shown to have 
anti-cancer effects in mice xenograph experiments (229, 230). It is therefore 
important to fully understand the action of this drug. 
 In cell westerns reflect the total epitope availability within a cell and with a 
highly specific antibody such as DO1 (used in this study) all the p53 within the cell 
can be quantified. However, any technique may have a degree of unspecificity and 
therefore it is advantageous to confirm the results by another technique. Western 
blotting was employed to confirm the reduction of p53 by IMD0354 as this is a long 
standing reliable technique. Fig 4.2 shows the results of this, as well as in cell 
western results for comparison. As can be seen in Fig. 4.2 western blotting replicates 
the reduction of p53 levels in T47D cells after IMD0354 treatment and shows a 
reduction in mtp53 levels over a similar concentration range (~6.3-50µM). This 
confirms that treatment of T47D cells with IMD0354 does lead to a reduction in 




Fig 4.2. IMD0354 treatment leads to a reduction in mtp53 levels in T47D. (A) T47D cells were 
treated with IMD0354 at the indicated concentration for 16Hrs. p53 levels were then assessed by in 
cell western. The levels of p53 were assessed using the p53 specific antibody DO1 and were 
normalised to DRAQ5 levels to control for cell number variation. Values of p53 levels are mean values 
from results in triplicate from a single plate. Error bars show standard deviation. (B) T47D cells were 
treated with IMD0354 at the indicated concentration for 16Hrs. Cell lysates (20µg/well) were then 
assessed by western blotting to determine relative levels of p53 by western blotting using anti-p53 




4.2.2 Wild-type p53 is also reduced by IMD0354. 
p53 is a tightly regulated protein which is affected by a number of systems 
(231). Mutation in p53 often leads it to escape from some normal forms of 
regulation but still retain other forms (50). Mutation in p53 may also cause it to 
become differently regulated by certain mechanisms in comparison to the wild type 
form (51). It is therefore important to know whether the inhibition of IKKβ will affect 
wtp53 in the same way as it affects mutant p53.  
As shown in Fig. 4.3A treatment of A375 cells (wtp53) also leads to a 
reduction in the levels of p53 as observed using in cell western. Once again, 
following this result it was sought to confirm whether such an effect could be 
observed using western blotting. As seen in Fig 4.3B western blotting showed that 
wtp53 in A375 cells was generally reduced by IMD0354 treatment, however, 
fluctuations were seen in the levels of p53 across the concentration range. Whilst a 
reduction in wtp53 was seen using both techniques minor differences in the levels 
of p53 at each concentration were observed and it should be noted that a strict 
concentration dependent effect was not seen.  
Western blotting showed that IMD0354 caused small fluctuations in the 
expected steady decrease in p53 being observed. Fluctuations in p53 pathway 
proteins are often observed as a result of regulatory feedback mechanisms (164). 
Such fluctuations were not seen in mtp53 cells, this is perhaps unsurprising as 
mtp53 does not induce MDM2 and so is not subject to the same regulatory 
feedback mechanisms (163). Furthermore, mtp53 frequently accumulates as it 
escapes normal degradation and thus has significantly enhanced stability (50). As 
the level of wtp53 will, to a relatively small degree, be affected by where in the 
fluctuating cycle p53 is when the snapshot is taken this may explain why some 
differences are observed in the effects seen by western blotting and in cell western. 
As discussed whilst the results from the two techniques showed a similar 
trend they were not identical. Result from such different techniques are likely to 
vary as in cell westerns will detect p53 in the cell, which has an available DO1 
epitope after cell permeabilisation, whereas western blotting relies on a lysis buffer 
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to extract p53 prior to detection. Therefore, there may be differences in the pools of 
p53 available in the two techniques. As western blotting is the more fully defined 





Fig 4.3. IMD0354 treatment leads to a reduction in mtp53 levels in A375. (A) A375 cells were 
treated with IMD0354 at the indicated concentration for 16Hrs. p53 levels were then assessed by in 
cell western. The levels of p53 were assessed using the p53 specific antibody DO1 and were 
normalised to DRAQ5 levels to control for cell number variation. Values of p53 levels are mean values 
from results in triplicate from a single plate. Error bars show standard deviation. (B) A375 cells were 
treated with IMD0354 at the indicated concentration for 16Hrs. Cell lysates (20µg/well) were then 
assessed by western blotting to determine relative levels of p53 using anti-p53 (DO1). Equal loading 




4.2.3 IMD0354 leads to a reduction in the levels of p53 pathway proteins. 
 The stability and activity of p53 is often best considered in the context of its 
pathway proteins. Whilst the p53 in T47D cells is mutated it can still be subject to 
some, although more limited, alteration by its pathway proteins, for example whilst  
MDM2 poorly ubiquitinates p53, it can still play some, albeit more limited, role in 
mtp53 degradation (50). Additionally some mtp53 has been shown to be able to 
cause the basal transcription of some of its normal responsive genes (37). For these 
reasons the levels of the p53 pathway proteins MDM2 and p21 were investigated 
when T47D cells were treated with IMD0354. As can be seen in Fig. 4.4 both MDM2 
and p21 appear to be reduced by IMD0354 treatment. As can be seen in Fig. 4.4 B, C 
MDM2 is the most acutely affected by IMD0354 with p21 affected second and p53 
sometime after that. The order of loss of the p53 pathway proteins appears to 
reflect the relative stability of these proteins within the cell (Fig 4.4D). As can be 
seen in Fig 4.4 MDM2, which is lost first, has the fastest turnover.  
Subsequent work focuses on investigating the effect of IKKβ on MDM2 as it is 
the most rapidly and acutely affected p53 pathway protein identified. Furthermore 
MDM2 is also considered to be an oncogenic protein and is overexpressed in a 
number of cancers (26). It appears to promote oncogenicity both via its inhibition of 
p53 but also via a number of p53 independent mechanisms (232). Thus reduction of 
MDM2 protein levels or activity may be advantageous. Inhibition of MDM2 activity 
by Nutlin, which was specially designed to inhibit MDM2 repression of p53, is 
thought to be beneficial in cells with wild-type p53 (108). However some studies 
also suggest that Nutlin can also have p53 independent anti-tumourigenic effects 
(233). Knock-down of MDM2 has revealed that reduction of MDM2 can, at least in 







Fig 4.4 IMD0354 leads to a reduction in p53 pathway proteins; MDM2 and p21. (A) T47D cells were 
treated with IMD0354 at the indicated concentration for 16Hrs. Cell lysates (20µg/well) were then by 
western blotting assessed to determine relative MDM2 and p21 levels by western blotting using anti-
MDM2 (2A10) and anti-p21 antibodies. Equal loading was also assessed using anti-β-actin antibody. 
(B) T47D cells were treated with IMD0354 for the indicated time. Cell lysates (20µg/well) were then 
assessed by western blotting to determine relative p53, MDM2 and p21 levels by western blotting 
using anti-p53 (DO1), anti-MDM2 (2A10) and anti-p21 antibodies. Equal loading was also assessed 
using anti-β-actin antibody. (C) T47D cells were treated with 5µM IMD0354 for the indicated time. 
Cell lysates (20µg/well) were then assessed by western blotting to determine relative MDM2 levels 
using the anti-MDM2 antibody, 2A10. Equal loading was also assessed using anti-β-actin antibody.  
(D) T47D cells were treated with 10µM cycloheximide (CHX) for the indicated time. Cell lysates 
(20µg/well) were then assessed by western blotting to determine relative p53, MDM2 and p21 levels 
by western blotting using anti-p53 (DO1), anti-MDM2 (2A10) and anti-p21 antibodies. Equal loading 
was also assessed using anti-β-actin antibody. (E) Schematic showing the model that IKKβ enhances 
the stability of p53, MDM2 and p21, and that when inhibited the observed order of loss will depend 




4.2.4 IMD0354 leads to a reduction in MDM2 protein. 
Western blotting using the MDM2 specific antibody, 2A10 (Fig 4.4 A-D) 
showed that MDM2 appear to be reduced by IMD0354 treatment. However, several 
bands are seen with 2A10 and this result is based on the assumption that MDM2 is 
represented by the higher band of ~90KDa. This is consistent with the fact that 
MDM2 is usually expected to run at ~90KDa on an SDS gel. However in order to 
confirm this, siRNA targeting MDM2 was used. As shown in Fig 4.5A MDM2 siRNA 
leads to a reduction in the higher 2A10 band confirming that the ~90KDa band does 
represent a form of MDM2.  
2A10 is a widely used and specific antibody however it has been shown that 
phosphorylation of the protein can mask the epitope (236). This suggests that the 
observed loss of the 2A10 epitope with IMD0354 treatment could be due to either 
phosphorylation changes or a change in total MDM2. In order to ascertain which is 
the case a second antibody, 4B2, was used. Whilst 2A10 binds MDM2 at amino acids 
390-396, 4B2 binds at a distinct site at amino acids 19-50. As can be seen in Fig. 
4.5B-E the reduction in MDM2 occurs at the same concentration of IMD0354 using 
either 2A10 or 4B2 by western blotting or in cell western. This confirms that 





Fig 4.5. Loss of the MDM2 epitope reflects the loss of the MDM2 protein. (A) T47D cells were 
treated with 40nM control non-targeting siRNA or siRNA targeting MDM2 for 48Hrs. Cell lysates 
(20µg/well) were then assessed by western blotting to determine relative MDM2 levels using the 
anti-MDM2 antibody, 2A10. Equal loading was also assessed using anti-β-actin antibody. (B, C) T47D 
cells were treated with IMD0354 for the indicated time. Cell lysates (20µg/well) were then assessed 
by western blotting to determine relative MDM2 levels using the anti-MDM2 antibody, 2A10. Equal 
loading was also assessed using anti-β-actin antibody.  (D,E) T47D cells were treated with the 
indicated concentration of IMD0354 for 16Hrs. Levels of MDM2 were then analysed by in cell 
western using the antibodies 2A10 and 4B2. The relative levels of fluorescence were then quantified 
using the Licor software. 4B2 (D) and 2A10 (E) levels were corrected for background (secondary only) 
fluorescence and normalised to DRAQ5 to control for cell number   
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4.2.5 The reduction in MDM2 is independent of p53 
 The level of MDM2 in a cell is regulated by a number of factors. MDM2 
protein levels are usually altered as a result of changes to transcription as well as 
post-translational modification altering degradation rate (237-239). Transcription of 
MDM2 is known to be under the control of p53 and acts in a positive feedback loop 
by negatively regulating p53 (239). Therefore the observed reduction in MDM2 
could result from a loss of p53. Mutant p53 frequently losses its ability to transcribe 
genes normally under its control, however some studies have suggested that the 
loss of transcriptional activity is not absolute in some p53 mutations (37). As the 
reduction in MDM2 precedes the reduction in p53 this suggests that MDM2 loss is 
not dependent on p53 in this case. However, activity is not solely dependent on 
protein level and so a loss of activity of p53 could precede a loss of protein. To test 
whether the reduction in MDM2 is dependent on p53, the effect of IMD0354 was 
tested in a number of cell lines with different p53 statuses. A375, MDA-MB-231 and 
H1299 which have wtp53, mtp53 (R280K) and p53-null respectively were treated 
with IMD0354 and the effect on MDM2 level was tested by immunoblotting. As can 
be seen in Fig. 4.6 MDM2 was reduced in all the cells lines tested showing that the 







Fig 4.6. The reduction in MDM2 as a result of IKKβ inhibition is not dependent on p53 status. A375 
(A), MDA-MB-231 (B) and H1299 (C) cells were treated with the indicated concentrations of IMD0354 
for 16Hrs. Their p53 status is wild-type, mutant (R280K) and null respectively. Cell lysates (20µg/well) 
were then assessed by western blotting to determine relative MDM2 levels using the anti-MDM2 
antibody, 2A10. Equal loading was also assessed using anti-β-actin antibody.   
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4.2.6. IMD0354 inhibits the Nf-κB pathway in T47D cells 
Next, we wanted to assess whether IMD0354 effectively inhibits IKKβ. 
IMD0354 is thought to specifically inhibit IKKβ via inhibition of ATP binding (240). 
Therefore, the effect of IMD0354 on IKKβ can be measured indirectly through its 
effect on downstream components. Tanaka et al. (2006) investigated the effect of 
IMD0354 on the cell cycle and showed that a number of changes occurred which 
lead to cell cycle arrest (229). For example, they showed that IMD0354 leads to a 
reduction in IκB phosphorylation as well as reducing cyclin D1 and D3. Such changes 
are consistent with the effect of IKK inhibition. IκBα is one of the substrates of IKK 
(241, 242) and therefore will have reduced phosphorylation when IKK is inactive. 
Reduced phosphorylation would mean that more IκB is bound to Nf-κB keeping it in 
its inactive state and so the levels of proteins whose gene transcription is promoted 
by Nf-κB would fall, these genes include D-type cyclins (243). To see whether 
IMD0354 acts in this way, and is therefore hitting its target in T47D cells IκBα, 
phospho-IκBα, cyclin D1 and cyclin D3 levels were assessed by western blotting in 
cells treated with IMD0354. Due to the fact phosphorylation of IKBα leads to its 
rapid degradation cells were also treated with MG132 in order to observe phospho-
IKBα. As can be seen from Fig. 4.7 A-B there is a small increase in the levels of IKBα 
which is concomitant with a decrease in the relative phosphorylation levels after 
60mins. Interestingly however levels of phosphorylated IKBα temporarily increase 
after 30mins before dropping. Additionally levels of cyclin D1 and cyclin D3 were 





Fig 4.7. IMD0354 leads to a reduction in D-type cyclins and a reduction in IKBα phosphorylation. 
(A) T47D cells were treated with the 50µM IMD0354 for the indicated time. Cell lysates (20µg/well) 
were then assessed by western blotting to determine relative Cyclin D1 and Cyclin D3 levels using the 
anti-Cyclin D1 and Cyclin D3 antibodies. Equal loading was also assessed using anti-β-actin antibody. 
(B) T47D cells were treated with the MG132 for 3Hrs in addition to 5µM IMD0354 for 2Hrs, 1Hrs, 
30mins or 0mins . Cell lysates (20µg/well) were then assessed by western blotting to determine 
relative IKBα and phospho-IKBα levels using the anti-IKBα and anti-phospho-IKBα antibodies. Equal 
loading was also assessed using anti-β-actin antibody. (C) The change in phospho-IKBα relative to 
total IKBα was then quantified using ImageJ.  
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4.2.7 Inhibition of IKKβ reduces MDM2 
The above results demonstrate that IMD0354 leads to a reduction in MDM2 
levels as well as reducing the activity of IKKβ over a similar time scale. It is not clear 
however whether it is the ability to inhibit IKKβ that causes IMD0354 to reduce 
MDM2 levels. In order to establish whether this ability to reduce MDM2 levels is 
common to other chemical inhibitors of IKKβ two other IKKβ inhibitors were tested. 
The inhibitors used were IKK16 and BMS-345541, both of which are considered to 
be IKKβ specific inhibitors (244, 245). BMS-345541 was tested using concentrations 
ranging from 0.4µM-50µM, IKK16 was only tested from 0.4µM-25µM as, consistent 
with previous results, higher concentrations caused a high level of cell death. As 
shown in Fig 4.8. in T47D cells both IKK16 and BMS-345541 lead to a reduction in 
MDM2 levels. Whilst these three compounds all target IKKβ they are structurally 
unrelated (Fig 4.9), this suggests the chemical perturbation of IKKβ function 
consistently leads to a reduction in MDM2.  
IKK16 and BMS-345541 were also tested in A375 cells in order to ascertain 
their effect on wtp53. A375 appeared to be more sensitive to IKK16 than T47D cells 
and lead to significant cell death; as such no results were obtained for this drug in 
A375 cells. However, consistent with the results of IMD0354, BMS-345541 also lead 
to a reduction in MDM2 in A375 cells (Fig 4.10). Of the 3 drugs tested IMD0354 
appeared to be the most effective in reducing MDM2 in both cell lines and could 
reduce MDM2 levels at concentrations as low as ~800nM.  
Together, the results of treatment of cells with IMD0354, IKK16 and BMS-
345541 demonstrate that chemical inhibition of IKKβ leads to a reduction in MDM2 
protein levels which is independent of p53 status. Chemical inhibition generally 
reduces the kinase activity of its given target. However a number of kinases 
including the IKK family protein IKKα have been shown to have additional functions 
independent of their kinase activity (246). Any kinase independent function of IKKβ 
may remain undisrupted by chemicals inhibiting it kinase function but this is not 
assured. Potentially reducing its kinase function could make the protein more 
available for other non-kinase functions. In order to confirm that the reduction in 
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MDM2 results from a reduction of IKKβ function and not as a result of an increase in 
non –kinase function or, alternatively, off-target effects of the specific inhibitors, 
siRNA targeting IKKβ was utilised to disrupt IKKβ.  
T47D and A375 cells were treated with either siRNA targeting IKKβ or non-
targeting siRNA. As can be seen in Fig 4.11 treatment of T47D and A375 cells with 
IKKβ siRNA leads to a reduction in MDM2 levels compared to treatment with non-
targeting siRNA. This reduction appears to be less substantial than with inhibitor 
treatment. This shows that, at least qualitatively, the effect of chemical and genetic 






Fig 4.8. IKKβ inhibitors BMS-345541 and IKK16 led to a reduction in MDM2 in T47D cells.  T47D cells 
were treated with the indicated concentration of BMS-345541 (A) or IKK16 (B) for 16Hrs. Cell lysates 
(20µg/well) were then assessed by western blotting to determine relative MDM2 levels using the 
anti-MDM2 antibody, 2A10. Equal loading was also assessed using anti-β-actin antibody. 
 






Fig 4.10. IKKβ inhibitor BMS-345541 led to the reduction of MDM2 in A375 cells. A375 cells were 
treated with the indicated concentration of BMS-345541 for 16Hrs. Cell lysates (20µg/well) were 
then assessed by western blotting to determine relative MDM2 levels using the anti-MDM2 antibody, 





Fig. 4.11. siRNA targeting IKKβ recapitulates the reduction of MDM2 seen with chemical inhibition. 
T47D (A) and A375 (B) cells were transfected with control, non-targeting and IKKβ specific siRNA.  
Cell lysates (20µg/well) were then assessed by western blotting to determine relative MDM2 and 
IKKβ levels using anti-MDM2 and anti-IKKβ antibodies. Equal loading was also assessed using anti-β-
actin antibody.   
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4.2.8 Overexpression IKKβ does not lead to substantial changes in MDM2 levels 
This study shows that inhibition of IKKβ by siRNA or chemical inhibition leads 
to the reduction of MDM2. The next question to be addressed therefore was 
whether overexpression of IKKβ would similarly lead to an increase in MDM2. 
Therefore we sought to investigate the effect on MDM2 of the overexpression of 
wild-type, constitutively active and kinase dead IKKβ. IKKβ is activated when 
phosphorylated at two serines, 177 and 181, within the T-loop domain (242, 247). It 
has been shown that if these serines are replaced with glutamic acid to mimic the 
phosphorylated form, the protein becomes constitutively active (241, 242). 
Conversely mutation at the K44 residue within the ATP binding domain can cause 
reduced kinase activity presumably as a result of poor ATP binding (241, 242).  
In order to assess the effect of overexpression of the different IKKβ mutants, 
stable cell lines expressing wild-type, K44M (KM) and S177E/S181E (SSEE) IKKβ were 
created. One main problem when making stable cells, by the classic method of 
random integration of the gene into the cells genome, is that the integration can 
occur anywhere in the genome and at any number of locations. This is particularly 
problematic when comparing between different stable cell lines. For example, if the 
mutant form were integrated at more locations or at locations with higher 
transcriptional activity than the wild-type then the two cells would have a different 
level of overexpression which could skew results. In order to avoid this, the Gateway 
Flp-In system was used. The work-flow for this is detailed in Fig.4.12. Briefly this 
involves the integration of a single FRT site within a cell line (in this case A375 cells), 
as well as cloning the gene of interest into a gateway vector with an FRT site. When 
the vector is transfected into the cells along with the pOG44 enzyme vector, the 
enzyme catalyses recombination of between the FRT sites. This means that every 
time a gene is transfected into the parental cell recombination will happen only 
once at the same site in the genome. In this experiment A375 cells with a single 




As can be seen in Fig 4.13A integration of the wt-IKKβ and KM-IKKβ into the 
A375-FRT cells lead to a similar level of overexpression. However, slightly reduced 
overexpression of the SSEE-IKKβ form is observed in comparison to wt and KM IKKβ. 
As the Flp-In system means this should not be due to differential gene integration it 
suggests that this could be due to differential regulation of active and inactive forms 
of the kinase. IKK degradation is only recently being understood and may involve 
both proteasomal degradation and autophagy (248, 249). Whilst it would be 
imagined that activation would, if anything, lead to increased stability of the 
protein, such pathways often have negative feedback mechanisms which act to shut 
off the pathway after a period of time. For example IKK activation of Nf-kB via the 
classical pathway is transient and when IKKβ is activated by phosphorylation this 
leads to auto-phosphorylation near the C-terminus which inhibits activity (247). This 
result potentially suggests that increased kinase activity could also lead to negative 
regulation of protein stability.  
As can be seen in Fig 4.13 B overexpression of wild-type, KM and SSEE IKKβ 
lead to a slight increase in the amounts of MDM2 compared to the parental cell line. 
With IMD0354 treatment no clear difference in MDM2 levels with overexpression of 
the different IKKβ mutants is perceptible. The levels of MDM2 however should really 
be compared between cell lines overexpressing the different mutants as these cells 
have undergone the same selection procedure. It would be anticipated therefore 
that if overexpression of IKKβ was leading to an increase in MDM2 that 
overexpression of SSEE IKKβ would led to substantially higher levels of MDM2 than 
KM IKKβ. Overexpression of SSEE IKKβ appeared to lead to very slightly higher levels 
of MDM2 than wt IKKβ or KM IKKβ. However, this was not substantial and thus it 
cannot be concluded at this time that overexpression of IKKβ leads to an increase in 
MDM2 protein levels. It should be noted that just because IKKβ inhibition reduces 
MDM2 it does necessarily mean that an increase in IKKβ would led to an increase in 






Fig 4.12 Work-flow of the creation of stable cell lines. FRT-lac Zeo is transfected into the chosen cell 
line. Colonies which have one integrated FRT site are then selected, this is termed the parental cell 
line. In parallel to this the destination clone is created; the gene of interest (GOI) is cloned into an 
entry vector such as pDONR221 by BP reaction. The GOI is then transferred to the destination vector 
(pEF5/FRT/V5-DEST) by an LR reaction. The destination clone and pOGG44 is then transfected into 
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the parental cell line. pOGG44 then catalyses the recombination between the FRT sites allowing the 




Fig 4.13 IKKβ overexpression does not lead to substantial changes in the levels of MDM2. (A) A375 
cells overexpressing wt-IKKβ, K44M-IKKβ (KM) and S177E/S181E-IKKβ (SSEE) were made using the 
Gateway Flp-In system. Cell lysates (20µg/well) were then assessed by western blotting to determine 
relative IKKβ levels  using an anti-IKKβ antibodies. Equal loading was also assessed using anti-β-actin 
antibody. (B) Cells overexpressing IKKβ (wt, KM, SSEE) were treated with 5µM IMD0354 or DMSO for 
2Hrs. Cell lysates (20µg/well) were then assessed by western blotting to determine relative MDM2 
levels using the anti-MDM2 antibody 2A10. Equal loading was also assessed using anti-β-actin 
antibody.   
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4.2.9 Increased cell density reduces MDM2 and D type cyclins. 
Research from Moshe Oren’s group has shown that the p53 pathway can be 
attenuated by high density (250) in addition to this previous work within the lab has 
shown that MDM2 levels specifically can be effected regulated by cell density 
(unpublished data). As shown in Fig 4.14, MDM2 is likewise regulated by cell density 
in T47D cells with higher densities; leading to a reduction in MDM2 levels. It was 
investigated whether other proteins altered by IKK inhibition are also affected by 
this mechanism. As can be seen in Fig 4.14 cyclin D1 is initially increased as cell 
density increases. This is expected as cyclin D1 is required for the cell cycle and so 
will be at higher levels in proliferating cells. Cyclin D1 is thought to be required for, 
and is increased during G1 and G2 phase but is reduced during S phase of the cell 
cycle (251). As the cells were asynchronous it can be expected that cyclin D1 
expression would be higher in the cells overall when they are replicating. As cells 
reach a higher level of density the cells will have stop dividing due to contact 
inhibition. Interestingly cyclin D1 is lost at the same time-point at which MDM2 is 
reduced. 
A number of kinase inhibitors have been shown to be able to overcome the 
reduction in MDM2 as a result of density (Y Lin. Unpublished data). It could be 
speculated that manipulation of these same pathways could also overcome MDM2 
reduction as a result of IMD0354 treatment, therefore these kinase inhibitors 
(detailed in Table 4.1) were tested by in cell western for their ability rescue MDM2 
loss after IMD0354 treatment. As can be seen from Fig 4.15A only one of these 
inhibitors, Ki-8751, which inhibits VEGFR, appeared able to increase MDM2 levels. 
Further analysis by in cell western (Fig 4.15B) revealed that Ki-8751 alone does not 
lead to significant changes in MDM2 levels but treatment of T47D cells with 50µM 
or 25µM Ki-8751 appears to be able to partially overcome the loss of MDM2 
resulting from IKKβ inhibition (PVal= 0.002, 0.024 respectively). Western blotting 
was then used in order to try to validate this result; however, this did not 
demonstrate any rescue of MDM2 levels resulting from Ki-8751 treatment. 
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Potentially, this could result from the better sensitivity of in cell western in 





Fig 4.14. High cell density leads to a reduction in MDM2 and D-type cyclins. T47D cells were grown 
at 6 different densities.  Cell lysates (20µg/well) were then assessed by western blotting  to 
determine relative MDM2, IKKβ, cyclin D1 and cyclin D3 levels using anti-MDM2 (2A10), anti-IKKβ, 
anti-Cyclin D1 and anti Cyclin D2 antibodies. Equal loading was also assessed using anti-β-actin 
antibody.   
 
Table 4.1. Compounds identified as potentially reducing MDM2 loss at high density 
Name Target kinase 
ZM 306416 hydrochloride VEGFR 
Compound 401 DNA-PK 
PD 198306 MEK 
GW 583340 dihydrochloride EGFR 
CGP 53353 PKC 
Ki 8751 VEGFR 
Aminopurvalanol A cdk 
SD 208 TGFbR1 







Fig 4.15 In cell western but not western blotting suggests Ki-8751 can partially rescue the loss of 
MDM2 by IMD0354. (A) T47D cells were treated with 5µM IMD0354 as well as 50µM of the 
indicated compound for 2Hrs. MDM2 levels were then quantified by in cell western using the MDM2 
specific antibody 4B2. Columns show means of results in triplicate and error bars indicate standard 
deviation. * denotes a significant change, assessed by T-test, in MDM2 level compared to IMD0354 
treated cells (PVal>0.05) (B) T47D cells were treated with IMD0354 and Ki-8751 as indicated for 2Hrs. 
MDM2 levels were then quantified by in cell western using the MDM2 specific antibody 4B2. 
Columns show means of results in triplicate and error bars indicate standard deviation. Statistical 
significance between DMSO versus Ki-8751 and IMD0354 Versus IMD0354 + Ki-8751 was assessed by 
T-Test. * denotes a significant change in MDM2 level (PVal>0.05) (C) T47D cells were treated with 
IMD0354 and Ki-8751 as indicated for 2Hrs. Cell lysates (20µg/well) were then assessed by western 
blotting to determine relative MDM2 levels using the anti-MDM2 antibody, 2A10. Equal loading was 




4.2.10 IMD0354 does not increase MDM2 turnover rate  
IKKβ inhibition could potentially lead to a reduction in the levels MDM2 by a 
number of mechanisms e.g. it could lead to an increase in protein degradation or 
lead to a reduction in protein synthesis. MDM2 is normally degraded via the 
ubiquitin-proteasome system and therefore it was investigated whether inhibiting 
the proteasome would prevent the loss of MDM2. Alteration of MDM2 stability is 
thought to be an important mechanism in the regulation of the p53 pathway. For 
example after DNA damage MDM2 is phosphorylated by CK1 which promotes it’s 
ubiquitination by β-TRCP, leading to rapid degradation (252). This allows p53 
activation by reducing its degradation by MDM2. As shown in Fig 16A the 
proteasome inhibitor MG132 was only capable of a partial rescue of MDM2 levels if 
cells were treated with MG132 and IMD0354 at the same time. If pre-treated with 
IMD0354 then rescue was not possible. This implies that once the MDM2 that is 
present in the cell is degraded, the levels of MDM2 cannot be re-established by 
blocking degradation. This means that degradation does contribute to the reduction 
of MDM2, but such reduction does not result from changes to proteasomal 
degradation.  
However there are multiple mechanisms of degradation within a cell and it is 
therefore possible that MDM2 is lost as a result of trafficking into a different 
degradative system. In order establish whether the rate of degradation is affected by 
entering a different degradation system the turnover rate of MDM2, with and 
without IMD0354, was assessed. As can be seen in Fig 16B-C the rate of turnover 
was not increased as a result of IMD0354 but turnover rate appeared to be 
marginally decreased. This shows that changes in degradation rate is not a major 





Fig. 4.16. IMD0354 does not increase the turnover rate of MDM2. (A) T47D cells were treated with 
MG132 and IMD0354 for 2Hrs. Cells were additionally pre-treated with IMD0354 for an additional 0, 
30, 60 or 120mins. Cell lysates (20µg/well) were then assessed by western blotting to determine 
relative MDM2 levels using the anti-MDM2 antibody, 2A10. Equal loading was also assessed using 
anti-β-actin antibody. (B) T47D cells were treated with cycloheximide (CHX) with and without 
IMD0354 for the indicated time. Cell lysates (20µg/well) were then assessed by western blotting to 
determine relative MDM2 levels using the anti-MDM2 antibody, 2A10. Equal loading was also 
assessed using anti-β-actin antibody. (C). The graph shows the quantification of MDM2 levels in (B) 
normalised to B-actin levels expressed as a % of untreated cells (0mins time-point). The western blot 




4.2.11 MDM2 mRNA levels are reduced by IMD0354 treatment 
As the degradation of MDM2 is not increased by IMD0354 this implies that de 
novo production must be being inhibited to bring about MDM2 loss. This is 
consistent with the fact that MDM2 loss resulting from IMD0354 treatment occurs 
at a rate roughly equal to its rate of turnover. Proteins are made in a number of 
distinct steps; first mRNA is transcribed from DNA, the mRNA is then processed and 
relocated to the transcription machinery and finally the protein is produced by 
transcription.  
The levels of MDM2 are known to be regulated at the level of transcription. 
MDM2 transcription is most typically thought to be controlled by p53 (163), 
however this study has demonstrated that the reduction in MDM2 levels resulting 
from IMD0354 is independent of p53. Nonetheless, this does not discount that the 
idea that transcriptional changes could be important, as MDM2 transcription is not 
solely a result of p53 activity, and other transcription factors are known to promote 
MDM2 transcription (27).  Therefore, the response of MDM2 mRNA levels to 
IMD0354 treatment was investigated. MDM2 mRNA levels were assessed by qPCR 
and were compared with β-Actin mRNA levels as a control. The percentage change 
in mRNA levels was analysed by the 2-ΔΔCt method (Detailed in the Methods 
Chapter). As can be seen in Fig 4.17A, mRNA was significantly reduced by IMD0354 
and ~40% reduction was observed. The reduction in mRNA levels appears to be less 
acute in comparison to the reduction in protein level (Fig 4.16B) however the 
dynamic range of these two techniques likely differs. Furthermore different 
transcripts of MDM2 lead to different rates of synthesis meaning that a relatively 
small change in mRNA levels could lead to a bigger change in protein level (25). 
Nevertheless the relatively small change in mRNA levels does suggest that other 
contributing mechanisms to the reduction of MDM2 protein level are possible and 





Fig. 4.17. IMD0354 leads to a reduction in MDM2 mRNA concomitant with a reduction in MDM2 
protein. (A) T47D cells were treated with 5µM IMD0354 for 2Hrs. MDM2 mRNA levels were then 
assessed by qtPCR. Relative changes in mRNA levels were analysed using 2
-ΔΔCt
 method. The statistical 
significance of the change in ΔΔCt between β-actin and MDM2 was assessed by T-Test and the P-
Values indicated. (B) T47D cells were treated with 5µM IMD0354 for 2Hrs. Cell lysates (20µg/well) 
were then assessed by western blotting to determine relative MDM2 levels using the anti-MDM2 




This study shows that the IKKβ inhibitor IMD0354 leads to a reduction in a 
number of proteins including mtp53, MDM2, p21 and Cyclin D. It also further 
defines IKKβ as an important factor for the maintenance of the cellular levels of 
MDM2. IKK is a multi-subunit complex with known roles in allergy, inflammation, 
immunity and cancer (211, 212). IKK is best known as an activator of Nf-κB (See Fig 
4.1); a family of related transcription factors (99, 100). However, in addition to 
activation of Nf-κB, IKK can also phosphorylate a variety of other substrates (211). 
The IKK complex is composed of IKKα (IKK1), IKKβ (IKK2) and nemo (IKKδ) subunits. 
IKK complex can be made up of various combinations of these three subunits. Not 
all complexes necessarily contain all three and these different complexes are known 
to contribute to different pathways. For example, activation of Nf-κB (Fig 4.1) by the 
classical pathway relies on complexes composed of 2 nemo molecules and a hetero 
or homodimer of IKKα and/or IKKβ, whilst activation by the non-classical pathway 
relies on only IKKα (212). α and β subunits both have kinase activity whereas nemo 
has only a regulatory role (212).  
Whilst this study initially set out to characterise IKKβ in terms of its ability to 
regulate p53 levels it quickly became apparent that IKKβ inhibition by IMD0354 can 
lead to the reduction of a number of other proteins. This work has largely used 
MDM2 as a surrogate marker of IKKβ regulated proteins as it responds rapidly after 
IKKβ inhibition. The order in which the different proteins (p53, MDM2, p21) are lost 
appears to reflect the relative stabilities of each protein suggesting that the more 
rapidly turned over proteins will be lost first. 
Identification of factors affecting MDM2 such as IKKβ is critical as MDM2 is 
considered to be an oncogene and so its loss is considered to be beneficial for 
therapy (108, 233, 253). When MDM2 levels are reduced in cell lines using siRNA 
this can lead to reduced cell growth and apoptosis independent of p53 status (234, 
235). MDM2 is considered to be oncogenic via a number of mechanisms and it is 
frequently seen to be overexpressed in cancer cells (26). Originally its oncogenicity 
was thought to be due to its ability to supress p53 and prevent its action as a 
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tumour suppressor, however more recently it has become apparent that it has a 
number of other mechanisms are also responsible for its action (235). MDM2 is now 
considered to have many p53 independent roles in a number of cellular processes 
including cell cycle control, proliferation and differentiation (232). 
This study mainly focussed on using IMD0354 to inhibit IKKβ. This IKKβ specific 
inhibitor was first reported in 2004 and since been used in various studies to 
investigate the importance of IKKβ in cancer pathways (229, 230). Experiments in 
mice have shown that IMD0354 does not lead to general toxicity and IMD0354 has 
been proposed to be an important line of inquiry for future study as it may 
potentially be useful in treating cancer as well as other disorders (229, 230, 240). 
Although mainly focussed on IMD0354, in total three small molecule inhibitors 
targeting IKKβ; IMD0354, IKK16 and BMS-345541 were shown in this study to 
reduce levels of MDM2. IKKα and IKKβ can function as both hetero and 
homodimers, but the results presented here suggest that inhibition of IKKβ is 
sufficient to lead to the reduction in MDM2. A number of studies have shown that 
IKKβ appears to have greater activity than IKKα in the classical pathway which is 
reliant on both isoforms (241, 242). However, the relative contribution of each is 
hard to determine and it has been suggested that inhibition of one may well affect 
activity of the other (241). IKKβ inhibitors tend to also show activity towards IKKα 
albeit at a higher concentration (244, 245). This study mainly focused on using 
chemical inhibitors as therapy currently largely relies on such therapeutics. 
Unfortunately, no specific IKKα inhibitors are to our knowledge commercially 
available and so the effect of inhibiting IKKα was not specifically assessed. 
Therefore, it cannot be ruled out that IKKα may also be able to contribute to MDM2 
stability. 
siRNA knock-down of IKKβ supports the results from chemical inhibitor data as 
siRNA knock-down of IKKβ similarly lead to a reduction in MDM2. However, there 
were notable differences in the extent of MDM2 reduction in the two techniques. 
IMD0354 caused a substantial loss of MDM2 whereas IKKβ targeting siRNA lead to a 
more subtle reduction. There are a number of potential reasons for this. Firstly, 
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siRNA leads to target knock-down and is unable to lead to a total loss of IKKβ 
protein. Basel levels of IKK activity may not require 100% of the protein present. The 
IKK pathway is thought to be activated by phosphorylation of IKKβ (247) and the 
level of IKK present in the cell may not be the limiting factor with base level activity. 
Therefore, reduction observed with siRNA may not bring about as dramatic a 
change as with a chemical inhibitor, which is likely to be in excess. The alternative is 
that the fact that inhibition of IKKβ by siRNA is a slower process, reducing IKKβ over 
days rather than minutes, may mean that the cell has time to adapt to the changes 
occurring. MDM2 levels are tightly regulated and siRNA experiments have shown in 
many cases that excessive reduction of MDM2 in cancer cells is not tolerable (235, 
254) and thus, it is possible that the cell may have an adaptive responsive to an 
indirect reduction in MDM2. 
The levels of MDM2 can be regulated by a number of processes including the 
density of cells (data not published) and, as also shown here, MDM2 is reduced at 
higher densities. Analysis of a number of compounds, that have previously been 
shown to reduce MDM2 loss at high density (data not published), by in cell western 
technique showed that inhibition of VEGFR by Ki-8751 may partially rescue the 
reduction in MDM2 by IMD0354 treatment. As growth factors including VEGF are 
secreted it is logical that at higher densities more VEGF may be present in the 
media. However it is less clear how VEGF could contribute to the IMD0354 mediated 
down-regulation of MDM2. IKK has been shown to be an upstream regulator of 
VEGF (255, 256) meaning that IKK inhibition should also act to inhibit VEGF 
expression. MDM2 has also been shown to positively regulate VEGF via HIF-1 (257), 
and there does not appear to be any established mechanisms of VEGF regulation of 
MDM2. Western blotting was unable to reproduce the rescue of MDM2 by Ki8751. 
This could be due either to intrinsic differences in the available/extractable pools of 
MDM2 in the two techniques or, could potentially reflect the greater sensitivity of 
the in cell western technique (205). The results from the in cell western technique 
showed that MDM2 recovery was modest and protein levels were still substantially 
below the levels seen in untreated cells. Such a small recovery therefore may be 
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undetectable by western blotting. This does however suggest that if VEGFR does 
play a role in the dissemination of this pathway it is only a very minor one and is 
non-essential. It should also be noted that a significant recovery was only seen with 
a relatively high concentration of Ki8751. 
 The study showed that IKKβ inhibition by IMD0354 leads to a reduction in 
MDM2 protein which is concomitant with a reduction in MDM2 mRNA levels. The 
turnover rate of MDM2 protein was not increased by IMD0354 but in fact appeared 
to slightly decrease the rate of degradation. Potentially the mechanism by which 
IKKβ prevents MDM2 production could induce an adaptive response whereby the 
loss of existing protein is slowed. Quantitative PCR suggest that the reduced level of 
MDM2 may in part be due to a reduction in mRNA levels. Together these results 
suggest that IKKβ is required for maintaining mRNA levels, either by sustaining 
transcription or by preserving the stability of mRNA. However, mRNA levels were 
only reduced modestly (by ~40%), whilst protein levels appear to be much more 
dramatically reduced. Differences in the dynamic ranges of the two techniques 
could be contributing the observed disparity; however other mechanisms of 
regulation may be of importance and were not excluded in this study. Another 
potentially important mechanism could be mRNA localisation and storage. Future 
work could assess mRNA localisation using fluorescent in situ hybridisation (FISH). It 
may also be useful in future work to define the rates of transcription using a nuclear 
run-on assay.  
The relationship between IKK and the p53 pathway including MDM2 is 
complicated. Whilst it has been shown there are a large number of ways in which 
the pathway can interact (39) the dominant outcome is difficult to predict. The 
importance of IKK in MDM2 regulation has previously mainly been investigated in 
terms of p53 i.e. investigating the effect of IKK perturbation on MDM2 as a 
consequence of, or subsequent to, p53 change. As such, this axis has been little 
investigated in mtp53 cells. MDM2 has been previously been shown to be reduced 
as a consequence of IMD0354 treatment. Tanaka et al. (2006) showed that IMD0354 
lead to cell cycle arrest and apoptosis by reducing the levels of cell cycle regulators 
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and anti-apoptotic proteins (229). One of the cell cycle regulators they considered 
was MDM2 and showed it was reduced in MDA-MB-231 cells at concentrations 
down to 5µM, but no reduction was seen at 1µM. This study found that in T47D, 
H1299, A375 and MDA-MB-231 cells MDM2 was reduced as low as 400-800nM. The 
comparison of western blots shows that the reduction in MDM2 in MDA-MB-231 
cells as a result of IMD0354 treatment may be more subtle; however comparison 
between western blots is problematic and within this study any difference between 
sensitivities cannot be confirmed. They concluded that the changes in MDM2 were 
not due to any alteration in p53 as the p53 in this cell line is mutant and no changes 
in p53 level were observed. Whilst this study similarly concluded that MDM2 
reduction was p53 independent a reduction in p53 levels was observed. Such 
differences could potentially reflect differences in the cell lines used (MDA-MB-231 
versus T47D and A375 cells). Although alternatively it is possible that the turnover 
rate of mtp53 in MDA-MB-231 is too slow to observe any decrease within the time 
period used and that the effects of IMD0354, but not the kinetics, were the same as 
in the cell lines used in this study.  
The literature shows that manipulation of IKK or Nf-κB could lead to changes in 
MDM2 via a number of different mechanisms. Lau et al. (2012) showed that 
activation of the IKK pathway via disruption of cIAP2 could lead to post-translational 
modifications of MDM2 enhancing its activity (222). Post-translation modifications 
leading to altered stability, do not however, appear to be important within this study 
as turnover of MDM2 was not increased upon IKK inhibition. However this study 
investigated chemical inhibition of basal activity rather than changes after induced 
Nf-kB activity so such differences are not at odds.  
Consistent with the work presented here other studies have also shown that 
inhibition of the IKK pathway can lead to changes in the levels of transcription. 
Tergaonkar et al. (2002) observed that in IKKβ-/- MEFs MDM2 levels were lower 
than in those reconstituted with IKKβ (220). They also showed that IKKβ-/-MEFs had 
reduced MDM2 mRNA levels; again this is consistent with the findings in this study. 
However one major difference was that they found that increasing MDM2 levels by 
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IKKβ reconstitution was dependent on p53. However Tergaonkar et als study 
focused on using MEFs and it is highly likely that different regulatory mechanisms 
exist in MEF compared to cancer cell lines. Furthermore they largely relied on 
knock-out technology whereas this study mainly, although not exclusively, 
investigated chemical inhibition. They also found that a lack of IKKβ in MEFs 
promoted the stabilisation of p53 in response to doxorubicin. Interestingly whilst it 
was shown in this study that IMD0354 can reduce wtp53 the effect was not 
consistent across different concentrations. Within the previous chapter screening of 
the Tocris kinase inhibitor library did not identify IMD0354 as a p53 activator and 
furthermore such a dramatic reduction in MDM2 seems inconsistent with p53 
activation. However, within this chapter the effect of IMD0354 on wtp53 activation 
was not specifically assessed and further work would be required in order to 
conclusively show changes in p53 activity with IMD0354. 
A study by Busuttil et al. (2010) also found that in T-cells Nf-κB can lead to 
increased transcription of MDM2 (221). Consistent with the data here they did not 
find that this process was dependent on p53 but rather suggested that transcription 
may result from direct binding of Nf-κB to the P1 promoter.  
In conclusion, IKKβ is known to be responsible for negatively regulating the 
stability of IKB and this research supports the idea that IKKβ can also lead to positive 
regulation of a separate subset of proteins including mtp53, D-type cyclins and 
MDM2 (Fig 4.18), all of which have been shown to contribute to oncogenesis. This 
potentially occurs by a mechanism which increases the levels of mRNA, although 
the mediators of this effect remain unidentified. As discussed an exploration of the 
literature does provide some potential possibilities, however such an approach can 
bias our investigation towards better understood mechanisms and leave other 
contributing pathways unidentified. As such, the following chapter will use a 







Fig 4.18 Model of the regulation of IKB and MDM2 by IKKβ (A) IKKβ phosphorylates IKB leading to 
its degradation by the proteasome. Conversely IKKβ promotes the stability of MDM2 potentially via 
increased transcription and translation. (B) IKKβ inhibition leads to reduced IKB phosphorylation 
allowing IKB to escape to its degradation by the proteasome. Conversely IKKβ inhibition reduces the 








Proteomic investigation into the effect of the 
IKKβ inhibitor, IMD0354 on T47D cells 
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5. Proteomic investigation into the effect of the IKKβ inhibitor, 
IMD0354 on T47D cells. 
5.1 Introduction 
The previous chapter investigated the effect of IKKβ inhibition on the p53 
pathway. This mainly focused on characterising the effect of the IKKβ inhibitor 
IMD0354 and showed this inhibitor lead to a reduction in MDM2 protein levels 
consistent with the effects of other IKKβ inhibitors as well as RNAi inhibition. In 
addition it was shown that inhibition of IKKβ using IMD0354 led to the reduction of 
mtp53, p21 s as well as D-type cyclins (D1 & D3). This chapter aims to further 
explore the IKKβ pathway in terms of the effects on the proteasome after IKKβ 
inhibition. Specifically, this chapter aimed to identify other proteins regulated by 
IMD0354 treatment to identify both co-regulated factors with, and mediating 
factors of, MDM2 reduction. Furthermore this will help  address how specific the 
requirement of IKKβ is in reducing p53 regulated proteins and Cyclin Ds; i.e. does it 
maintain a limited number of pathways or does it have a more general effect on the 
proteome.  IKKβ is known to affect a wide number of proteins, directly by 
phosphorylating substrates and indirectly as many of these substrates are 
transcription factors (211). In an attempt to take an unbiased approach to 
investigating this pathway, proteomic analysis was employed. 
Due to the fact that there is so much cross talk between different pathways 
within the cell it is becoming increasingly apparent that the response of the 
proteome as a whole is important in analysing outcomes of pathway perturbation. 
Such analysis is termed proteomics; a phase which was coined by Marc Wilkins at 
Macquarie University (1994) (258). Proteomic analysis is used for the discovery of 
new biomarkers for cancer and other disease, exploring the interactome of a given 
protein or for identification of pathways regulated by a given manipulation (259-
262). 
Analysing the proteome however is not simple, and whilst significant 
progress is being made in proteomic methods no technology exists which can detect 
169 
 
and quantitate all proteins within the cell. Current proteomic analysis typically relies 
on mass spectrometry (MS) techniques. For the analysis of complex samples 
proteomic techniques rely on the extraction of proteins and digestion of these 
proteins to produce peptides which can be analysed by Tandem MS (MS/MS). Mass-
spectrometry identifies the mass/charge ratio of the molecule which can be used to 
identify the molecule or compound in question. Due to the complexity of peptides, 
tandem mass spectrometry is required for identification. Once samples have been 
ionised they are analysed by the 1st MS in order to identify the precursor or parental 
peaks. This gives the mass-charge ratio of the whole peptide, due to the existence of 
many possible peptides with variable lengths this information is not enough for 
identification of the peptide/molecule. Therefore peaks are selected and the 
peptides are subjected to fragmentation to identify the secondary or daughter 
peaks. This second MS will provide identification of the peptide in terms of its amino 
acids. This is possible as there are only a limited number of amino acids with 
different masses. The differences in mass between each of the y and b ions will be 
the mass of the specific amino acid (Fig 5.1). For example, if a mass shift of 71 is 
observed this would be most likely explained by the loss of an alanine residue.  
Fractionation of the sample is also critical to ensure a maximal identification 
of proteins within the sample (263, 264). To some degree, fractionation will also aid 
in the identification of lower abundance species as each of the fractions will be less 
complex (263, 264). Fractionation can be achieved by a number of techniques, 
including subcellular fractionation, gas phase fractionation or, as used here, strong 
cation exchange (SCX). 
 Proteomic analysis generally requires comparison of two or more samples 
i.e. comparison of a control or base level sample versus a diseased or manipulated 
sample.  In order to do this a number of labelling techniques have been developed 
which allows peptides from different samples to be labelled and then analysed 
together by MS. Two different labelling techniques were used in the experiments 
presented here. The first experiment used a common post-digestion labelling 
system; isobaric tags for relative and absolute quantitation (iTRAQ) (265). iTRAQ 
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tags are covalently attached to digested peptides of the different samples. There are 
8 different iTRAQ tags typically available, however here only four tags, or a 4-plex 
experiment was conducted. One advantage of fewer samples analysed is that the 
mixture is less complex and so generally a greater depth of data is achieved. The 
individual iTRAQ tags have the same overall mass but are composed of different 
weight reporter mass groups and variable balancer mass groups which act to keep 
total mass the same (265) (Fig 5.2A). As the total mass of the iTRAQ tags is the 
same, the same peptides from different treatment groups, and so different labels, 
will be detected together in MS1. When fractionated, the reporter group will is 
released and the relative intensities of each tag will indicate the relative amount of 
each peptide within the sample. Fig 5.2B shows an example of this within one of the 
iTRAQ data sets presented here. The graph shows the Mass/change peaks obtained 
from fractionating the peptide DELADEIANSSGK. As can be seen at the lower 
mass/charge end there are 4 peaks corresponding to mass of the labels used (114-
117). The intensities of these indicates the relative abundance of this peptide in 
each sample. 
Another commonly used labelling method which is utilised in this study is 
stable isotope labelling by amino acids in cell culture (SILAC) (266). SILAC involves 
growing cells in media containing either light or heavy isotopes for example 
commonly used isotopes are C12/13 and N14/15. As the cells grow they will use the 
labelled elements (e.g. C12/13 and N14/15) from the media for protein synthesis. This 
means that after a period of time all proteins within the cell will be either “light” or 
“heavy” labelled depending on the media used. This results in mass shift in 
otherwise identical peptides that can be detected by MS1. Commonly used light and 
heavy isotopes are C12/13 and N14/15. SILAC is a particularly useful labelling method 
for studying phosphoproteomics as it means that after labelling all samples can be 
processed together (267). This means that any sample handling that could affect the 
sample should affect both equally; this is particularly useful when using an 
enrichment technique such as in phosphoproteomics as significant sample 
processing is required. However, SILAC does have the disadvantage that analysis is 
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limited to 3 samples; “Heavy”, “Medium” and “Light” labelled samples. 
Furthermore, SILAC cannot be used in clinical samples due to the impracticality of 
labelling patients. 
As proteomics has advanced it is becoming an increasingly useful technique 
to analyse proteins with specific modifications. For example, there is significant use 
of MS in phosphoproteomics and glycoproteomics (267, 268). In terms of 
phosphoproteomics, MS can be used to infer activity within a specific pathway or 
the activity of a given kinase (262, 267, 269). A number of methods have been 
developed to extract phosphorylated peptides or proteins from total peptides and 
commonly used techniques include Titanium dioxide (TiO2) enrichment and 
immobilized metal affinity chromatography (IMAC) (270, 271). In the IMAC 
technique, phosphopeptides are extracted by the interaction of the negatively 
charged phosphate groups with positively charged metal ions (Fe3+, Ga3+, and 
Al3+)(270, 272). Phosphopeptides can also interact with metal oxides, a fact 
exploited by TiO2 bead enrichment (271). TiO2 is generally thought to be a more 
robust technique which shows greater affinity to mono-phosphorylated peptides 
over multi-phosphorylated peptides, on the other hand IMAC is better at enriching 
for multi-phosphorylated peptides (273) (Information for supplier: 
http://www.piercenet.com/browse.cfm?fldID=87231F16-AA7F-A46A-2046-
D3B47B35012D). 
In this study, mass spectrometry will be used to discover the changes to the 
proteome resulting from drug treatment with IMD0354. Two approaches are 
explored to investigate the effects of IMD0354. The first sought to identify proteins 
which are up or downregulated in response to IMD0354 treatment utilising isobaric 
tags for relative and absolute quantitation (iTRAQ). The second was a study to 
identify changes to the phosphoproteasome resulting from IMD0354 treatment 
which could provide leads as potential IKKβ substrates. This was conducted by 
phosphoenrichment by TiO2 beads of peptides from the tryptic digest of protein 





Fig 5.1 Peptide sequencing by Tandem MS. During Tandem mass spectrometry primary peaks are 
identified during MS1 and represent whole ionised peptides. These peptides are then fractionated 
into y and b ions as shown. The mass difference between the ions enables identification of amino 







Fig 5.2. iTRAQ MS/MS. (A) iTRAQ tags are used to label different samples within mass spectrometry 
experiments. These tags contain 3 groups, reporter, balance and peptide reactive groups as shown in 
the top panel. In the 4plex set of tags the reporter group has a mass of between 114-117Da, the total 
tag mass is kept the same with a balance group of between 28-31Da. The Reactive group allows the 
tag to be covalently bonded to the peptides as shown in the bottom panel. In MS1 the same peptide 
with different tags will form one parental peak. Figure adapted from Ross et al. (2004). (B) During 
tandem mass spectrometry the peptides are fractionated at the MS2 stage, at this point the reporter 
group on the tags will break off and the relative intensities of each tag will allow relative quantitation 
of the peptides in each group. The expanded section shows the tag reporter group intensities. The 





5.2.1 Preliminary analysis of samples 
Primarily, this study was designed to identify proteins which were regulated 
by IKKβ inhibition by proteome analysis. In this pilot screen, samples were prepared 
for analysis by iTRAQ by growing T47D cells to ~80% confluency and treating with 
5µM IMD0354. Cells were then harvested at 0, 30, 60 and 120 minutes after 
treatment and prepared for iTRAQ analysis. Previous work in this study has shown 
that this treatment window should lead to the reduction of the MDM2 protein level 
(Fig 4.4C). Whilst this treatment was never seen to fail to reduce the levels of MDM2 
it was considered prudent to check this in samples used for mass spectrometry 
analysis. As shown in figure 5.3A, MDM2 protein expression is, as expected, reduced 
overtime in the samples used.  
A second aim of this study was to identify changes to the phosphoproteome 
resulting from IMD0354 treatment. This may provide potential IKKβ substrates 
relevant for this system; substrates phosphorylated by IKKβ would be expected to 
demonstrate reduced levels of phosphorylation upon IKKβ inhibition. For this 
experiment, cells treated for 120mins with IMD0354 were compared to cells treated 
with drug vehicle, DMSO. For this approach, cells were labelled prior to treatment 
using SILAC. After labelling, cells were then grown to ~80% confluency and treated 
with 5µM IMD0354 or DMSO for 120mins. Again, prior to MS/MS analysis, samples 
were checked to ensure that IMD0354, had, as anticipated led to a reduction in 
MDM2 protein expression. As can be seen in Fig 5.3B MDM2 had been reduced by 
IKKβ inhibition in this sample. This also indicates that SILAC labelling did not affect 







Fig 5.3. Western blotting confirms IMD0354 reduces MDM2 in samples used for MS analysis. (A) 
T47D cells were treated with 5µM IMD0354 for the indicated time. Cell lysates (20µg/well) were then 
assessed by western blotting to determine relative MDM2 levels using the anti-MDM2 antibody, 
2A10. Equal loading was also assessed using anti-β-actin antibody.  (B) T47D cells labelled using 
“Heavy” and “Light” media were treated with DMSO or 5µM IMD0354 respectively for 120mins. Cell 
lysates (20µg/well) were then assessed by western blotting to determine relative MDM2 levels using 
the anti-MDM2 antibody, 2A10. Equal loading was also assessed using anti-β-actin antibody.   
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5.2.2 Analysis of proteome changes resulting from IMD0354 using iTRAQ 
The first proteomic experiment presented here aimed to identify proteins 
which are regulated by treatment with IMD0354. This approach utilised iTRAQ 
analysis and the work flow of this experiment can be seen in Fig 5.4. Briefly, cells are 
treated with IMD0354 for 0, 30, 60 and 120 mins. Proteins are then extracted by cell 
lysis and trypsinised to attain tryptic peptides. The peptides in the different samples 
are then labelled with iTRAQ tags. The four samples were combined and subject to 
strong cation exchange (SCX) to fractionate the sample and then analysed by 
tandem mass spectrometry. For full method see Chapter 2.  
The iTRAQ sample was then divided into two and half of the sample was 
analysed on an ABSciex QStar Elite LC MS/MS. The remaining sample was analysed 
on an ABSciex 5600 LC MS/MS. The numbers of peptides identified and quantitated 
are summarised in Table 5.1. The ABSciex Qstar Elite detected 2692 proteins (with 
an unused score ≥ 1.3) with a low false discovery rate of 0.07%; 2654 of these 
proteins had sufficient data to quantify. The ABSciex 5600 detected slightly fewer 
proteins with a total of 2323 (with an unused score ≥1.3) with a false discovery rate 
of 0.04%; 2276 proteins had sufficient data to quantify. All data is expressed as a 
ratio using the zero minute time point as the subject. Up-regulated and down-
regulated proteins were defined as having ratios of <0.83 or >1.20 respectively with 
a P-Value <0.05. The highest up and down regulated proteins are detailed in Tables 
5.2 and 5.3. Full details of up and down regulated proteins are shown in 




Fig 5.4 iTRAQ proteomics experiment workflow. T47D cells were treated with 5µM IMD0354 for the 
indicated time. Samples were then lysed to extract soluble proteins. One hundred micrograms of 
each sample were then reduced, alkylated and subsequently trypsinised overnight. Each sample was 
incubated with the iTRAQ tags indicated in order to label peptides. The four samples were then 













ABSciex QStar Elite 2692 16398 2 0.07% 




Table 5.2 Top 5 up/down regulated proteins after IMD0354 treatment. Data from iTRAQ proteomics experiment (5600 data set with corresponding Qstar values.) 
Accession Symbol Name Instrument % Cov. Peptides 30:0 P value  60:0 P value 120:0 P Value 
P07910 HNRPC Heterogeneous nuclear 
ribonucleoproteins C1/C2  
5600 42.81 17 0.46 <0.01 1.10 0.27 0.93 0.43 
Qstar 35.95 13 0.70 <0.01 1.00 0.98 0.94 0.45 
P05114 HMGN1 Non-histone chromosomal 
protein HMG-14  
5600 43.00 9 0.46 <0.01 1.27 0.10 1.13 0.25 
Qstar 43.00 6 0.64 0.02 0.96 0.68 0.94 0.62 
P62805 H4 Histone H4  5600 51.46 26 0.51 <0.01 1.29 0.11 0.95 0.67 
Qstar 63.11 28 0.66 <0.01 1.01 0.90 0.92 0.43 
P22626 ROA2 Heterogeneous nuclear 
ribonucleoproteins A2/B1  
5600 54.96 45 0.53 <0.01 0.98 0.81 0.83 0.04 
Qstar 56.37 28 0.69 <0.01 0.93 0.16 0.90 0.04 
P14866 HNRPL Heterogeneous nuclear 
ribonucleoprotein L  
5600 24.62 13 0.58 <0.01 1.01 0.91 0.88 0.21 
Qstar 29.88 15 0.81 <0.01 1.01 0.81 0.94 0.23 
P62277 RS13 40S ribosomal protein S13  5600 22.52 6 1.34 0.02 1.31 0.02 1.62 0.02 
Qstar 35.10 7 1.19 0.09 1.22 0.08 1.29 0.10 
P39019 RS19 40S ribosomal protein S19  5600 48.28 8 1.39 0.01 1.32 0.02 1.46 0.01 
Qstar 42.80 9 1.09 0.16 1.11 0.10 1.14 0.06 
P06733 ENOA Alpha-enolase  5600 50.69 30 1.43 <0.01 1.30 <0.01 1.27 <0.01 
Qstar 55.80 37 1.09 0.10 1.04 0.34 1.06 0.15 
P20700 LMNB1 Lamin-B1  5600 11.09 7 0.72 <0.01 1.43 0.01 1.29 0.01 
Qstar 20.48 10 0.75 0.03 1.34 <0.01 1.21 <0.01 
P49207 RL34 60S ribosomal protein L34  5600 35.90 5 1.07 0.41 1.24 0.05 1.43 0.01 
Qstar 28.20 4 0.91 0.20 1.15 0.20 1.32 0.07 
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Table 5.3 Top 5 up/down regulated proteins after IMD0354 treatment. Data from iTRAQ proteomics experiment (QStar data set with corresponding 5600 values.) 
Accession Symbol Name Instrument % Cov Peptides 30:0 P Value 60:0 P Value 120:0 P Value 
P38159 RBMX Heterogeneous nuclear 
ribonucleoprotein G  
Qstar 28.13 9 0.63 <0.01 0.91 0.20 0.82 0.01 
5600 28.39 12 0.58 <0.01 1.01 0.70 0.87 <0.01 
P05114 HMGN1 Non-histone chromosomal 
protein HMG-14  
Qstar 43.00 6 0.64 0.02 0.96 0.68 0.94 0.62 
5600 43.00 9 0.46 <0.01 1.27 0.10 1.13 0.25 
Q9UKV3 ACIN1 Apoptotic chromatin 
condensation inducer 1 
Qstar 9.77 11 0.64 <0.01 0.88 0.07 0.87 0.04 
5600 8.95 13 0.64 <0.01 0.92 0.14 0.87 0.11 
P62805 H4 Histone H4 Qstar 63.11 28 0.66 <0.01 1.01 0.90 0.92 0.43 
5600 51.46 26 0.51 <0.01 1.29 0.11 0.95 0.67 
P07919 UQCRH Cytochrome b-c1 complex 
subunit 6, mitochondrial  
Qstar 39.56 3 0.67 0.04 1.29 0.09 1.24 0.12 
5600 16.48 2 0.84 0.28 1.09 0.42 1.15 0.29 
P21266 GSTM3 Glutathione S-transferase 
Mu 3  
Qstar 42.67 11 1.35 <0.01 1.30 0.01 1.23 0.03 
5600 12.89 3 1.38 0.12 1.35 0.05 1.28 0.07 
P20700 LMNB1 Lamin-B1  Qstar 20.48 10 0.75 0.03 1.34 <0.01 1.21 <0.01 
5600 11.09 7 0.72 <0.01 1.43 0.01 1.29 0.01 
P49720 PSMB3 Proteasome subunit beta 
type-3  
Qstar 45.85 8 1.27 0.01 1.13 0.15 1.23 0.06 
5600 21.46 3 1.30 0.09 1.05 0.68 1.17 0.21 
P46781 RPS9 40S ribosomal protein S9  Qstar 32.47 9 1.26 0.02 1.20 0.01 1.25 0.02 
5600 20.62 6 1.19 0.18 1.14 0.40 1.23 0.12 
P62195 PSMC5 26S protease regulatory 
subunit 8  
Qstar 28.57 10 1.26 0.02 1.19 0.05 1.23 0.08 
5600 22.91 6 1.23 0.04 1.17 0.09 1.11 0.22 
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5.2.3 Analysis of phosphoproteome changes resulting from IMD0354 using SILAC 
The second experiment detailed here attempted to analyse changes to the 
phosphoproteome resulting from IMD0354 treatment using SILAC labelled cells. For 
SILAC analysis cells were labelled by growing in “heavy” or “light” media for 6 
passages prior to treatment with IMD0354. The “light” media used was control 
SILAC DMEM media containing unlabelled arginine and lysine amino acids (R0K0), 
whereas “heavy” media was SILAC DMEM media containing 13C and 15N labelled 
arginine, and 13C and 15N labelled lysine (R10K8). As IKKβ is a kinase, its inhibition 
would be expected to result in a reduction in phosphorylation of its substrates as 
well as further downstream components. This SILAC analysis aimed to identify 
potential substrates of IKKβ important in mediating the effects of treatment of 
IMD0354 in T47D cells. The workflow for the SILAC analysis is detailed in Fig 5.5 Full 
methods are detailed in Chapter 2. Briefly, cells were labelled with heavy and light 
media and then treated with IMD0354 or DMSO for 2hrs. Samples were then 
subject to processing including trypsinisation and purification. Phosphopeptides 
were then extracted by TiO2
 enrichment and samples were again purified. Once 
samples were processed they were analysed on an ABSciex QStar Elite Hybrid LC 
MS/MS.  
This approach led to the identification of 108 unique peptides (with an 
unused score of ≥1.3), 90 of which were quantified and represented a total of 63 
proteins. The false discovery rate was calculated based on the number of reversed 
protein IDs identified; as no reversed proteins were identified in this analysis the 
false discovery rate was 0%. It is likely that this represents a reasonably low false 
discovery rate combined with few protein identifications. Again, up-regulated and 
down-regulated phosphopeptides were defined as having ratios of <0.83 or >1.20 
respectively. Nineteen phosphopeptides were identified as down-regulated whereas 
twenty-six phosphopeptides were identified as up-regulated. The highest up and 
down-regulated phosphopeptides are detailed in Table 5.5 and 5.6. A large 
proportion of peptides appeared to have missed cleavage sites and further analysis 
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revealed that the efficiency of tryptic digestion was poor and only 49.7% of peptides 




Fig 5.5. Work flow for SILAC phosphoproteomics experiment. Samples are labelled with heavy and 
light media prior to treatment with DMSO or IMD0354. Samples were lysed and immediately 
combined. Samples were then reduce and alkylated. Proteins were precipitated using acetone and 
subsequently trypsinised, Samples were then cleaned on C18 columns and phosphopeptides were 
extracted using TiO2. Phosphopeptides were further purified on graphite columns and analysed by 
LC/MS/MS. 
 









ABSciex QStar Elite 108 90 63 0% 
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Table 5.5 Top 5 Down-regulated Phosphopeptides after IMD0354 treatment. 
Accession Symbol Names % Cov. Sequence Modifications Cleavages H:L % Error  
Q09666 AHNAK Neuroblast differentiation-
associated protein AHNAK  
1.61 GHYEVTGSDDETGKLQGSGVSLASK Phospho(S)@8 missed  
K-L 
0.45 5.58 
Q9P206 K1522 Uncharacterized protein 
KIAA1522  
1.55 ASPVPAPSSGLHAAVR Phospho(S)@2  0.57 4.01 
Q9NYF8 BCLF1 Bcl-2-associated 
transcription factor 1  
4.13 YSPSQNSPIHHIPSR Phospho(S)@2; 
Phospho(H)@10 
 0.59 1.95 
Q9H3N1 TMX1 Thioredoxin-related 
transmembrane protein 1  
7.50 KVEEEQEADEEDVSEEEAESK Phospho(S)@14 missed  
K-V 
0.60 2.18 
Q13247 SFRS6 Splicing factor, 
arginine/serine-rich 6  





Table 5.6 Top 5 Up-regulated Phosphopeptides after IMD0354 treatment. 
Accession Symbol Names % Cov. Sequence Modifications Cleavages H:L % Error 
P27816 MAP4 Microtubule-associated 
protein 4  
1.21 DMESPTKLDVTLAK Phospho(S)@4 missed  
K-L 
2.09 4.09 
Q09666 AHNAK Neuroblast differentiation-
associated protein AHNAK  
1.61 LKSEDGVEGDLGETQSR Phospho(S)@3 missed  
K-S 
2.09 3.37 
Q09666 AHNAK Neuroblast differentiation-
associated protein AHNAK  





Q09666 AHNAK Neuroblast differentiation-
associated protein AHNAK  





P46937 YAP1 Yorkie homolog  3.57 QASTDAGTAGALTPQHVR Phospho(S)@3  1.96 2.36 
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5.2.4 iTRAQ data analysis 
5.2.4.1 Qstar Elite Vs. 5600 
Whilst the ABSciex Qstar Elite lead to the identification of more proteins 
than the ABSciex 5600, the ABSciex 5600 identified more proteins defined as up or 
down regulated as can be seen in Fig 5.6. The two machines are broadly similar in 
design and are both quadrupole time of flight mass-spectrometers. The ABSciex 
5600 identified 60 up-regulated protein and 88 down-regulated proteins, whereas 
the ABSciex QStar Elite identified 19 up-regulated proteins and 79 down-regulated 
proteins.  
Whilst this appears to suggest a large number of disagreements between the 
two instruments, this is not the case. For analysis a strict cut-off value for up and 
down-regulation has to be selected. This means that when using data from two 
MS/MS analyses the two values can fall either side of the cut-off. For example, using 
the ABSciex Qstar Elite, snRNP200 was defined as not changing after 30mins 
IMD0354 treatment as it had a ratio of 0.836 whereas the ABSciex 5600 generated a 
ratio of 0.826 and thus was deemed to have changed. However, the two 
instruments are clearly producing similar results; further examples are shown in 
Table 5.2 & 5.3 and supplementary Tables S2-S4. Whilst this example is one the 
most extreme, when analysing all protein hits identified by only one instrument it 
was noted that the corresponding value on the other instrument showed a non-
significant change but in the same direction 96% of the time (139/145).  
Whilst the data between the two MS/MS analysis are broadly similar the 
data from the QStar Elite appears to identify more conservative changes than the 
5600. In order to take forward the most promising leads further analysis largely 




Fig 5.6 Comparison of proteins identified with either the ABSciex 5600 or ABSciex QStar Elite MS 
instrument in this study.  T47D cells treated with 5µM IMD0354 for 0, 30, 60, 120mins and the 
proteome was analysed by two different MS instuments. MS/MS analysis by the ABSciex Qstar Elite 
lead to the identification of more proteins than the ABSciex 5600 but identified fewer proteins 
up/down regulated with IMD0354 treatment. (A) Shows the total number of protein identified using 
the two instuments (ABSciex 5600/ABSciex QStar Elite) as well as the number identified by either 
instument alone. (B) Shows the up and down regulated proteins at each time point in the ABSciex 
5600 data set. (C) Shows the up and down regulated proteins at each time point in the ABSciex Qstar 




5.2.4.2 Pathway analysis 
In order to assess the potential interaction between protein hits, a network 
was created using STRING 9.0 (http://string-db.org/). STRING is a database of known 
and predicted protein interactions. As can be seen in Fig 5.7, many of the proteins 
identified in the ABSciex QStar Elite data set as changing following IMD0354 
treatment interact with each other and form a large interaction network. This is 
anticipated as proteins can rarely be altered in isolation from their networks. 
Observing such changes in networks of interacting proteins supports the validity of 
each individual result. This network includes a large map with a number of smaller 
more closely connected groups, as well as some smaller isolated networks. One 
large group of closely linked proteins which are seen to change in response to 
IMD0354 treatment are a group of RNA processing and splicing proteins (e.g. SF3A3, 
HnRNPA2B1) which have decreased expression. Smaller interlinked groups include a 
group of ATP synthase proteins (ATPA1, ATP5B, ATP5H and ATP5J) which are both up 
and down regulated at different time points and a group of three ribosomal proteins 
(RPS3, RPS4X and RPS9) which are all up-regulated.  
The up-regulated and down-regulated proteins were also analysed for 
enrichment of pathways, biological process and molecular function represented 
within the data sets. This was analysed using Panther pathway analysis 
(http://www.pantherdb.org/pathway/). This software was designed to analyse 
microarray data but is capable of categorising any protein/gene lists and placing 
them in functional categories. There was no significant enrichment of any (Panther) 
pathways found by the software, however four Go biological processes and five Go 
molecular functions were enriched in the down-regulated data set in comparison to 
all the identified proteins.  These are shown in Fig 5.8 and Fig 5.9. Both analysis 
types suggest that proteins involved in RNA processing are over-represented in the 
down-regulated data set. This is consistent with the network analysis showing that 
an interlinked group of RNA processing and splicing proteins were down-regulated. 
As no pathways were seen to be enriched in either the up or downregulated 
data set a more in-depth analysis was attempted. The entire data set with 
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corresponding ratio values was analysed to identify subtle changes in pathways 
regulated by IKKβ inhibition. The data was then analysed using Panther pathway 
analysis (http://www.pantherdb.org/pathway/). This analysis does not rely on the 
<0.83 or >1.2 cut-off points and instead uses all the available data. By looking at the 
pathways as a whole, smaller changes can be identified; greater confidence results 
from similar changes in a larger group of interlinked proteins. For example a small 
change in one protein maybe chance but a small change in all the proteins in the 
same pathway is likely to be more meaningful. The pathways identified by this 
software are detailed in Table 5.4. and as can be seen, a number of pathways are 
identified to have changed following IMD0354 treatment. Interestingly, more 
pathways appear to be up-regulated than down regulated in T47D cells following. 
Surprisingly the p53 pathway is identified as possibly up-regulated, however, clearly 
this is unlikely in T47D cells as they only express mutant p53 which does not possess 
wild-type activity (274). Factors involved in Huntington disease are also suggested to 
be increased, this is of particular interest as IKK has been suggested to be important 
in the degradation of the normal huntingtin protein (Htt) (275). As Huntington’s 
disease is associated with accumulation of an aberrant form of Htt, it seems entirely 
conceivable that blocking normal degradation of Htt could lead to some changes 
associated with Huntington’s disease. Four adrenergic receptor pathways as well as 
the adrenaline and noradrenaline biosynthesis pathway are shown to be 
downregulated in T47D cells, 120 minutes following IMD treatment. This is of 
particular interest as MDM2 has been implicated in the ubiquitination of a number 






Fig 5.7 Interaction network of proteins identified as changing after IMD0354 treatment (Using data 
generated by the ABSciex QStar Elite). Interaction network was created on STRING (http://string-
db.org/) using the following settings: Active prediction methods – Databases and Experiments, 
Required confidence –Medium (0.400), View - Confidence view. Thicker lines indicate greater 




Fig 5.8 The relative abundance of proteins grouped by functions (Go-term) in both total detected 
proteins and those downregulated proteins identified after IMD0354 treatment. Functional groups 
which are significantly enriched in the downregulated group (bottom) in comparison to the total data 
set (top chart) are labelled and P-Values indicated. The corresponding groups are labelled in the total 
detected proteins group for comparison. No functional groups were seen to be significantly enriched 




Fig 5.9 The relative abundance of proteins grouped by process (Go-term) in both total detected 
proteins and those downregulated proteins identified after IMD0354 treatment. Groups which are 
significantly enriched in the downregulated group (bottom) in comparison to the total data set (top 
chart) are labelled and P-Values indicated. The corresponding groups are labelled in the total 
detected proteins group for comparison. No functional groups were seen to be significantly enriched 





Table 5.7 Pathways identified as potentially altered after IMD0354 treatment by Panther pathway 
analysis. All proteins as well as the ratio fold change after IMD0354 treatment identified from mass 
analysis were submitted to panther pathway analysis. (http://www.pantherdb.org/pathway/). 
Detailed are all pathway identified to be significantly altered by this analysis  (PVal>0.05). ↑ Indicates 
positive regulation of the pathway, ↓ indicates negative regulation of the pathway, – indicates no 
change. 
 
Pathway 30 mins 60 mins 120mins 
Ubiquitin proteasome pathway ↑ ↑ ↑ 
Angiogenesis ↑ ↑ ↑ 
De novo purine biosynthesis ↑ ↑ ↑ 
EGF receptor signalling pathway ↑ ↑ ↑ 
Parkinson disease ↑ ↑ ↑ 
ATP synthesis ↓ - - 
FGF signalling pathway ↑ ↑ ↑ 
Glycolysis ↑ ↑ ↑ 
Ras Pathway ↑ ↑ ↑ 
PDGF pathway ↑ ↑ ↑ 
Vitamin D metabolism and pathway ↓ ↓ ↓ 
Interleukin signalling pathway ↑ ↑ ↑ 
De novo pyrimidine deoxyribonucleotide 
biosynthesis 
↑ ↑ ↑ 
p53 pathway glucose deprivation ↑ - - 
p53 pathway ↑ ↑ - 
Axon guidance mediated by nectrin ↓ - - 
PI3 kinase pathway ↑ ↑ ↑ 
Mannose metabolism ↑ - - 
Cytoskeletal regulation by Rho GTPase ↑ - - 
mRNA splicing ↓ - - 
Huntington disease ↑ ↑ ↑ 
FAS signalling pathway - ↑ ↑ 
De novo pyrmidine ribonucleotides biosynthesis - ↑ ↑ 
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T cell activation - ↑ ↑ 
Purine metabolism - ↑ - 
Axon guidance by semaphorins - ↑ ↑ 
Beta1 adrenergic receptor signalling pathway - - ↓ 
Beta2 adrenergic receptor signalling pathway - - ↓ 
Alpha adrenergic receptor signalling pathway - - ↓ 
Thyrotropin-releasing hormone receptor 
signalling pathway 
- - ↓ 
Oxytocin receptor mediated signalling pathway - - ↓ 
5HT2 type receptor mediated signalling pathway - - ↓ 
Wnt signalling pathway - - ↓ 
Cortocotropin releasing factor receptor signalling 
pathway 
- - ↓ 
Beta3 adrenergic receptor signalling pathway - - ↓ 
5HT4 type receptor mediated signalling pathway - - ↓ 
5HT1 type receptor mediated signalling pathway - - ↓ 
Adrenaline and noadrenaline biosynthses - - ↓ 





5.2.5 SILAC data analysis 
The phosphorylation status of peptides identified in this experiment were 
again deemed to be up or down regulated if the ratio to control was <0.83 or >1.2. 
This led to the identification of relatively few phosphopeptides “hits”. However, the 
proportion of phosphopeptides deemed to have changed as a result of IMD0354 
treatment are a large proportion of the total peptides identified (43/90=48%). This 
is a surprising result as such large scale changes to the phosphoproteome would not 
be anticipated so rapidly after a specific kinase inhibitor. The small number of 
phosphopeptides identified rules out a number of types of analysis; i.e. pathway 
analysis which relies on a large dataset to be successful. Interestingly, one of the 
phosphopeptides hits identified by SILAC analysis was a cAMP-dependent protein 
kinase type II-alpha regulatory subunit which is known to be important in G-Protein 
coupled receptor (GPCR) pathways including adrenergic pathways, adding 
confidence to the idea that this pathway may be affected by IMD0354. 
The SILAC experiment was initially intended to identify potential substrates 
of IKKβ in un-stimulated T47D cells. IKKβ are known to phosphorylate substrates 
with a consensus motif of DSΨXXS/T (279)(Fig 5.10) were Ψ indicates a hydrophobic 
residue, X indicates any residue and S/T indicates a serine or a threonine. Therefore, 
phosphopeptides hits were analysed for the presence of this motif. Unfortunately 
peptides hits with this motif were not identified. This is not entirely unanticipated, 
as IKKβ has also been shown to phosphorylate a number of proteins without the 








Fig 5.10 Consensus motif of IKKβ substrates (Figure adapted from Kuo et al. (2009) (279). Ψ 




5.2.6 Preliminary validation 
Proteomic analysis, such as the data presented here, gives large quantities of 
data that needs to be processed. Initial analysis of proteome changes resulting from 
IMD0354 treatment lead to the identification of a total of 96 proteins identified with 
the ABSciex QStar Elite data set and analysis of the phosphoproteome using SILAC 
led to the identification of 31 proteins with altered phosphorylation states. The 
proteins identified to have changed may well represent proteins which have been 
altered by IMD0354. However in this pilot study the mass spectrometry data only 
represents a single replicate, therefore, further analysis is needed to validate these 
results. However, clearly there are too many proteins to validate them all. There are 
various methods of analysis available aimed at trying to select the most interesting 
or relevant data from a large data set. Two different approaches are presented here. 
The first utilises our own knowledge to select data which fits in with what we know 
about MDM2 and aimed to investigate one of the potentially important pathways 
revealed by the data analysis. Specifically, the effect of IMD0354 on the β-adrenergic 
pathway and proteins involved in GPCR pathways were investigated by western blot 
(in collaboration with George Baillie and Krishna Yalla, University of Glasgow). The 
second approach specifically tried to identify those proteins which are likely to be 
mediators of the reduction of MDM2 protein expression and utilised an empirical 
approach. Seventy five protein hits were selected from iTRAQ and SILAC 
experiments, these targets were then knocked-down in T47D cells using siRNA to 
determine what effect, if any, there was on MDM2 protein levels. 
 
5.2.6.1 β-adrenergic and β-arrestin pathway. 
 The potential down-regulation of the β-adrenergic pathway in response to 
IMD0354 treatment was of particular interest due to the fact that MDM2 has been 
shown to be an important factor within this pathway (277, 278, 282). One 
component of this pathway is β-arrestin, which is important in GPCR turnover and 
desensitisation. β-arrestin is ubiquitinated by MDM2 after GPCR stimulation and this 
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ubiquitination is required for the internalisation of GPCR (282). β-arrestin oligomers 
have also been shown to control MDM2 localisation and promote MDM2 nuclear 
export (278). Furthermore MDM2 is also required for the ubiquitination of G-
protein coupled receptor kinase 2 (GRK2), which promotes GRK2 degradation and is 
also dependent upon β-arrestin. GRK2 phosphorylates GPCRs after agonist 
stimulation and plays a role in receptor desensitisation (277).  
In order to assess the effect of IMD0354 on the β-adrenergic pathway, the 
effects of IMD0354 treatment on a number of proteins within this pathway were 
assessed. The effect of IMD0354 treatment on PKA subunits C and R1α, β-arrestin 
and phospho-β2-adrenergic receptor were assessed by Krishna Yalla (University of 
Glasgow). As can be seen in fig 5.11 IMD0354 treatment does not appear to lead to 
any substantial changes in the levels of any of these proteins within the β adrenergic 
cascade. It was initially intended to assess total β2-adrenergic receptors levels as 
well as phospho-β2-adrenergic receptors levels however unfortunately we were 
unable to identify antibodies which could successfully detect total protein in this cell 






Fig 5.11. β2-adrenergic receptor pathway components remain unaltered by IMD0354 treatment. 
T47D cells were treated with DMSO or IMD0354 for the indicated time. Cell lysates were then 
assessed by western blotting to determine relative levels of PKA-C, PKA-R1α, β-arrestin and phospho-
β2-adrenergic receptor using the anti-PKA-C, anti-PKA-R1α, anti-β-arrestin and anti-phospho-β2-
adrenergic receptor antibodies. Equal loading was also assessed using anti-Tubulin/anti-GAPDH 





5.2.6.2 siRNA screen 
 An siRNA screen was set up to identify mediators of MDM2 stability; 75 hit 
proteins were selected from the QStar Elite iTRAQ data set and the SILAC data set 
for analysis. The phosphoproteome experiment was a more complex procedure 
which identified relatively few peptides and the experiment suffered from poor 
trypsinisation efficiency, therefore it was considered that the confidence in the 
iTRAQ data set was higher. As such, most of the 75 targets selected were selected 
from the iTRAQ data set. For details of all targets selected and targeting siRNA for 
each see Supplementary Data (Table S7).  
 A siRNA treatment of 40nmol for 48hrs was selected as experience within 
the lab suggests that this is a concentration and timescale which should lead to a 
reduction of most targets (J. O’Donoghue and A-S. Huart, Personal Communication). 
In addition, this treatment time and siRNA concentration was shown to successfully 
reduce MDM2 in Fig 4.5A. Initially, the siRNA screen was conducted without 
IMD0354 treatment. Specifically, the screen aimed to identify up-regulated protein 
hits whose siRNA knockdown increased MDM2 protein expression and down-
regulated hits whose siRNA knockdown decreased MDM2 levels. This strategy is 
summarised in Fig 5.12. The reason for this is assuming that these hits identified by 
MS are upstream of MDM2 then an up-regulated protein ought to be a negative 
regulator of MDM2 stability whereas a down-regulated protein ought to be a 
positive regulator of MDM2 stability. When analysing the SILAC phosphopeptide 
hits, a change in MDM2 levels in either direction was considered. This is because the 
effect of changes in phosphorylation status of hit proteins on its activity is not 
certain. 
 By utilising this approach, only one hit lead to the expected effect on MDM2 
in the desired direction. As can be seen in Fig 5.13A, siRNA targeting RPS3, which 
was shown to be up-regulated by IMD0354 in MS/MS analysis, lead to a subtle 
increase in MDM2 levels. This is particularly interesting as RPS3 has been shown to 
interact with MDM2 and additionally has been suggested to be a component of the 
Nf-κB pathway (279, 283). 
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 Next, siRNAs targeting up-regulated MS hits were also screened with the 
addition of IMD0354 for those which could rescue the reduction in MDM2 protein. 
T47D cells were treated with 40nM siRNA for 48Hrs followed by 5µM IMD0354 for 
2Hrs. Three targets were identified which appeared to be able to rescue the loss of 
MDM2 expression which were RPS3, RPS4X and RPS9 (Shown in Fig 5.13B). These 
proteins are all ribosomal subunit proteins. However many ribosomal proteins, 
including RPS3 and RPS4X, have recently been revealed to additionally have non-
ribosomal functions (284). Interesting all three of these proteins are known to 






Fig 5.12 Schematics of potential mechanisms by which IKKβ could control MDM2, mtp53 and p21 
protein levels; (A) IKKβ may promote a factor(s) which enhances the stability of proteins including 
MDM2, p21 and p53. Inhibition of IKKβ would reduce this factor(s) and reduce levels of MDM2, p21 
and p53. Alternatively (B) IKKβ may down-regulate a factor(s) which reduces the stability of proteins 
including MDM2, p21 and p53. Inhibition of IKKβ would allow this factor(s) to increase and reduce 
levels of MDM2, p21 and p53. (C) shows the workflow of an approach to identify such factors; cells 
were treated with IMD0354 and subject to tandem MS analysis. This allowed the identification of up 
and down regulated protein hits. Hit proteins were then screened by siRNA for those which affect 




Fig 5.13 RPS3, RPS4X and RPS9 can regulate the levels of MDM2 in cells treated with IMD0354. 75 
siRNAs targeting proteins seen to be up/down-regulated or have altered phosphorylation status after 
IMD0354 treatment were screened for their ability to alter the levels of MDM2 in T47D cells. T47D 
cells were treated with control or target siRNA 48Hrs prior to harvesting. Cell lysates (20µg/well) 
were then assessed by western blotting to determine relative MDM2 levels using the anti-MDM2 
antibody, 2A10. Equal loading was also assessed using anti-β-actin antibody.  Examples of 5 results 
from this experiment along with the non-targeting siRNA control are shown in (A). 19 siRNAs 
targeting proteins seen to be up-regulated or having altered phosphorylation status after IMD0354 
treatment were screened for their ability to rescue levels of MDM2 in T47D cells after IMD0354 
treatment. T47D cells were treated with control or target siRNA 48 Hrs prior to harvesting. Cells were 
additionally treated with 5µM IMD0354 2hrs prior to harvesting. Cell lysates (20µg/well) were then 
assessed by western blotting to determine relative MDM2 levels using the anti-MDM2 antibody, 
2A10. Equal loading was also assessed using anti-β-actin antibody. Examples of 5 results from this 




5.2.7 The role of RPS3 in the response to IMD0354 treatment  
 RPS3 siRNA was identified to lead to the up-regulation of MDM2 protein 
levels both with and without IMD0354, and as RPS3 has previously been seen to 
interact with proteins within both the p53 and IKK pathways (281, 283) it was 
selected for further analysis. siRNA screening suggests that RPS3 may be important 
in mediating IMD0354 induced reduction of MDM2 expression. The proteins 
selected for siRNA screening including the ribosomal proteins; RPS3, RPS4X and 
RPS9 were selected for analysis as they were seen to be altered by IMD0354 in the 
ABSciex Qstar Elite iTRAQ results (Table  5.8). The ABSciex Qstar Elite data set was 
investigated rather than the ABSciex 5600 technical replicate as it had more 
conservative results. However, retrospective analysis shows that RPS3 was identified 
as “hits” in the 5600 data set (Table 5.8). RPS4X and RPS9 showed increased levels in 
the ABSciex 5600 data set at 120mins after IMD0354 treatment (1.21 and 1.23 
respectively) but failed to achieve a significant P-value (0.07 and 0.12 respectively). 
This may have resulted from decreased coverage in this data set compared to the 
ABSciex QStar Elite data set (for RPS9 6 peptides versus 9 peptides, for RPS4X 7 
peptides versus 5). Network analysis of the ABSciex 5600 data set as a whole (Fig 
5.14) indicates that a large number of interlinked ribosomal proteins were affected; 
strengthening the idea that IMD0354 may disrupt the ribosomal proteins. 
As can be seen in Fig 5.15A, results showed, in agreement to the results of 
MS/MS, that overtime IMD0354 leads to the up-regulation of RPS3. Whilst the 
general pattern of RPS3 levels after IMD0354 treatment remained largely consistent 
between MS/MS and western blotting, western blotting revealed a much greater 
level of up regulation of RPS3 overall (Fig 5.16). This is perhaps not surprising as 
research has shown that iTRAQ MS can underestimate the relative changes 
occurring (285). As a relatively large number of proteins were analysed by siRNA 
screen, it was not possible to confirm that siRNA was successful with each target 
and therefore this means that some false negatives may be present in the screen. 
However, it was confirmed that the treatment with 40nM RPS3 targeting siRNA was 
sufficient to lead to a reduction in RPS3 protein expression (Fig 5.15B). When 
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attempting to reproduce the effect of RPS3 siRNA seen in the screen, RPS3 targeting 
siRNA did not appear to alter MDM2 levels without IMD0354 treatment. However 
with IMD0354 treatment RPS3 targeting siRNA reduced the loss of MDM2 protein 






Fig 5.14 Interaction network of proteins identified as changing after IMD0354 treatment (Using 
data generated by the ABSciex 5600). Interaction network was created on STRING (http://string-
db.org/) using the following settings: Active prediction methods – Databases and Experiments, 
Required confidence –Medium (0.400), View - Confidence view. Thicker lines indicate greater 
confidence in the interaction.  
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Table 5.8 Ribosomal proteins identified to be up-regulated after IMD0354 treatment ( QStar data set with corresponding data from the 5600) 





40S ribosomal protein S3  
  
Qstar 44.9 14 1.21 0.01 1.04 0.44 1.11 0.21 





40S ribosomal protein S9  
  
Qstar 32.5 9 1.26 0.02 1.20 0.01 1.25 0.02 





40S ribosomal protein S4,  
X isoform  
  
Qstar 28.9 7 1.22 0.04 1.20 0.05 1.25 0.02 






Fig 5.15 Reduction of MDM2 by IMD0354 is partially dependent upon RPS3. (A) T47D cells were 
treated with 5µM IMD0354 for the indicated time. Cell lysates (20µg/well) were then assessed by 
western blotting to determine relative RPS3 levels using an anti RPS3 antibody. Equal loading was 
also assessed using anti-β-actin antibody. (B) T47D cells were treated with either non-targeting siRNA 
(NT) or siRNA targeting RPS3. Cells were then treated with 5µM IMD0354 or DMSO for 2Hrs. Cell 
lysates (20µg/well) were then assessed by western blotting to determine relative RPS3 levels using 
an anti RPS3 antibody. Equal loading was also assessed using anti-β-actin antibody. (C) T47D cells 
were treated with either non-targeting siRNA (NT) or siRNA targeting RPS3. Cells were then treated 
with 5µM IMD0354 for 2Hrs (2), DMSO for 1Hrs and then 5µM IMD0354 for 1Hr (1) or DMSO for 2Hrs 
(0). Cell lysates (20µg/well) were then assessed by western blotting to determine relative MDM2 
levels using the anti-MDM2 antibody, 2A10. Equal loading was also assessed using anti-β-actin 






Fig 5.16 Western blotting reveals a greater increase than mass spectrometry in RPS3 induced by 
IMD0354. Shown are relative levels of RPS3 after IMD0354 treatment at the indicated time-points 
relative to the 0hrs time-point. Data from western blotting was quantified using ImageJ software and 





This study used a proteomic approach to investigate proteins up-stream of 
MDM2 and co-regulated with MDM2, after IMD0354 treatment. Analysis of the 
whole proteome allows for a much less biased analysis of changes resulting from a 
specific manipulation or stress. This is due to the fact that, at least initially, the 
analysis is not driven or limited by our current knowledge. 
 In this study, 4plex iTRAQ was used to assess proteome changes resulting 
from treatment of T47D cells with the IKKβ inhibitor IMD0354 over time. This study 
showed that IMD0354 lead to relatively few changes in the total proteome within 
the first 2Hrs. This is reassuring as it suggests that inhibition is not leading to mass 
down-stream changes within the time scale. Interestingly, a large number of hit 
proteins were seen to be changed at 30 minutes after IMD0354 treatment but 
returned to control levels by 1hr after treatment. This suggests that IMD0354 may 
lead to different types of changes with differing dynamics. IMD0354 immediately 
leads to the transient regulation of a number of proteins as observed by MS/MS. A 
number of proteins are also subject to a much more sustained change. It is tempting 
to speculate that this second wave of changes may result from the initially transient 
wave however this remains to be established. 
 Network analysis of all proteins seen to have changed following IMD0354 
treatment identified two large hubs of proteins. Specifically, it identified a group of 
proteins involved in mRNA splicing and transport and a second smaller network 
composed of ribosomal proteins. This is particularly interesting in view of the fact 
that previous experiments (Fig 4.16 and Fig 4.17) have shown that the down 
regulation of MDM2 following IMD0354 treatment is likely resulting from alteration 
in de novo protein production. It was shown earlier that MDM2 mRNA levels were 
reduced by about 40% after 2Hrs of IMD0354 treatment (Fig 4.17). This suggests 
that mRNA reduction, as well as potentially other mechanisms involved in protein 
synthesis are important in MDM2 regulation. It was also shown that a change in 
protein turnover was not involved in MDM2 reduction. The results presented here 
suggest that a number of proteins involved in mRNA processing and RNA binding are 
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altered in response to IMD0354 which is consistent with the changes observed in 
MDM2 mRNA levels. The degree of specificity of such changes is a yet not clear. 
In Chapter 4 it was shown that p53 pathway and D-type cyclins are down-
regulated as a result of IMD0354 treatment. The mass spectrometry data presented 
here shows that only a small proportion of proteins are changing in response to 
IMD0354 treatment. However, if protein synthesis is altered, proteins with faster 
turnover rates will be lost earlier. Faster turnover rates may be more common in 
lower abundance proteins which are less likely to be identified by mass 
spectrometry. Further work will be needed to explore the generality of the effect of 
IMD0354 on protein synthesis and mRNA processing. It should be noted that many 
types of cellular stress lead to reduced protein synthesis, however, the synthesis of 
certain proteins particularly those involved in survival or apoptosis are sustained 
and others are stabilised by reduced degradation (286, 287). Thus, the effect on the 
p53 pathway under such conditions is important. Furthermore, inhibitors of 
transcription and/or translation are being explored, or in some cases being used, as 
cancer therapy as they have been shown to selectively kill cancer cells (210). This 
specificity is thought to be related to the reduction of specific short lived oncogenic 
proteins to which the cancers are addicted. 
 Changes in ribosomal proteins may be of particular interest in future studies 
as screening of siRNAs targeting a number of hit proteins indicated that RPS3 and 
potentially RPS4X and RPS9 may be important in the IMD0354 mediated loss of 
MDM2 protein. The proteins that were selected for siRNA screening were proteins 
identified as changing in the QStar Elite iTRAQ data set. This data set was analysed 
as it showed more conservative changes than the data from the ABSciex 5600. 
However, the three ribosomal proteins; RPS3, RPS9 and RPS4X were all identified in 
both data sets and showed broadly similar patterns of change . RPS3 is a 40S 
ribosomal subunit although it, like many other ribosomal proteins, also has a 
number of non-synthesis roles (281, 284). A number of ribosomal subunit proteins 
have been shown to interact with the p53 pathway (283, 288, 289). Evidence 
suggests that ribosomal subunits may be important for coupling ribosome stress to 
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the p53 apoptotic pathway (288, 289), for example, RPL11 has been shown to 
induce p53 activity. Other evidence suggests that ribosome-p53 pathway interaction 
is not limited to ribosome stress conditions (283). For example, the ribosomal 
protein RPL26 has been shown to be able to bind p53 mRNA and enhance it 
translation (290), whilst binding of MDM2 to RPL11 repressed this effect (291). This 
effect does not appear to be dependent upon ribosomal stress. 
RPS3 has been shown to interact with both MDM2 and p53 and 
consequently protects p53 from ubiquitination. Yadavilli et al. (2009) showed that 
siRNA targeting RPS3 leads to a reduction in MDM2 protein levels which appears 
contradictory to data here (283). However, they showed that RPS3 siRNA reduced 
the levels of MDM2 in response to H2O2 treatment and MDM2 levels were broadly 
similar in untreated cells. Similarly in this study RPS3 siRNA appeared to have a 
greater influence on the levels of MDM2 in IMD0354 stimulated cells. This indicates 
the possibility that the effect of RPS3 on MDM2 may depend on pathway 
stimulation. Yadavilli et al. (2009) also showed that the RPS3 siRNA used lead to a 
reduction in cytosolic, free RPS3 but did not affect RPS3 bound to ribosomes. 
Potentially, different siRNA may differentially alter the pools of target protein so 
care must be taken when comparing siRNA experiments. 
To our knowledge RPS4X is not known to directly interact with either p53 or 
MDM2 however as RPS4X interacts with other ribosomal proteins which are known 
to interact with both p53 and MDM2 there is the possibility of indirect regulation. 
Furthermore, the importance of interactions between many ribosomal proteins and 
the p53 pathway are only just coming to light and clearly there is the possibility that 
further interactions will be identified in future. RPS9 has however been noted to 
affect the p53 pathway, Lindstrӧm and Nistér (2010) showed that knock-down of 
RPS9 lead to an activation of the p53 pathway as a result of increased p53 stability 
which was dependent upon RPS11 (292). RPS11 has been shown to increase p53 
stability via a negative regulation of MDM2 (288). 
 Whilst it is interesting that ribosomal proteins such as RPS3 and RPS9 can 
influence both p53 and MDM2 at the protein level, the data here suggests that 
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changes in MDM2 protein level after IMD0354 treatment occur as a result of 
changes at a translational or pre-translational level. Research does suggest that 
RPS3 may play a role in controlling transcription of particular genes has also 
suggested a link between IKKβ and RPS3. In fact RPS3 has been suggested to be a 
non-Rel member of the Nf-κB family and can control the transcription of a subset of 
Nf-κB induced genes (293). Furthermore, the activation of RPS3 in this pathway is 
thought to rely on phosphorylation by IKKβ (281). On the face of it therefore, it may 
seem contradictory that IKKβ inhibition would lead to an increase in RPS3 levels, 
however it remains undetermined as to whether this RPS3 increase is indicative of 
increased activity. Interestingly, a number of stimuli that promote the activity of p53 
and inhibition of MDM2 via RPL11 activity actually lead to a decrease in the levels of 
RPL11 (292) supporting the idea that protein level is in some cases a poor indicator 
of activity. 
 Whilst siRNA targeting of RPS3 lead to reduced loss of MDM2, with IMD0354 
treatment this did not represent total recovery of Mdm2 levels to control. In fact, at 
the longer treatment time of 2hrs, no effect of RPS3 siRNA was observed. As a large 
number of ribosomal proteins have been shown to bind to MDM2, there is the 
potential for some redundancy in these roles and may be a point of interest in 
further studies. This may be supported by the fact that the data presented here 
suggests as many as 13 other ribosomal proteins may also be altered by IMD0354  
and the siRNA screen suggests that RPS4X and RPS9 are also potential regulators of 
MDM2 within an IMD0354 treated system. Alternatively, RPS3 changes could simply 
have a modulating, but not essential, role in this pathway. It must be stressed that 
further work will be required to definitively show that RPS3 is regulated by IMD0354 
and that inhibition of this protein affects MDM2 protein reduction in the context of 
IKKβ inhibition. Current data shows that RPS3 protein levels appears to be increased  
over time with IMD0354; however other changes in the tissue culture environment 
over time have yet to be specifically excluded. Furthermore only one type of siRNA 
was used in this study which could have non-specific effects therefore further work 
should aim to confirm this result with a range of RPS3 targeting siRNAs. 
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 This chapter also attempted to identify potential IKKβ substrates by virtue of 
a phosphoproteome approach. In this approach, cells were treated with IMD0354 or 
DMSO control and phosphopeptides were extracted using TiO2 beads. Cells used for 
this experiments were pre-labelled  using stable isotope labelling of cells in culture 
(SILAC) (266). Unfortunately this approach was largely unsuccessful and a number of 
factors may have contributed to this. One important factor was that trypsin 
efficiency was very low which leads to a number of problems. This may have 
occurred as a result of high concentrations of urea in the buffer when trypsinising. 
Although the concentration of urea within the reaction was reasonably high, this 
concentration (1.6M) has been shown not to have a detrimental effect on trypsin 
activity (294). Nonetheless as trypsin efficiency was so low, further work should seek 
to confirm whether this was a confounding factor in the efficiency. If peptides within 
a sample are not cleaved this leads to much larger peptides than normal. This 
increases the chance of one or more amino acids not being properly identified in 
MS2 and thus the data for that peptide being unusable. Additionally, the software 
used (Protein pilot) is designed to analyse peptides with one SILAC label 
incorporated. In a normal experiment this is ideal; as arginine and lysine are the 
labelled amino acids and trypsin cuts after these residues each peptide should 
contain one label. In certain situations, two labels may be found in one peptide even 
if trypsin efficiency is good, this is primarily due to the fact that the presence of a 
proline residue, after either arginine or lysine residues, will prevent cleavage by 
trypsin and the software is able to cope with this eventuality. However, when 
trypsin efficiency is poor this can lead to more than two labels per peptide. The 
large number of mass shifts required to make the peptide fit a normal sequence is 
then interpreted as making the confidence in the overall sequence lower. This 
presents a problem in analysing such data. 
 A further potential problem with this experiment may be that using two 
different types of peptide clean-up; namely C18 and graphite columns may have 
increased the loss of peptides from the mixture. A more protracted method with 
more steps inevitably leads to increased loss of peptides. Graphite columns are 
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recommended in the purification of phosphopeptides as they are particularly good 
at binding hydrophilic peptides whereas C18 columns are particularly successful in 
the purification of hydrophobic peptides (Data from manufacturer: 
http://www.piercenet.com/browse.cfm?fldID=B5283A74-5056-8A76-4E39-
AEC4C18EBE57). Potentially this may mean that sequential use of the two columns 
increased the loss of peptides as both columns may poorly bind different groups of 
peptides.  
 Whilst the data attained from this experiment is of limited use in the 
exploration of the MDM2-IKKβ axis, the results of this experiment are being used to 
troubleshoot an improved method of phosphoproteome analysis. 
  
 In conclusion, mass spectrometry analysis has shown that a limited number 
of proteins are altered in the early response to IMD0354 treatment. Screening of a 
number of these hits led to the identification of RPS3 as a potential regulator of 
MDM2. Whilst further work will be needed to confirm this, the identification of this 
protein is of particular interest due to the fact that it has been shown to interact 
with both the p53 and IKK pathways. This study highlights the usefulness of a 
proteomics approach to identify proteins or pathways involved in mediating a 
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215 
 
Chapter 6 Conclusions and future perspectives 
 
The primary aim of this work was to identify and explore dominant 
regulators of wild-type or mutant p53. Identification of potential factors was 
conducted by the use of screening methods and included: 
1. Screening of compounds to identify those that could activate wtp53 
2. Screening of polymers (& hydropolymers) to identify those that could 
activate wtp53 (or repress activation by Roscovitine) 
3. Screening of compounds to identify those that could reduce levels of 
mtp53 
Both screen 1 and screen 3 successfully identified a number of compounds that are 
potentially able to modify the p53 pathway. Screen 2 aimed to identify polymers 
which activated p53.  Whilst this represents an interesting and novel use of 
biopolymers, the screen was unfortunately unsuccessful in the identification of such 
polymers.  
The purpose of these various screens was to generate leads of potentially 
interesting and dominant, compounds or targets, regulating p53. Whilst a huge 
number of proteins have been shown to affect p53 (22) the outcome of 
perturbation is often difficult to predict. I.e. if a large number of proteins pushes 
p53 toward degradation and a separate group pushes toward activation this 
equilibrium is not necessarily going to be substantially altered by perturbing one 
protein in one of these groups. Screening therefore is a useful way of identifying 
dominant factors as well as dominant outcomes of target perturbation.  
Whilst the screens conducted did lead to the identification of a number of 
potentially interesting compounds the conclusions that can be made are limited. 
These screens provided lead generation but further work is needed to confirm 
whether the hits identified lead to the anticipated outcome. Two compounds which 
target IKKβ and appeared to be able to reduce mtp53 levels were selected for 
further examination; the control of the p53 pathway by IKKβ was the subject of 
further investigation within this project. Nonetheless the identification of the other 
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hits still represents valuable work. Future studies could explore the control of the 
p53 pathway by other compounds or hits identified. Particularly the control of the 
p53 pathway by GSK-3 may be an interesting line of inquiry. Evidence in the 
literature supports the idea that GSK-3 inhibition could lead to the activation of p53 
(189, 190). It has therefore been suggested that GSK-3 inhibition may be useful in 
the treatment of cancers; in vivo experiments in mice support this (189). However, 
evidence that GSK-3 is an anti-apoptotic factor is not unequivocal and it has been 
shown that at least in certain situations GSK-3 can act as a pro-apoptotic factor 
(188). Thus further exploration of this pathway may be beneficial. 
Within the confines of this study the influence of IKKβ inhibition on the p53 
pathway was selected for further analysis. It was shown that inhibition of IKKβ by 
IMD0354 led to a reduction of both mtp53 and MDM2. The loss of MDM2 was 
independent of p53 and was rapidly and acutely affected by IMD0354 and as such 
the study concentrated on investigating the effects of IMD0354 on MDM2. This 
study mainly used IMD0354 to inhibit IKKβ, however other IKKβ inhibitors, as well as 
RNAi, were tested and shown to reduce MDM2 protein levels. The study mainly 
focussed on using chemical inhibition as the effect of the drug per se and it’s 
mechanisms of action are critical to our understanding of pathway manipulation. If 
IKKβ inhibition is to become a cancer therapy it is likely that such inhibition will be 
by chemical, not genetic, manipulation. In fact IMD0354 specifically has been 
proposed as a potential cancer therapy (229, 230), although significant work will be 
required to validate this. 
The mechanisms of action of IMD0354 as well as other IKKβ inhibitors are 
largely explored in the literature in terms of their effects on Nf-κB. In fact IMD0354 
is often considered as an Nf-κB specific inhibitor despite the fact that the drug was 
designed to inhibit IKKβ by binding of the ATP domain (240) and IKKβ is known to 
have a number of other substrate targets (211). To our knowledge no study has yet 
used this drug to investigate the effect on IKKβ dependent, but Nf-κB independent, 
pathways. This study therefore aimed to take a less bias approach to identification 
of mediating factors by the use of mass spectrometry. This led to the identification 
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of RPS3 as a potentially important factor in MDM2 regulation by IMD0354. This is 
particularly interesting as RPS3 has been previously described as an IKKβ substrate 
(281).  Future work should first aim to confirm the effects of RPS3 siRNA on 
IMD0354 mediated MDM2 reduction using a wider range of siRNAs. Further work 
should also explore whether IMD0354 is altering the phosphorylation of RPS3 and 
whether the effects of RPS3 in this pathway involve its ribosomal or non-ribosomal 
roles. 
As a side note, within a separate project it may be interesting to explore the 
effects of IMD0354 on other described Nf-κB independent IKKβ pathways. Mass 
spectrometry analysis indicated that pathways involved in Huntington’s disease may 
be up-regulated by the drug. The huntingtin protein has been described as a 
substrate for IKKβ and IKKβ acts to promote its degradation (275). This pathway may 
provide an interesting starting point in the exploration as to the effects of IKKβ 
inhibition on non-Nf-κB pathways. 
Overall this study demonstrated that IMD0354 appears to be capable of 
reducing a number of oncogenic proteins including mtp53, MDM2 and Cyclin D1, 
with MDM2 responding most rapidly. Inhibition of MDM2 may be of great clinical 
use. There has been much effort within research to identify drugs that inhibit 
MDM2, although this has largely focussed on inhibiting MDM2 mediated negative 
regulation of p53. One major issue with this approach is that even in cancers with 
wtp53 cells, p53 may be supressed by other mechanisms. To date, one drug which 
inhibits the MDM2 –p53 interaction, Nutlin, has entered clinical trials (295). Current 
available data comes from small scale proof-of-mechanism studies. In one such 
study a partial response was seen in only 1 of 20 patients (295). Clearly larger scale 
studies are needed to assess clinical outcomes and success in this particular study 
will have been limited by the short time scale of inhibitor treatment. Nonetheless 
this suggests that exploration of other drugs targeting MDM2 and the p53 pathway 
may be beneficial. 
A wider approach to MDM2 inhibition would be to reduce MDM2 at the 
protein level, as is achieved by IMD0354. This would be useful as the oncogenic 
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capacity of MDM2 is not thought to be limited to only p53 dependent mechanisms. 
Therefore a reduction in MDM2 at the protein level should reduce all its oncogenic 
capability. Wang et al. (2001) showed that MDM2 antisense oligonucleotides 
showed an anticancer effect in treatment of both mice bearing MCF-7 (wtp53) or 
MDA-MB-468 (mtp53) xenographs (296). This suggests that the effect of MDM2 
inhibition is not limited to tumours with wtp53. IMD0354 may be of particular use in 
tumours expressing mtp53 and/or high MDM2 expression as it appears to lead to a 
reduction in both oncogenic proteins. This study supports the need for future work 
on the effect of IMD0354 and IKKβ inhibition on MDM2 and mtp53.  
Potentially the number of cases where any given MDM2 or p53 directed 
therapy may be useful will be limited. Cancer is a hugely diverse and heterogeneous 
disease and whilst pathways such as p53 are often deranged the exact mechanism 
of this may vary substantially. Therefore much further into the future successful 
treatment of cancer may require highly personalised therapy. With regards to 
targeting the p53 pathway this may mean knowing not just the mutational or 
amplification status of p53 and MDM2, but also the status of a number of other 
interacting genes. Clearly before this is possible we would need a much greater 
understanding of why some drugs work in some patients and not others and further 
increasingly sophisticated and financially viable methods of profiling individual 
cancers. Nonetheless it is something we could strive towards. 
 
In conclusion, this study identified that IKKβ inhibition by IMD0354 is 
capable of reducing MDM2, mtp53 and cyclin D in cancer cell lines. Within the p53 
pathway MDM2 appears to be the most acutely and rapidly lost. Through the use of 
mass spectrometry a number of other proteins potentially regulated by IMD0354 
treatment were identified and RPS3 was identified as a potential regulator of MDM2 
loss. IMD0354 has previously been suggested to be a potential cancer therapy and 
thus this work suggests that its effects on MDM2 and mtp53 could potentially 
contribute to an anti-tumorigenic effect and should be an area of future interest. 
Further work is required to define whether the reduction of MDM2 and/or mtp53 
219 
 
contributes to cell death, to further explore the mechanism of mtp53 and MDM2 
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Table S1 Tocris Library compounds 
Compound Name Formula Target Description 
AG 490 C17H14N2O3 EGFR EGFR-kinase inhibitor. Also 
JAK2, JAK3 inhibitor 
ML 9 hydrochloride C15H17ClN2O2S.HCl MLCK Myosin light chain kinase 
inhibitor 
AG 213 C10H8N2O2S EGFR EGFR/PDGFR-kinase inhibitor 
Fasudil hydrochloride C14H17N3O2S.HCl ROCK Inhibitor of cyclic nucleotide 
dependent- and Rho-kinases 
GF 109203X C25H24N4O2 PKC Protein kinase C inhibitor 
Genistein C15H10O5 EGFR EGFR kinase inhibitor. Also 
estrogen and PPARγ ligand 
LY 294002 
hydrochloride 
C19H17NO3.HCl PI3K Selective PI 3-kinase inhibitor 
U0126 C18H16N6S2 MEK Potent, selective inhibitor of 
MEK1 and 2 
PD 98059 C16H13NO3 MEK Specific inhibitor of MEK 
Y-27632 
dihydrochloride 
C14H21N3O.2HCl ROCK Selective p160ROCK inhibitor 
SB 202190 C20H14N3OF p38 MAPK Potent, selective inhibitor of 
p38 MAPK 
Olomoucine C15H18N6O cdk Cyclin-dependent kinase 
inhibitor 




ZM 336372 C23H23N3O3 Raf Potent, selective c-Raf 
inhibitor 




C23H25NO.HCl JAK3 Potent, selective JAK3 
inhibitor 
GW 5074 C15H8Br2INO2 Raf Potent, selective c-Raf1 
kinase inhibitor 
PP 1 C16H19N5 Src Potent, selective Src inhibitor 
SB 203580 
hydrochloride 
C21H16FN3OS.HCl p38 MAPK Selective inhibitor of p38 
MAPK; water-soluble 
(-)-Terreic acid C7H6O4 BTK Selective inhibitor of BTK 
PP 2 C15H16ClN5 Src Potent, selective Src inhibitor 
SU 4312 C17H16N2O VEGFR Potent inhibitor of VEGFR 
tyrosine kinase 
SP 600125 C14H8N2O JNK Novel and selective JNK 
inhibitor 
Purvalanol A C19H25ClN6O cdk Cyclin-dependent kinase 
inhibitor 
Purvalanol B C20H25ClN6O3 cdk Cyclin-dependent kinase 
inhibitor 
Rottlerin C30H28O8 PKC Reported PKCδ inhibitor 
SB 431542 C22H16N4O3 TGFbR1 Potent, selective inhibitor of 
TGF-βRI, ALK4 and ALK7 




SB 415286 C16H10ClN3O5 GSK-3 Potent, selective GSK-3 
inhibitor 
Arctigenin C21H24O6 MEK Potent MKK1 inhibitor. Also 
inhibits IκBα phosphorylation 
NSC 693868 C9H7N5 cdk Cdk inhibitor. Also inhibits 
GSK-3 
SB 239063 C20H21FN4O2 p38 MAPK Potent, selective p38 MAP 
kinase inhibitor; orally active 
SL 327 C16H12F3O3S MEK Selective inhibitor of MEK1 
and MEK2; brain penetrant 
Ro 31-8220 mesylate C25H23N5O2S.CH3SO3H Broad 
Spectrum 
Inhibitor 
Protein kinase inhibitor 
Aminopurvalanol A C19H26ClN7O cdk Cyclin-dependent kinase 
inhibitor 
API-2 C13H16N6O4 PKB Selective inhibitor of Akt/PKB 
signaling. Antitumor and 
antiviral 




C28H25ClFN5O3S2.2HCl EGFR Potent dual EGFR/ErbB2 
inhibitor; orally active 
Ro 08-2750 C13H10N4O3 TrkA Inhibits NGF binding to 
p75NTR and TrkA 
TBB C6HBr4N3 CK2 Selective cell-permeable 




C6H6Br6 JAK2 Inhibits JAK2 
autophosphorylation 






C18H19ClFN7.2HCl EGFR Highly selective EGFR-kinase 
inhibitor 
CGP 53353 C20H13F2N3O2 PKC Selective inhibitor of PKCβII 
Arcyriaflavin A C20H11N3O2 cdk Potent cdk4/cyclin D1 and 
CaM Kinase II inhibitor. 
Antiviral agent (anti-HCMV) 
ZM 447439 C29H31N5O4 Aurora Inhibits Aurora kinase B 
ER 27319 maleate C18H20N2O.C4H4O4 Syk Selective Syk kinase inhibitor 
ZM 323881 
hydrochloride 




C16H13N3O2FCl.HCl VEGFR Inhibitor of VEGF receptor 
tyrosine kinase 
IKK 16 C28H29N5OS.HCl IKK Selective inhibitor of IKK 
Ki 8751 C24H18F3N3O4 VEGFR Potent, selective VEGFR-2 
inhibitor 
10-DEBC hydrochloride C20H25N2OCl.HCl PKB Selective Akt/PKB inhibitor 
TPCA-1 C12H10FN3O2S IKK Potent, selective inhibitor of 
IKK-2 
SB 218078 C24H15N3O3 Chk1 Inhibitor of checkpoint kinase 
1 (Chk1) 
TCS 359 C18H20N2O4S FLT3 Potent FLT3 inhibitor 
PD 198306 C18H16F3IN2O2 MEK Selective inhibitor of MEK1/2 




IMD 0354 C15H8ClF6NO2 IKK Inhibitor of IKK-2 
CGK 733 C23H18Cl3FN4O3S ATR/ATM Selective inhibitor of ATR and 
ATM kinases 
PHA 665752 C32H34Cl2N4O4S cMET Potent and selective MET 
inhibitor 
PD 407824 C20H12N2O3 Chk1 Selective inhibitor of Chk1 
and Wee1 
LY 364947 C17H12N4 TGFbR1 Selective inhibitor of TGF-βRI 
CGP 57380 C11H9FN6 Mnk1 Selective inhibitor of Mnk1 
PQ 401 C18H16ClN3O2 IGF-1R IGF-IR inhibitor 
PI 828 C19H18N2O3 PI3K PI 3-kinase inhibitor, more 
potent than LY 294002 
(Cat.No. 1130) 
NU 7026 C17H15NO3 DNA-PK Selective DNA-dependent 
protein kinase inhibitor 
D 4476 C23H18N4O3 CK1 Selective Casein Kinase 1 
(CK1) inhibitor. Also inhibits 
TGF-β RI 
EO 1428 C20H16BrClN2O p38 MAPK Selective inhibitor of p38α 
and p38β2 
H 89 dihydrochloride C20H20BrN3O2S.2HCl PKA Protein kinase A inhibitor 
FPA 124 C11H9Cl2CuN3O2S PKB Akt/PKB inhibitor 
GW 843682X C22H18F3N3O4S PLK Selective inhibitor of polo-like 
kinases, PLK1 and PLK3 




SU 5416 C15H14N2O VEGFR VEGFR inhibitor. Also inhibits 
c-kit, Ret, MET and FLT3 
1-Naphthyl PP1 C19H19N5 Src Src family kinase inhibitor; 
also inhibits c-Abl 
Dorsomorphin 
dihydrochloride 
C24H25N5O.2HCl AMPK Potent and selective AMPK 
inhibitor 
BIO C16H10BrN3O6 GSK-3 Potent, selective GSK-3 
inhibitor 
SD 208 C17H10ClFN6 TGFbR1 Potent ATP-competitive TGF-
βRI inhibitor 
Compound 401 C16H15N3O2 DNA-PK Selective DNA-PK and mTOR 
inhibitor 
BI 78D3 C13H9N5O5S2 JNK Selective, competitive JNK 
inhibitor 






















Table S3 Proteins identified as down-regulated (>1.20, Pval <0.05) after IMD0354 treatment using iTRAQ MS/MS  




30 mins 30mins 
Pval 
60 mins 60mins 
Pval 






ABSciex Qstar Elite 1.45 2 9.15 0.85   1.03   1.03   





ABSciex Qstar Elite 14.84 7 17.17 0.76 0.00 0.98 0.70 0.95 0.39 





ABSciex Qstar Elite 14.57 8 19.76 0.73 0.06 0.95 0.61 0.88 0.34 





ABSciex Qstar Elite 35.51 19 11.72 0.90 0.06 0.97 0.51 0.91 0.02 





ABSciex Qstar Elite 35.52 17 26.65 1.00 0.93 0.88 0.01 0.82 0.00 





ABSciex Qstar Elite 33.3 19 40.05 0.75 0.00 1.05 0.35 0.96 0.54 





ABSciex Qstar Elite 23.86 12 13.27 0.88 0.01 1.06 0.14 1.02 0.62 





ABSciex Qstar Elite 14.64 7 4.26 0.84 0.02 0.92 0.22 0.89 0.10 





ABSciex Qstar Elite 14.17 7 6.16 0.72 0.00 0.76 0.10 0.69 0.04 
ABSciex 5600 10.38 5 5.87 0.93 0.32 1.08 0.55 0.82 0.06 
O95831 AIFM1 ABSciex Qstar Elite 13.71 7 14.52 0.88 0.08 0.97 0.65 1.00 0.95 
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ABSciex Qstar Elite 50.17 56 57.66 0.74 0.00 0.97 0.47 0.92 0.04 





ABSciex Qstar Elite 7.39 5 22.68 0.82 0.15 0.98 0.86 0.90 0.35 





ABSciex Qstar Elite 21.46 13 35.95 0.70 0.00 1.00 0.98 0.94 0.45 





ABSciex Qstar Elite 7.92 4 10.76 0.85 0.25 1.01 0.94 1.03 0.82 





ABSciex Qstar Elite 15.95 11 70.37 0.86 0.07 1.05 0.54 0.96 0.53 





ABSciex Qstar Elite 1.92 1 10.67 0.72 0.24 1.08 0.70 1.04 0.80 





ABSciex Qstar Elite 40.77 20 12.57 0.82 0.00 0.89 0.00 0.91 0.03 





ABSciex Qstar Elite 31.91 23 28.57 0.91 0.09 0.90 0.26 0.81 0.00 





ABSciex Qstar Elite 7.76 5 15.83 0.78 0.12 0.93 0.45 0.88 0.21 





ABSciex Qstar Elite 24.75 15 29.88 0.81 0.00 1.01 0.81 0.94 0.23 
ABSciex 5600 23.42 13 24.62 0.58 0.00 1.01 0.91 0.88 0.21 
P14923 PLAK ABSciex Qstar Elite 27.25 17 28.72 0.95 0.59 0.87 0.02 0.81 0.03 
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ABSciex Qstar Elite 21.25 19 39.82 0.77 0.03 0.88 0.15 0.86 0.13 





ABSciex Qstar Elite 12.65 7 10.08 0.86 0.06 0.87 0.08 0.75 0.01 
ABSciex 5600 4.67 2 3.66 0.76 0.04 0.82 0.09 0.75 0.05 
P18583 SON  ABSciex Qstar Elite 19.65 10 5.40 0.77 0.00 0.98 0.62 0.95 0.32 





ABSciex Qstar Elite 8.46 5 40.74 0.74 0.02 1.06 0.50 1.02 0.77 





ABSciex Qstar Elite 16.79 9 47.37 0.92 0.63 0.86 0.42 0.76 0.27 





ABSciex Qstar Elite 7.29 5 16.82 0.78 0.04 0.93 0.42 0.88 0.17 





ABSciex Qstar Elite 38.37 28 56.37 0.69 0.00 0.93 0.16 0.90 0.04 





ABSciex Qstar Elite 30.17 18 20.93 0.82 0.00 1.14 0.01 1.09 0.06 





ABSciex Qstar Elite 43.61 31 43.76 0.73 0.00 0.97 0.44 0.93 0.07 





ABSciex Qstar Elite 14.25 8 17.14 0.89 0.20 1.04 0.62 0.96 0.59 
ABSciex 5600 15.16 7 16.38 0.81 0.04 1.03 0.70 0.95 0.51 
P27824 CALX ABSciex Qstar Elite 35.86 20 31.93 0.82 0.00 1.04 0.25 1.03 0.62 
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ABSciex Qstar Elite 12.07 8 23.70 0.72 0.01 0.97 0.71 0.94 0.39 





ABSciex Qstar Elite 18.28 12 22.96 0.81 0.00 0.90 0.08 0.90 0.09 





ABSciex Qstar Elite 19.61 9 28.13 0.63 0.00 0.91 0.20 0.82 0.01 





ABSciex Qstar Elite 32.63 21 23.49 0.83 0.00 0.93 0.08 0.86 0.00 





ABSciex Qstar Elite 19.26 11 16.61 0.77 0.00 0.98 0.68 0.96 0.44 





ABSciex Qstar Elite 10.03 8 21.69 0.75 0.04 0.96 0.63 0.93 0.47 





ABSciex Qstar Elite 19.39 28 57.14 0.76 0.02 1.06 0.45 0.99 0.95 





ABSciex Qstar Elite 16.2 13 52.32 0.89 0.08 0.91 0.13 0.83 0.01 





ABSciex Qstar Elite 15.07 15 37.82 0.90 0.11 0.95 0.38 0.83 0.02 





ABSciex Qstar Elite 10.66 6 38.57 0.81 0.03 0.92 0.30 0.91 0.20 
ABSciex 5600 11.08 8 31.43 0.82 0.05 0.91 0.19 0.90 0.15 
P84103 SFRS3 ABSciex Qstar Elite 17.51 10 43.29 0.81 0.02 0.96 0.55 0.92 0.34 
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ABSciex Qstar Elite 12.53 6 7.20 0.81 0.01 0.86 0.04 0.85 0.03 





ABSciex Qstar Elite 12.54 8 13.24 0.74 0.01 0.76 0.03 0.71 0.01 





ABSciex Qstar Elite 18.15 11 57.43 0.80 0.01 0.87 0.05 0.79 0.02 





ABSciex Qstar Elite 12.04 6 31.21 0.71 0.01 1.00 0.99 1.04 0.70 





ABSciex Qstar Elite 30.98 15 32.89 0.82 0.00 1.03 0.50 1.06 0.19 





ABSciex Qstar Elite 18.46 12 42.34 0.80 0.00 0.89 0.10 0.87 0.03 





ABSciex Qstar Elite 13.45 8 10.08 0.90 0.15 0.78 0.01 0.80 0.03 





ABSciex Qstar Elite 12.77 8 18.96 0.82 0.04 0.88 0.08 0.86 0.06 





ABSciex Qstar Elite 27.15 15 14.20 0.82 0.01 0.90 0.07 0.93 0.19 





ABSciex Qstar Elite 24.46 14 19.24 0.76 0.00 0.96 0.34 0.93 0.12 
ABSciex 5600 28.68 14 19.24 0.75 0.00 0.91 0.04 0.86 0.00 
Q13185 CBX3 ABSciex Qstar Elite 6.33 3 22.40 0.87 0.40 1.04 0.76 0.97 0.86 
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ABSciex Qstar Elite 17.45 10 40.72 0.72 0.00 0.93 0.21 0.83 0.02 





ABSciex Qstar Elite 38.94 24 30.28 0.77 0.00 0.91 0.08 0.89 0.03 





ABSciex Qstar Elite 12.03 6 13.62 0.77 0.02 0.92 0.28 0.92 0.28 





ABSciex Qstar Elite 108.94 53 26.98 0.83 0.00 0.93 0.00 0.86 0.00 





ABSciex Qstar Elite 14.22 7 11.00 0.84 0.03 0.77 0.01 0.76 0.00 





ABSciex Qstar Elite 5.28 6 8.92 0.72 0.06 1.16 0.23 0.96 0.72 





ABSciex Qstar Elite 18.09 10 30.60 0.97 0.65 0.93 0.33 0.99 0.83 





ABSciex Qstar Elite 81.97 41 26.19 0.83 0.00 1.01 0.75 0.98 0.54 





ABSciex Qstar Elite 12.47 7 10.38 0.71 0.02 1.01 0.91 0.92 0.31 





ABSciex Qstar Elite 24.81 12 21.06 0.76 0.00 0.86 0.02 0.86 0.03 
ABSciex 5600 16.45 9 13.49 0.80 0.00 0.93 0.30 0.93 0.22 
Q16629 SFRS7 ABSciex Qstar Elite 12.97 11 27.31 0.74 0.00 0.95 0.28 0.89 0.11 
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ABSciex Qstar Elite 21.62 11 20.21 0.80 0.00 0.88 0.01 0.87 0.01 





ABSciex Qstar Elite 8.18 4 8.15 0.81 0.03 0.94 0.43 0.92 0.30 





ABSciex Qstar Elite 17.17 9 19.93 0.84 0.01 1.02 0.68 1.01 0.84 





ABSciex Qstar Elite 47.61 23 19.60 0.80 0.00 1.00 0.89 0.97 0.49 





ABSciex Qstar Elite 12.37 7 37.74 0.77 0.04 0.95 0.56 0.93 0.42 





ABSciex Qstar Elite 5.26 3 5.46 0.90 0.59 0.96 0.68 0.96 0.67 





ABSciex Qstar Elite 9.49 5 6.55 0.82 0.04 0.90 0.12 0.84 0.02 





ABSciex Qstar Elite 14.35 8 8.78 0.77 0.00 0.94 0.29 0.89 0.06 





ABSciex Qstar Elite 6.21 6 7.41 0.78 0.09 1.01 0.92 1.03 0.77 





ABSciex Qstar Elite 14 8 9.31 0.83 0.03 0.88 0.09 0.85 0.05 
ABSciex 5600 19.09 10 10.96 0.81 0.04 0.94 0.57 0.94 0.35 
Q92896 GSLG1 ABSciex Qstar Elite 12.39 7 6.53 0.92 0.37 0.96 0.53 0.78 0.03 
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ABSciex Qstar Elite 11.72 6 10.94 0.72 0.02 0.82 0.13 0.75 0.03 





ABSciex Qstar Elite 8.67 4 14.00 0.79 0.03 0.84 0.07 0.87 0.24 





ABSciex Qstar Elite 16.39 9 17.08 0.88 0.13 0.99 0.84 0.97 0.56 





ABSciex Qstar Elite 13.36 7 41.00 1.17 0.39 0.81 0.03 0.71 0.01 





ABSciex Qstar Elite 0 0               





ABSciex Qstar Elite 19.22 12 20.78 0.79 0.01 0.98 0.79 0.98 0.82 





ABSciex Qstar Elite 7.35 4 37.91 0.82 0.07 0.93 0.39 0.76 0.04 





ABSciex Qstar Elite 11.45 6 17.32 0.71 0.00 0.97 0.72 0.88 0.06 





ABSciex Qstar Elite 16.99 11 9.77 0.64 0.00 0.88 0.07 0.87 0.04 





ABSciex Qstar Elite 14.65 9 25.79 0.80 0.03 0.99 0.92 0.94 0.45 
ABSciex 5600 8.98 7 18.65 0.77 0.05 1.00 1.00 0.93 0.47 
Q9UPT8 ZC3H4 ABSciex Qstar Elite 4.09 2 2.69 0.87 0.41 1.02 0.86 0.96 0.75 
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ABSciex Qstar Elite 51.2 27 15.66 0.83 0.00 0.98 0.64 0.98 0.56 





ABSciex Qstar Elite 13.36 6 15.50 0.75 0.03 0.97 0.62 0.91 0.17 





ABSciex Qstar Elite 6.09 3 16.94 0.68 0.03 0.96 0.55 0.90 0.19 




Table S4 Proteins identified as Up-regulated (<0.83, Pval <0.05) after IMD0354 treatment using iTRAQ MS/MS 














ABSciex Qstar Elite 28.12 15 38.25 1.14 0.02 1.12 0.04 1.18 0.02 





ABSciex Qstar Elite 46.1 29 58.99 1.11 0.01 1.07 0.05 1.05 0.18 





ABSciex Qstar Elite 41.23 45 65.07 1.02 0.81 0.96 0.70 0.99 0.91 





ABSciex Qstar Elite 26.85 15 43.53 1.09 0.09 1.02 0.68 1.02 0.60 





ABSciex Qstar Elite 51.04 37 55.76 1.09 0.10 1.04 0.34 1.06 0.15 





ABSciex Qstar Elite 19.81 12 68.57 1.11 0.08 1.09 0.15 1.09 0.18 





ABSciex Qstar Elite 11.25 10 36.67 1.16 0.12 1.14 0.16 1.17 0.11 





ABSciex Qstar Elite 107.11 91 58.33 1.04 0.41 1.01 0.85 1.02 0.70 
ABSciex 5600 85.01 78 49.18 1.23 0.01 1.15 0.08 1.14 0.15 
P08133 ANXA6 ABSciex Qstar Elite 64.25 38 49.03 1.18 0.00 1.12 0.01 1.15 0.00 
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ABSciex Qstar Elite 47.54 82 56.91 1.05 0.30 1.03 0.56 1.05 0.43 





ABSciex Qstar Elite 29.18 22 52.19 1.22 0.00 1.08 0.20 1.08 0.19 





ABSciex Qstar Elite 14.25 8 17.79 1.17 0.02 1.11 0.10 1.14 0.10 





ABSciex Qstar Elite 83.83 56 44.87 1.10 0.00 1.07 0.03 1.08 0.02 





ABSciex Qstar Elite 62.19 45 62.15 1.12 0.00 1.07 0.11 1.07 0.05 





ABSciex Qstar Elite 15.91 11 42.67 1.35 0.00 1.30 0.01 1.23 0.03 





ABSciex Qstar Elite 23.34 11 26.82 1.14 0.11 1.11 0.09 1.13 0.05 





ABSciex Qstar Elite 20.63 14 44.86 1.21 0.01 1.04 0.44 1.11 0.21 





ABSciex Qstar Elite 14.22 8 26.82 1.08 0.22 1.07 0.22 1.10 0.18 
ABSciex 5600 12.35 6 21.07 1.16 0.27 1.15 0.07 1.26 0.05 
P26639 SYTC ABSciex Qstar Elite 20.14 10 16.18 1.10 0.11 1.12 0.03 1.11 0.05 
263 
 





ABSciex Qstar Elite 12.67 7 55.80 1.13 0.07 1.13 0.06 1.11 0.11 





ABSciex Qstar Elite 34.81 29 32.74 1.00 0.95 1.02 0.69 1.06 0.29 





ABSciex Qstar Elite 32.55 24 62.95 1.14 0.01 1.09 0.05 1.09 0.11 





ABSciex Qstar Elite 9.4 7 31.55 1.21 0.05 1.14 0.13 1.11 0.19 
ABSciex 5600 7.77 6 28.16 1.16 0.11 1.09 0.30 1.05 0.50 
P30044 PRDX5 ABSciex Qstar Elite 16.03 8 44.39 1.09 0.19 1.11 0.18 1.12 0.14 





ABSciex Qstar Elite 15.12 11 37.88 1.04 0.49 1.08 0.19 1.09 0.17 





ABSciex Qstar Elite 14.65 8 53.30 1.20 0.04 1.20 0.04 1.14 0.13 





ABSciex Qstar Elite 20.53 14 37.09 1.09 0.07 1.05 0.27 1.08 0.09 





ABSciex Qstar Elite 15.01 9 42.76 1.09 0.16 1.11 0.10 1.14 0.06 
ABSciex 5600 15.99 8 48.28 1.39 0.01 1.32 0.02 1.46 0.01 
P39023 RL3 ABSciex Qstar Elite 13.91 7 21.09 1.04 0.46 1.08 0.15 1.19 0.01 
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ABSciex Qstar Elite 17.44 9 32.47 1.26 0.02 1.20 0.01 1.25 0.02 





ABSciex Qstar Elite 17.75 15 47.55 1.08 0.21 0.98 0.70 1.06 0.32 





ABSciex Qstar Elite 8.08 5 32.73 1.18 0.23 1.14 0.25 1.14 0.13 





ABSciex Qstar Elite 10.05 6 25.27 1.09 0.26 1.02 0.83 1.05 0.57 





ABSciex Qstar Elite 16.96 12 26.32 1.05 0.53 1.07 0.34 1.06 0.40 





ABSciex Qstar Elite 6.81 4 28.21 0.91 0.20 1.15 0.20 1.32 0.07 





ABSciex Qstar Elite 140.59 80 33.05 1.11 0.00 1.06 0.01 1.05 0.02 
ABSciex 5600 90.97 61 23.74 1.25 0.00 1.14 0.00 1.15 0.00 
P49720 PSB3 ABSciex Qstar Elite 15.43 8 45.85 1.27 0.01 1.13 0.15 1.23 0.06 





ABSciex Qstar Elite 12.46 9 22.36 1.10 0.15 1.10 0.17 1.06 0.38 
ABSciex 5600 14.32 8 21.74 1.21 0.01 1.09 0.18 1.10 0.16 
P54578 UBP14 ABSciex Qstar Elite 9.34 5 10.73 1.07 0.35 1.05 0.50 1.04 0.67 
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ABSciex Qstar Elite 32.02 18 17.51 1.21 0.00 1.23 0.00 1.16 0.00 





ABSciex Qstar Elite 13.38 10 28.57 1.26 0.02 1.19 0.05 1.23 0.08 





ABSciex Qstar Elite 18.18 11 45.21 1.16 0.01 1.12 0.04 1.15 0.02 





ABSciex Qstar Elite 18.12 18 56.86 1.13 0.14 1.12 0.06 1.16 0.02 





ABSciex Qstar Elite 9.34 7 35.10 1.19 0.09 1.22 0.08 1.29 0.10 





ABSciex Qstar Elite 11.35 7 28.90 1.21 0.04 1.19 0.05 1.25 0.02 





ABSciex Qstar Elite 7.26 4 15.95 1.00 1.00 1.05 0.63 1.23 0.13 





ABSciex Qstar Elite 12.11 7 29.94 1.04 0.52 1.05 0.50 1.08 0.28 





ABSciex Qstar Elite 7.88 4 17.35 1.03 0.71 1.12 0.38 1.17 0.15 
ABSciex 5600 6.51 3 16.84 1.06 0.47 1.23 0.04 1.22 0.05 
Q05639 EF1A2 ABSciex Qstar Elite 9.62 23 36.72 1.17 0.10 1.24 0.04 1.20 0.06 
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ABSciex Qstar Elite 20.67 14 47.24 1.11 0.15 1.09 0.21 1.12 0.12 





ABSciex Qstar Elite 71.62 37 9.49 1.21 0.00 1.14 0.00 1.19 0.00 





ABSciex Qstar Elite 29.45 18 35.45 1.03 0.73 1.04 0.65 1.07 0.18 





ABSciex Qstar Elite 5.88 4 78.95 1.12 0.22 1.13 0.28 1.14 0.26 





ABSciex Qstar Elite 17.26 10 8.54 1.09 0.15 1.06 0.36 1.09 0.14 





ABSciex Qstar Elite 8.4 5 7.32 1.06 0.54 1.19 0.06 1.23 0.04 





ABSciex Qstar Elite 17.42 13 51.85 0.95 0.69 1.16 0.07 1.20 0.06 





ABSciex Qstar Elite 8 4 8.89 1.01 0.93 1.00 0.97 0.95 0.60 





ABSciex Qstar Elite 22.83 14 31.98 1.13 0.03 1.10 0.04 1.14 0.01 
ABSciex 5600 25.72 13 29.95 1.25 0.01 1.20 0.00 1.22 0.01 
Q9Y6B6 SAR1B ABSciex Qstar Elite 4 2 17.17 1.23 0.36 1.16 0.63 1.17 0.40 
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ABSciex Qstar Elite 17.23 8 27.99 1.15 0.01 1.12 0.03 1.16 0.01 






Table S5 Proteins identified as up and down regulated (>1.20 or  <0.83, PVal <0.05 ) at different time point after IMD0354 treatment using iTRAQ MS/MS 












ABSciex Qstar Elite 13.3 7 57.14 0.78 0.00 1.12 0.07 1.05 0.41 





ABSciex Qstar Elite 64.82 45 49.25 0.73 0.00 1.11 0.00 1.03 0.26 





ABSciex Qstar Elite 8.03 6 43.00 0.64 0.02 0.96 0.68 0.94 0.62 





ABSciex Qstar Elite 5.53 3 39.56 0.67 0.04 1.29 0.09 1.24 0.12 





ABSciex Qstar Elite 18.97 10 20.48 0.75 0.03 1.34 0.00 1.21 0.00 





ABSciex Qstar Elite 17.49 28 63.11 0.66 0.00 1.01 0.90 0.92 0.43 





ABSciex Qstar Elite 13.97 18 47.79 0.81 0.01 1.10 0.12 1.05 0.38 




Table S6 Phospho-proteins identified to be up-regulated after IMD0354 treatment using SILAC MS/MS 
Assession Symbol 
%Cov 
(95) Conf Sequence Modifications Ratio 
P27816 MAP4 1.21 99 DMESPTKLDVTLAK Phospho(S)@4 2.09 
Q09666 AHNK 1.61 99 LKSEDGVEGDLGETQSR Phospho(S)@3 2.09 
Q09666 AHNK 1.61 99 SSKASLGSLEGEAEAEASSPK Phospho(S)@2; Phospho(S)@8 2.07 
Q09666 AHNK 1.61 99 SSKASLGSLEGEAEAEASSPK Phospho(S)@5; Phospho(S)@8 2.00 
P46937 YAP1 3.57 99 QASTDAGTAGALTPQHVR Phospho(S)@3 1.96 
Q96TC7 RMD3 3.83 99 SQSLPNSLDYTQTSDPGR Phospho(S)@3 1.66 
P62995 TRA2B 6.94 99 RPHTPTPGIYMGRPTYGSSR Phospho(T)@4 1.65 
Q14157 UBP2L 3.59 99 RYPSSISSSPQKDLTQAK Phospho(S)@9 1.61 
P51858 HDGF 15.00 99 GNAEGSSDEEGKLVIDEPAKEK Phospho(S)@6; Phospho(S)@7 1.59 
Q15019 SEPT2 5.54 99 IYHLPDAESDEDEDFKEQTR Phospho(S)@9 1.58 
P46937 YAP1 3.57 99 QASTDAGTAGALTPQHVR Gln->pyro-Glu@N-term; Phospho(S)@3 1.49 
P46937 YAP1 3.57 99 QASTDAGTAGALTPQHVR Gln->pyro-Glu@N-term; Phospho(T)@4 1.49 
P35222 CTNB1 2.05 99 RTSMGGTQQQFVEGVR Phospho(T)@7 1.43 
P35222 CTNB1 2.05 99 RTSMGGTQQQFVEGVR Phospho(S)@3 1.43 
Q9NYF8 BCLF1 4.13 99 LKDLFDYSPPLHK Phospho(S)@8 1.41 
Q92538 GBF1 0.91 99 GYTSDSEVYTDHGRPGK Phospho(S)@4 1.37 
Q9H1E3 NUCKS 8.23 99 TPSPKEEDEEPESPPEKK Phospho(S)@13 1.28 
Q9UHD8 SEPT9 2.73 99 SFEVEEVETPNSTPPR Phospho(S)@1 1.28 
Q8IYB3 SRRM1 3.65 99 KETESEAEDNLDDLEK Phospho(S)@5 1.27 
P25788 PSA3 5.49 99 ESLKEEDESDDDNM Phospho(S)@9 1.21 
Q15149 PLEC 0.38 99 SSSVGSSSSYPISPAVSR Phospho(S)@3 1.21 
P42167 LAP2B 14.10 99 QNGSNDSDRYSDNEEDSKIELK 
Gln->pyro-Glu@N-term; 
Phospho(S)@11 1.21 




Table S7 Phospho-proteins identified to be down-regulated after IMD0354 treatment using SILAC MS/MS 
Assession Symbol 
%Cov 
(95) Conf Sequence Modifications Ratio 
P27824 CALX 11.82 97.7 AEEDEILNRSPR Phospho(S)@10 0.83 
Q9NYF8 BCLF1 4.13 99 RIDISPSTLR Phospho(S)@7 0.82 
O94826 TOM70 3.95 99 ASPAPGSGHPEGPGAHLDMNSLDR Phospho(S)@2;Oxidation(M)@19 0.78 
Q13547 HDAC1 6.85 99 MLPHAPGVQMQAIPEDAIPEESGDEDEDDPDKR Phospho(S)@22 0.78 
P35659 DEK 5.60 99 EESEEEEDEDDEEEEEEEKEK Phospho(S)@3 0.77 
O94826 TOM70 3.95 99 ASPAPGSGHPEGPGAHLDMNSLDR Phospho(S)@2 0.74 
Q14157 UBP2L 3.59 99 SPAVATSTAAPPPPSSPLPSK Phospho(S)@16 0.74 
P49736 MCM2 1.77 99 GLLYDSDEEDEERPAR Phospho(S)@6 0.73 
Q92733 PRCC 4.07 99 IAAPELHKGDSDSEEDEPTK Phospho(S)@11;Phospho(S)@13 0.72 
O15173 PGRC2 10.76 99 LLKPGEEPSEYTDEEDTKDHNKQD Phospho(T)@12 0.72 
P13861 KAP2 5.69 99 VADAKGDSESEEDEDLEVPVPSR Phospho(S)@8; Phospho(S)@10 0.70 
Q14980 NUMA1 0.90 99 TQPDGTSVPGEPASPISQR Phospho(S)@17 0.69 
P42167 LAP2B 14.10 99 SSTPLPTISSSAENTR Phospho(T)@3 0.68 
Q09666 AHNK 1.61 99 LPSGSGAASPTGSAVDIR Phospho(S)@9 0.66 
P42167 LAP2B 14.10 99 GPPDFSSDEEREPTPVLGSGAAAAGR Phospho(S)@6; Phospho(S)@7 0.62 
Q13247 SFRS6 3.20 99 SNSPLPVPPSK Phospho(S)@3 0.60 
Q9H3N1 TMX1 7.50 99 KVEEEQEADEEDVSEEEAESK Phospho(S)@14 0.60 
Q9NYF8 BCLF1 4.13 99 YSPSQNSPIHHIPSR Phospho(S)@2; Phospho(H)@10 0.59 
Q9P206 K1522 1.55 99 ASPVPAPSSGLHAAVR Phospho(S)@2 0.57 






Table S8 siRNA Screen 
Gene Symbol Description siRNA target sequence 
HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) AACGTCAGCGTGTATCAGGAA 
RALY RNA binding protein, autoantigenic (hnRNP-associated with lethal yellow homolog) AACGTACCTGTCAAGCTCTTT 
ACIN1 apoptotic chromatin condensation inducer 1 CTCGCTGCCCAAATCATTCAA 
HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 TTGGATTATTTAATAACATTA 
SAFB scaffold attachment factor B ACGGACTGTAGTAATGGATAA 
C1QBP complement component 1, q subcomponent binding protein CACGGTCACTTTCAACATTAA 
CPD carboxypeptidase D CAGGACTGGAACTATTTACAA 
CHTOP chromatin target of PRMT1 GAGGACGAGGCCTACCCATAA 
RBM10 RNA binding motif protein 10 CTCCAACGTGCGCGTCATAAA 
HMGN1 high mobility group nucleosome binding domain 1 GAAGCCAAGTCTGATTAATAA 
HNRNPL heterogeneous nuclear ribonucleoprotein L AAAGCCTACACGCTTGAATGT 
HNRNPUL2 heterogeneous nuclear ribonucleoprotein U-like 2 ACGGGCGAGATTATGAGTACA 
PBXIP1 pre-B-cell leukemia homeobox interacting protein 1 CTGGGAGATGTAGCAAATTGA 
HNRNPH3 heterogeneous nuclear ribonucleoprotein H3 (2H9) AGCGACCGGGACCATATGATA 
ATP5H ATP synthase, H+ transporting, mitochondrial Fo complex, subunit d ATGACTTTGAGAAGAAGTTTA 
ZC3H14 zinc finger CCCH-type containing 14 AAGACCGGACTGCACATTCTA 
ATP5A1 ATP synthase alpha chain, mitochondrial TTGGCTGGATTTGAAGCTTAA 
PNN pinin, desmosome associated protein CCGGAGGATGATGATGTTAAA 
SNW1 SNW domain containing 1 CCCGATGAAGAAGCTATTAAA 
SON SON DNA binding protein CCGGTCTATGATGTCGTCATA 
CCAR1 cell division cycle and apoptosis regulator 1 ATGGCTAGCCCTAGTATGGAA 
SF3B2 splicing factor 3b, subunit 2, 145kDa CCCATCGTATCCCAACCTGAA 
ALYREF Aly/REF export factor TTGCTGAATTTGGAACGCTGA 
SF3A1 splicing factor 3a, subunit 1, 120kDa CAGGATAAGACGGAATGGAAA 
RBM25 RNA binding motif protein 25 ATCGCAGTCGATCAAGAGAAA 
NOP58 NOP58 ribonucleoprotein homolog (yeast) AACCATGTACCAGCACAGCAA 
NOP56 NOP56 ribonucleoprotein homolog (yeast) CCCAGTTTATTGGAAACCGAA 
HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 AAGGGCAATAAGCATTAGGTA 
SATB1 SATB homeobox 1 TCCAAGCAATTCATACTATAA 
ILF3 interleukin enhancer binding factor 3, 90kDa CAAGCTGCACGTGGCCGTTAA 
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CKAP4 cytoskeleton-associated protein 4 AGGGCGCGGATTTAAAGTCCA 
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide AAGGTTGTCGATCTGCTAGCT 
MYL6 myosin, light chain 6, alkali, smooth muscle and non-muscle ACCTATGAGGATTATGTCGAA 
RBMX RNA binding motif protein, X-linked CTCAATGTTCTCAGTACGAAA 
PSMB3 proteasome (prosome, macropain) subunit, beta type, 3 AACGGTTTGGCCCTTACTACA 
ATP5J ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F6 CACGGATTAGTTGTACAACTA 
TPR translocated promoter region (to activated MET oncogene) CAGGAGGTTTCTAGAGAACAA 
SMARCC2 SWI/SNF complex subunit SMARCC2 CAGGTGGATGCTGAGAGTCGA 
NUMA1 nuclear mitotic apparatus protein 1 CAGCAGCGCATTGACCGCCTA 
SF3A3 splicing factor 3a, subunit 3, 60kDa CAGCGACATCTCACTCATGAA 
UBTF upstream binding transcription factor, RNA polymerase I CAGGACCGTGCAGCATATAAA 
SFPQ splicing factor proline/glutamine-rich AATATGGAGAACCAGGAGAAG 
EFHD1 EF-hand domain family, member D1 CTGGGTAATGGTGGGTCTTAA 
LMNB1 lamin B1 AACGCGCTTGGTAGAGGTGGA 
CHERP calcium homeostasis endoplasmic reticulum protein CTGGATGTTCAGCAATGCCAA 
CANX calnexin CCTGCATAATGTTAAGCTTTA 
TP53BP1 tumor protein p53 binding protein 1 TTGTTTGACCAGAGCAATAAA 
NDUFB11 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11 CAGCAAGATCCAGCTGCCAGA 
FBL fibrillarin ATCGTTGGTCCGGATGGTCTA 
LMNA lamin A/C CCAGGAGCTTCTGGACATCAA 
SARNP SAP domain containing ribonucleoprotein ACGGTGGAGCTCCATAAGCTA 
SRSF7 serine/arginine-rich splicing factor 7 CTGGATGATCTTTATACTAAT 
PRPF19 PRP19/PSO4 pre-mRNA processing factor 19 homolog AAGTACATTGCGGAGAATGGT 
SRSF9 serine/arginine-rich splicing factor 9 AATGGTTATGATTATGGCCAG 
SRSF3 serine/arginine-rich splicing factor 3 CTCGTAGTCGATCTAGGTCAA 
SRSF1 serine/arginine-rich splicing factor 1 TTGGCAGGATTTAAAGGATCA 
RPS4X ribosomal protein S4, X-linked CTGGAGGTGCTAACCTAGGAA 
ANXA5 annexin A5 CGCGAGACTTCTGGCAATTTA 
PSMC5 proteasome (prosome, macropain) 26S subunit, ATPase, 5 AAGGTACATCCTGAAGGTAAA 
RPS9 ribosomal protein S9 ACGGCGTCTGTTCGAAGGCAA 
RPS3 ribosomal protein S3 CGGCAAGATGGCAGTGCAAAT 
GSTM3 glutathione S-transferase mu 3 (brain) AACGGAAGAAGTTACCCTTAA 
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AHNAK2 AHNAK nucleoprotein 2 CCCGAGGTAGCCGGCCTCAAA 
BLVRB biliverdin reductase B (flavin reductase (NADPH)) CAAGAGCTTCAAATTACTCTA 
CSE1L CSE1 chromosome segregation 1-like (yeast) CAGGATAATGTTATCAAAGTA 
DYNC1H1 dynein, cytoplasmic 1, heavy chain 1 CAGGTGGGTGTACATTACGAA 
DEK DEK oncogene CAGAATATAATGTGCAGGCAA 
MCM2 minichromosome maintenance complex component 2 CTCATTGGAGATGGCATGGAA 
BCLAF1 BCL2-associated transcription factor 1 CACGCTTTACGATATTATAAA 
TOMM70A translocase of outer mitochondrial membrane 70 homolog A AAGACAATAAGAAGGAATGTT 
TMPO thymopoietin AAAGATGATCTAGATGTAACA 
HDGF hepatoma-derived growth factor AAGAGCTGTGTGGAAGAGCCT 
PSMA3 proteasome (prosome, macropain) subunit, alpha type, 3 AATGACCTGCCGTGATATCGT 
YAP1 Yes-associated protein 1 CAGGTGATACTATCAACCAAA 
NACA nascent polypeptide-associated complex alpha subunit AAGAAGGCACGGAAGGCTATG 
 
 
 
